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Acute cardiovascular syndromes are a major cause of death in Western society and 
are generally triggered by rupture of an atherosclerotic plaque.1 In 2008, 17.3 million 
people died of the consequences of cardiovascular disease, accounting for 30% of all 
reported deaths worldwide.2 Atherosclerosis is considered a chronic autoimmune-like 
disease related to high plasma cholesterol levels resulting in endothelial damage, 
subsequent vascular dysfunction, and cholesterol accumulation in the arterial wall.3 
Atherosclerosis mostly occurs in the medium and large sized arteries and is a slowly 
progressing disorder that already starts during early adolescence.4, 5 Depending 
on exposure to risk factors, atherosclerotic lesions can grow event-free until the 
manifestation of acute thrombotic complications and subsequent clinical events, such 
as stroke and acute myocardial infarction (Figure 1). Risk factors include high calorie 
intake, hypertension, smoking, stress and physical inactivity and diseases such as 
obesity, diabetes and dyslipidemia correlate with the incidence of cardiovascular 
diseases as well.3, 6 For many years it was believed that atherosclerosis was a lipid 
disorder that resulted in cholesterol accumulation within the arterial wall. However, 
the mechanism underlying the pathological process of atherosclerosis is much 
more complicated and the involvement of inflammatory cells in the development 
and progression of atherosclerosis was suggested after the discovery of T cells in 
atherosclerotic lesions in the 1980s.7 Patients suffering from cardiovascular disease 
are currently treated with statins to lower low-density lipoprotein (LDL) cholesterol. 
However, these drugs only lead to a risk reduction of 30% in cardiovascular patients, 
indicating an urgent need for new therapeutic strategies to inhibit atherosclerosis and 
to prevent cardiovascular complications. 
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Figure 1. Atherosclerosis develops already during early adolescence, where a normal artery (I) becomes 
susceptible for endothelial damage, which promotes the formation of a ‘fatty streak’ (II). After this initial 
stage the lesions can develop into stable or vulnerable lesions (III). The vulnerable lesion can rupture 
and cause thrombus formation (IV) eventually resulting in an acute myocardial infarction and subsequent 
death. Adapted and modified from The McGraw-Hill Companies, Inc.
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The development of atherosclerotic lesions 
Initial lesion development
As the major regulator of vascular homeostasis, the endothelium maintains the 
balance between vasodilation and vasoconstriction and inhibition and stimulation 
of smooth muscle cell proliferation (Figure 2A).8 When this balance is disturbed, 
endothelial dysfunction occurs, causing damage to the arterial wall. Endothelial 
damage can be induced by turbulent or oscillatory shear stress in combination with 
the presence of atherogenic factors such as high cholesterol levels, smoking, and 
hypertension. These factors enhance the permeability of the endothelial cell layer for 
lipoproteins and increase the expression of adhesion molecules such as vascular cell 
adhesion molecule-1 (VCAM-1) and E- and P-selectin on the surface of endothelial 
cells.9, 10 Endothelial dysfunction is considered an early marker for atherosclerosis. 
Both the increased permeability of the endothelial cell layer and the expression of 
adhesion molecules correspond with the location where a lesion is formed.11 The 
increased permeability causes lipoproteins, and especially LDL cholesterol particles, 
to migrate through the endothelial layer and to accumulate in the intima, the 
innermost layer of the artery.12 LDL, also known as ‘bad cholesterol’, is together with 
‘good cholesterol’, high-density lipoprotein (HDL), the most important lipoprotein in 
atherosclerosis.13 Whereas HDL is anti-atherogenic because it mediates cholesterol 
efflux from the periphery towards the liver, modified LDL is pro-atherogenic. LDL 
transports the circulating cholesterol and consists of triglycerides surrounded by a 
shell of phospholipids and apolipoproteins. The accumulation of LDL particles within 
the intima is an important initiating factor in early atherosclerosis. Within the intima, 
these particles are prone to oxidative modifications, which lead to alterations in 
charge, particle size and lipid content.14 Oxidized LDL (oxLDL), in turn, initiates innate 
inflammatory immune responses by activating the endothelial cells to upregulate 
adhesion molecules.15 
Simultaneously with upregulation of adhesion molecules, the endothelial cells start to 
produce chemokines, growth factors and vasoactive molecules, which results in the 
recruitment of monocytes to the site of injury.16 Monocytes attach to E- and P-selectin 
on the endothelium via capture and rolling.17 Firm adhesion of the monocytes is 
Figure 2. The normal artery consisting of the intima, media and adventitia (A) becomes damaged when 
the endothelial cell layer is impaired. Monocytes can enter the arterial wall and become foam cells, which 
accumulate and form a ‘fatty streak’ (B). Adapted and modified from Libby et al. Nature 2011;473:317.
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mediated via intracellular adhesion molecule–1 (ICAM-1) and VCAM-1.18-20 The 
monocytes spread and then migrate through the endothelial layer in a process called 
diapedesis. The monocytes enter the subendothelial layer with help of the chemokine 
receptor-2 (CCR2) and the monocyte chemoattractant protein-1 (MCP-1). CCR2 is 
expressed on monocytes and binds to MCP-1, which is a chemoattractant released by 
macrophages, smooth muscle cells and other cells in response to inflammatory 
signals.21 Once migrated into the subendothelial layer, the monocytes differentiate 
into macrophages, which subsequently engulf oxidized LDL via scavenger receptors 
and form lipid-rich foam cells, characteristic for the atherosclerotic lesion.14, 22, 23 These 
foam cells induce inflammation via cell-cell contact and secrete inflammatory 
mediators, which results in the activation and recruitment of more inflammatory cells 
such as T cells. This process leads to the formation of a yellowish, ‘fatty streak’, which 
does not cause any clinical symptoms (Figure 2B). 
Lesion progression
T cells, as well as endothelial cells, secrete cytokines and growth factors that promote 
the migration and proliferation of smooth muscle cells (SMCs).3 The progression of 
fatty streaks into more complex lesions involves the migration of SMCs from the media 
into the intima. The SMCs start to cover the fatty streak and secrete extracellular 
matrix proteins, which results in the formation of a fibrous cap covering a necrotic 
core. This necrotic core contains apoptotic cells, lipid deposition, and increased 
proteolytic activity. When the lesion size increases by further accumulation of foam 
cells and the expansion of the necrotic core, the arterial wall changes in composition, 
eventually leading to narrowing of the artery.24 The lesion is now called an advanced 
atherosclerotic lesion (Figure 3A). 
Unstable lesions
Lesions that are prone to rupture, generally have a high content of lipid and necrotic 
Figure 3. The progression of a fatty streak into more complex lesions involves the migration of smooth 
muscle cells from the media into the intima, forming a fibrous cap that covers a necrotic core (A). Lesions 
can develop into stable or vulnerable lesions. The vulnerable lesion (B) can rupture and cause thrombus 
formation eventually resulting in an acute myocardial infarction and subsequent death. Adapted and 




debris, a thin fibrous cap containing a low content of SMCs and collagen, and activated 
macrophages in the shoulder regions where rupture most often occurs.25, 26 Thinning 
of the fibrous cap is caused by increased activity of matrix metalloproteinases (MMPs), 
which can digest collagen.27 The production of these matrix degrading proteins can be 
increased by several components, such as oxidized lipids, inflammatory cytokines, heat 
shock proteins and hemodynamic stress. Additionally, unstable lesions contain a high 
content of tissue factor, which is a procoagulant and promotes thrombus formation. 
Upon rupture of the fibrous cap, the thrombogenic, lipid-rich core is exposed to the 
blood (Figure 3B), which can lead to thrombus formation and subsequent occlusion of 
the blood vessel, causing 75% of all myocardial infarctions.28 Besides rupture of the 
fibrous cap, thrombus formation can also be initiated via erosion of the endothelial 
monolayer.1 This results in exposure of collagen and von Willebrand factor to the 
blood, which promotes platelet adhesion and activation and eventually thrombus 
formation with subsequent myocardial infarction.29 Furthermore, outward and inward 
arterial remodeling also play an important role in lesion stability and the occurrence 
of clinical symptoms.30-32 When lesions expand outward, which means into the vessel 
wall, patients have a much higher risk to develop unstable angina. In contrast, inward 
remodeling, which means the lesion reduces the diameter of the lumen, is more 
common in stable angina. 
Biological age of atherosclerotic lesions
Recently, using 14C determination by mass spectrometry released into the atmosphere 
during the nuclear weapons tests in the 1950-60s, Gonçalves et al. showed that the 
biological age of human atherosclerotic lesion components varies between 5 and 15 
years of age, with the fibrous cap being the youngest.33 Although the lesion in it self 
is probably older due to the replacement of original lesion components, this study 
indicates that the turnover time of human atherosclerotic lesions is very slow and may 
explain the difficulties encountered when developing therapies to induce regression of 
atherosclerosis in cardiovascular intervention trials. 
The immune system in atherosclerosis
Besides lipid accumulation and matrix degradation, inflammation is considered a key 
process in atherosclerotic plaque development and specifically in the pathogenesis 
of plaque rupture.6, 34 Atherosclerosis involves both innate and adaptive immune 
responses. The innate immunity is the initial barrier against infections and several 
immune cells such as monocytes, macrophages, dendritic cells (DCs), neutrophils, 
natural killer (NK) cells and mast cells are programmed to detect foreign molecules 
of exogenous (eg lipopolysaccharide (LPS)) or endogenous (eg oxLDL and heat shock 
protein (HSP) 60) origin.35 These foreign molecules are called pathogen-associated 
molecular patterns (PAMPs) and are recognized by the innate immune cells via 
pattern recognition receptors, such as Toll-Like Receptors (TLRs) and scavenger 
receptors (SRs).36 The pathogens are internalized and degraded by phagocytosis. 
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Adaptive immune reactions are initiated when antigen-presenting cells (APCs), such 
as macrophages and DCs, display a surface complex consisting of an antigenic peptide 
bound to a major histocompatibility complex protein class I or class II (MHC I or MHC 
II) to a T or B cell. This leads to cytokine secretion, cytotoxicity, antibody production, 
memory formation and stimulation of a wide range of other components of an immune 
reaction.34 A significant number of cell types is involved in the immune response 
during the initiation and progression of atherosclerosis (Figure 4) and studies in mice 
and human have revealed their roles in the pathogenesis of atherosclerosis. 
To investigate the pathogenesis of atherosclerosis in mice, two mouse models, the 
LDL receptor deficient (LDLr-/-) mice and apolipoprotein E (ApoE-/-) mice, are widely 
used. LDLr-/- mice lack the LDL receptor, which impairs VLDL and LDL removal from 
the circulation, resulting in elevated serum cholesterol levels. Upon Western-type diet 
feeding LDLr-/- mice show strongly enhanced cholesterol levels and rapidly develop 
atherosclerosis. ApoE-/- mice do not have ApoE, the ligand for binding to the LDL 
receptor and lipoprotein receptor-related protein (LRP), which results in severe 
hypercholesterolemia even without a high-fat diet.
Figure 4. Atherosclerosis is considered a chronic autoimmune-like disease in which both innate and 
adaptive immunity play an important role. Endothelial injury results in the entry of modified LDL particles 
and monocytes into the arterial wall. This activates macrophages and T cells that produce cytokines such 
as IFN-γ that further enhance the immune response. Neutrophils and mast cells are also recruited to the 
site of inflammation and release their granules containing more pro-inflammatory compounds. Moreover, 
protective mechanisms such as B cells that secrete neutralizing antibodies and regulatory T cells that 




Monocytes play a crucial role in the initiation of the atherosclerotic lesion by 
differentiating into macrophages that engulf modified LDL and subsequently form 
foam cells after excessive accumulation of lipids in the arterial wall. Monocytes are 
recruited by inflammatory adhesion molecules and migrate into the intima as described 
above. Deficiencies in chemokine signaling pathways mediating this process, such as 
MCP-1 or its receptor CCR2, provides dramatic protection from monocyte recruitment 
and atherosclerotic lesion formation.37, 38 Moreover, during atherosclerotic lesion 
development, monocyte accumulation correlates to the lesion size.39 In mice two 
subsets of monocytes with distinct patterns of surface markers and behaviors during 
inflammation have been described; CD11b+Ly6Chigh monocytes and CD11b+Ly6Clow 
monocytes. Whereas the CD11b+Ly6Chigh monocyte subset infiltrates the intima via 
CCR2, CCR5, CXCR1 and CX3CR1 to eventually form foam cells and thus promotes 
inflammation40, the CD11b+Ly6Clow monocyte subset enters the atherosclerotic lesion 
less frequently.41 Depletion of monocytes in rabbits by using clodronate liposomes 
reduced atherosclerotic lesion formation.42 Furthermore, ApoE-/- mice with individual 
or combined deficiencies in the chemokine receptors CCR2, CCR5 and CX3CR1 showed 
dramatic reductions in infiltrating monocytes and lesion development.43-45  
Macrophages
Macrophages have an essential role in all phases of atherosclerosis, from development 
of the fatty streak to processes that eventually contribute to plaque rupture and 
myocardial infarction.24 Macrophages express several scavenger receptors that are 
capable of taking up oxidized LDL, such as SR-A and CD36.46, 47 OxLDL taken up 
by macrophages is delivered to lysosomes, where its cholesterol ester content is 
hydrolyzed to free cholesterol and fatty acids.24 Subsequently, peptide fragments 
are presented on MHC class I/II molecules and lipid antigens are presented on CD1 
molecules.48 T cells that carry the appropriate T cell receptors (TCRs) are activated 
by binding to the MHC I/II peptide complex or CD1-lipid complex in the presence of 
costimulatory factors such as CD40 and CD80/CD86 molecules. 
The important role of macrophages in atherosclerosis was first demonstrated by 
Smith et al. who showed that M-CSF-/-ApoE-/- mice develop 86% less atherosclerosis.49 
Furthermore, Stoneman transplanted CD11b depleted bone marrow in wild type 
ApoE-/- mice and observed reduced plaque development in early atherosclerosis.50 
However, in late stages CD11b depletion did not affect atherosclerosis, which could be 
explained by the heterogeneity of CD11b, which is also expressed on neutrophils and 
dendritic cells. These cells are also implicated in atherosclerosis development. 
The activation and function of macrophages residing within atherosclerotic lesions 
are influenced by various cytokines and microbial products in their environment. 
Two different macrophage subsets have been extensively characterized; classically 
activated (M1) and alternatively activated (M2) macrophages51, and recently two new 
subsets are included; Mox macrophages and M4 macrophages.52, 53
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M1 and M2 macrophages
M1 macrophages are activated by IL-1β, endotoxin (LPS) and IFN-γ and are considered 
pro-inflammatory due to their secretion of TNFα, IL-6, IL-12, MMP-1, reactive oxygen 
species (ROS), and nitrogen intermediates.54-57 M2 macrophages are induced by IL-
4, IL-13, adiponectin, and peroxisome proliferator-activated receptor-γ (PPAR-γ) 
activation and exert anti-inflammatory functions through the secretion of IL-10, 
transforming growth factor β (TGF-β), an IL-1 receptor antagonist and the upregulation 
of the mannose receptor CD206, and arginase-1.58 Additionally, M2 macrophages can 
promote wound healing through matrix remodeling, efferocytosis, and the recruitment 
of fibroblasts.57, 59 A number of subsets of M2 macrophages have been described: M2 
macrophages activated by IL-4 or IL-13 are also called M2a macrophages, activation 
by immune complexes results in M2b macrophages and stimulation by glucocorticoids 
or IL-10 results in M2c macrophages. 
Both M1 and M2 macrophages are located in human and murine atherosclerotic 
lesions.52, 60 Previously, it was shown that oxLDL increases the expression of both M1 
(MMP-1 and iNOS) and M2 (arginase-1) markers in macrophages.61, 62 In addition, 
foam cells isolated from atherosclerotic lesions express MMP-1 and have reduced 
arginase-1 expression suggesting a classical M1 phenotype, but also have elevated 
MMP-12 expression, which is another hallmark factor for alternatively activated M2 
macrophages.63 Although these studies suggest that both M1 and M2 macrophages 
are involved in aggravating atherosclerosis, recent studies show that the balance 
between M1 and M2 macrophages may greatly affect lesion development. El Hadri 
et al. showed that Thioredoxin-1, an oxidative stress-limiting protein, exerts 
atheroprotective effects by promoting polarization of human and murine macrophages 
towards an anti-inflammatory M2 phenotype.64 Furthermore, during regression of 
atherosclerosis, macrophages shift from an M1 phenotype towards an M2 phenotype 
and this shift promotes collagen synthesis, which contributes to the stabilization 
of the lesion after switching to a low fat diet.65, 66 Interestingly, M2 macrophages 
resident in atherosclerotic lesions contained smaller lipid droplets compared with 
M1 macrophages and were localized far from the lipid core in comparison with M1 
macrophages.67 
Mox macrophages and M4 macrohages
In 2010, Kadl et al. showed the existence of a new macrophage subset, Mox 
macrophages.52 Mox macrophages are induced by oxidized phospholipids, such 
as 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (oxPAPC), which 
generates a population of macrophages that express high levels of anti-oxidants, 
such as heme oxygenase-1, sufiredoxin-1 and thioredoxin reductase 1, and IL-10 and 
vascular endothelial growth factor (VEGF). Although Mox macrophages are found in 
aortas of LDLr-/- mice fed a Western-type diet for 30 weeks, their exact contribution to 
the pathogenesis of atherosclerosis remains unclear. 
Another newly discovered macrophage subset, the M4 macrophage, is induced upon 
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CXCL4 stimulation and is identified by the expression of high levels of CD86, tumor 
necrosis factor superfamily (TNFSF) 10, mannose receptor C type 1 (Mrc1), CC 
chemokines ligand (CCL) 18, CCL22, and low levels of CD36 and IL-10.53 It has been 
shown that M4 macrophages have an impaired capacity to phagocytose acLDL or 
oxLDL but studies showing their role in atherosclerosis are lacking.
Dendritic cells
Dendritic cells (DCs) are the most specialized antigen presenting cells that are required 
for the stimulation and differentiation of naive T cells and the development of antigen-
specific T cell-mediated immune responses.68 Immature dendritic cells (imDCs) patrol 
peripheral tissues, such as the artery wall, in search of antigens.34, 69 Following the 
recognition and uptake of the antigen by phagocytosis, imDCs exit the non-lymphoid 
tissues and migrate via the afferent lymphatic vessels to the T cell rich area of a 
draining lymph node. During the migration imDCs gradually differentiate into mature 
DCs (maDCs). Maturation of the DCs involves the downregulation of endocytic activity 
and the upregulation of some surface molecules, such as chemokine receptor CCR7, 
costimulatory molecules CD40, CD80 and CD86 and antigen presenting molecules, 
including MHC I and II and CD1 molecules.70 Once resident in the lymph nodes, 
the maDC presents its antigen via the MHC I/II molecules to naive and memory T 
cells, resulting in an adaptive immune response. The presence of both costimulatory 
and antigen presenting molecules on maDCs is required for T cell activation and 
differentiation into effector cells. MaDCs are also capable of activating natural killer T 
(NKT) cells by presentation of endogenous lipids via the CD1d molecule.48 While it is 
generally believed that imDCs migrate towards lymphoid organs during maturation, 
some DCs may stay behind in the atherosclerotic lesion and form clusters with T cells 
or NKT cells. This cluster formation in rupture-prone regions is associated with plaque 
destabilization.70, 71 The NKT cells secrete Th1 cytokines, such as IFN-γ, which may 
promote instability of the plaque by the inhibition of smooth muscle cells and their 
collagen synthesis.72, 73 
Numerous studies have shown the importance of DCs in atherosclerosis. The number 
of DCs increases with the progression of atherosclerosis in ApoE-/- mice.74, 75 Wu et al. 
showed that CD11c-/-ApoE-/- mice fed a Western-type diet have reduced atherosclerosis 
with a concomitant attenuation of lesional macrophages.76 Additionally, Paulson et al. 
showed that CD11c-diphtheria toxin receptor (DTR) LDLr-/- mice fed a cholesterol-rich 
diet for 5-10 days have a 55% reduced intimal lipid area in comparison with non-
depleted mice.77 In contrast, depletion of DCs in either chow fed or hypercholesterolemic 
CD11c-DTR ApoE-/- mice, does not affect atherosclerotic lesion size, while cholesterol 
levels are significantly enhanced.78 However, CD11c is not a unique marker for DCs, 
since it can also be found on macrophages and more specifically on foam cells, which 
complicates the outcome of these studies.79 Habets et al. used another approach to 
study DCs in atherosclerosis by vaccinating LDLr-/- mice with oxLDL-pulsed maDCs. 
These mice showed a dramatic reduction of atherosclerosis, due to increased plaque 
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stability, lowered plasma cholesterol levels, enhanced oxLDL-specific T cell responses 
and increased titers of oxLDL-specific IgG, which participates in immune-complex 
formation and reduces foam cell development.80 
Several subtypes of DCs have been described. Intimal DCs can be generated either 
from monocytes in an Flt3/Flt3 ligand-independent manner, the so-called ‘classical’ 
DC81, or from monocyte-independent precursors in an Flt3/Flt3 ligand-dependent 
manner, which represents the ‘non-classical DC’.82-84 Deficiency of Flt3 and thus a 
deficiency in non-classical DCs, enhances atherosclerosis in LDLr-/- mice through 
reduced Tregs and increased IFN-γ and TNFα levels.85 This suggests that non-classical 
DCs are tolerogenic, which means they are capable to suppress the immune system. 
Because tolerogenic DCs can inhibit inflammation, they are of particular interest 
for the prevention of atherosclerosis. Hermansson et al. treated human ApoB-100 
transgenic LDLr-/- mice with human ApoB-100 and IL-10 pulsed DCs.86 Treatment with 
these human apoB-100 loaded tolerogenic DCs attenuated atherosclerosis with 70% 
through reduced splenocyte proliferation, as a consequence of induced Tregs, which 
dampened Th1 and Th2 responses. Another subset of DCs, the plasmacytoid DCs 
(pDCs), mainly responds to viruses by the production of type I interferons but can 
also act as tolerogenic DCs.87 Daissormont et al. showed that depletion of pDCs by 
120G8 mAb administration results in increased atherosclerosis in LDLr-/- mice as a 
consequence of increased T cell proliferation and increased IFN-γ secretion.88 
T cells
After exposure to antigens via DCs in lymphoid organs, naive T cells undergo clonal 
expansion and differentiate into effector T cells. Upon re-activation of T cells by 
interaction with lesional macrophages or DCs, they produce large amounts of pro-
atherogenic cytokines that contribute to both the growth and destabilization of 
lesions, which can result in rupture of the lesion. To recognize antigens presented 
on MHC molecules of APCs, T cells express a T cell receptor (TCR). Depending on 
the composition of their TCR, T cells are divided in two subsets; γδ T cells and αβ 
T cells. γδ T cells represent a minor subset of T cells that are mainly known for 
their role in innate immunity against pathogens.89 High numbers of γδ T cells are 
present in gut and lung mucosa and they are triggered by antigens produced by 
stressed and damaged cells. Although γδ T cells also recognize lipid antigens, their 
role in atherosclerosis remains to be elucidated. The majority of T cells has a TCR 
consisting of an α- and β-chain and can in turn be divided into CD4+ and CD8+ T cells. 
Whereas CD4+ T cells recognize antigens presented on MHC II molecules, CD8+ T cells 
recognize antigens presented on MHC I. Besides the formation of the TCR-antigen 
complex, two other signals are required for optimal T cell activation; costimulation 
and cytokines. Costimulatory molecules on both the APCs and T cells must interact and 
can either provide costimulatory or coinhibitory signals. Signaling via costimulatory 
ligand/receptor pairs results in the activation of immune cells, whereas signaling 
through coinhibitory pairs blocks immune cell function. There are many costimulatory 
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and coinhibitory pathways and each pathway has its own unique effect on the fate 
of individual immune cells, which will be further discussed in Chapter 2. Strongly 
depending on the cytokine environment, naive CD4+ T cells differentiate into various T 
cell subsets, such as Th1 cells, Th2 cells, Th17 cells and Tregs, with each a distinct set 
of cytokines that is released upon activation (Figure 5). Nowadays, new T cell subsets 
are discovered, such as Th9 cells and Th22 cells and accumulating evidence suggests 
that the differentiation of CD4+ T cells displays plasticity.90, 91
CD8+ T cells
Cytotoxic CD8+ T cells can induce apoptosis in target cells via the release of the 
cytotoxins perforin and granzymes. Once activated CD8+ T cells can also produce 
large amounts of the pro-inflammatory cytokine IFN-γ.92 CD8+ T cells are present in 
atherosclerotic plaques of mice but their role in atherosclerosis is controversial.93, 94 
Kolbus et al. showed that CD8+ T cells are especially activated during initial stages of 
atherosclerosis in ApoE-/- mice95, and in humans, CD8+ T cells represented up to 50% 
of the lymphocytes in advanced atherosclerotic lesions and upon TCR and/or pro-
inflammatory cytokine activation could migrate into healthy or mildly affected sites 
of the vasculature.96 Mice deficient in MHC I show enhanced atherosclerosis, which 
suggests a possible role for CD8+ T cells in the development of atherosclerosis.97 
Recently, Chyu et al. showed that CD8+ T cells mediate the atheroprotective effect 
Figure 5. Naive T cells are activated by dendritic cells in lymphoid organs and differentiate into effector 
T cells. There are many effector T cell subsets known and a combination of costimulatory and coinhibitory 
molecules together with the present cytokine environment determines which T cell subset is formed. 
Adapted from Lahoute et al. Nat. Rev. Cardiol. 2011;8:348.
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of ApoB-100 related peptide immunization in ApoE-/- mice.98 In contrast, Elhage et 
al. showed that a deficiency in CD8 does not affect atherosclerosis development in 
ApoE-/- mice.99 
CD4+ T cells
CD4+ T cells are present in different stages of human plaques100, 101 and are also found 
in atherosclerotic lesions of both ApoE-/- and LDLr-/- mice.94 A deficiency in CD4+ T 
cells102-104 or TCRαβ cells105 and thus a deficiency in adaptive immunity leads to reduced 
atherosclerosis. In addition, a transfer of CD4+ T cells to immune-deficient SCID-/-
ApoE-/- mice accelerates atherosclerosis, indicating the importance of CD4+ T cells in 
atherosclerosis.104 Naive CD4+ T cells differentiate into various T cell subsets, such as 
Th1 cells (producing TNFα, IFN-γ, IL-1, IL-12 and IL-18), Th2 cells (producing IL-4, 
IL-5 and IL-13), Th17 cells (producing IL-6, IL-17 and IL-23) and Tregs (producing 
TGF-β and IL-10), which will be discussed below in more detail.
Th1 cells
Th1 cells produce pro-inflammatory cytokines, such as IFN-γ and TNFα, and express 
the Th1 specific transcription factor T-box expressed in T cells (T-bet). The majority 
of the pathogenic CD4+ T cells in atherosclerosis are Th1 cells. High levels of IFN-γ 
stimulate the recruitment of macrophages, DCs and T cells to the plaque, increase 
lipid uptake by macrophages and activate APCs.106, 107 In addition, IFN-γ inhibits 
vascular smooth muscle cell proliferation and reduces collagen production, thereby 
contributing to the instability of the fibrous cap. Correspondingly, LDLr-/- mice deficient 
in T-bet108 or ApoE-/- mice deficient in IFN-γ109 show attenuated atherosclerosis. In 
addition, deficiencies in other cytokines secreted by Th1 cells, such as TNFα110, IL-
1β111, IL-12112 or IL-18113, also reduced atherosclerotic lesion development. 
Th2 cells
Th2 cells are known to produce IL-4, IL-5 and IL-13, and are recognized by the 
expression of the transcription factor Trans-acting T-cell-specific transcription factor-3 
(GATA-3). Th2 cells also provide help to B cells and promote their differentiation 
into plasma cells. The role of Th2 cells in atherosclerosis remains controversial and 
depends on the stage of the lesion, as well as on the experimental mouse model.114, 
115 Several studies show an anti-atherogenic role for Th2 cells, since IL-4 secretion 
inhibits pro-atherogenic Th1 responses via downregulation of IFN-γ production. 
Furthermore, C57Bl/6 mice injected with IL-4 and BALB/c mice prone to Th2 immune 
responses are protected against early fatty streak formation.115 Other studies have 
shown that IL-5, another characteristic Th2 cytokine, reduces plaque formation 
in LDLr-/- mice in part by promoting oxLDL-specific IgM secretion by B1 cells.116 
Miller et al. showed that IL-33, a powerful inducer of Th2 responses, reduces the 
development of atherosclerosis in ApoE-/- mice via IL-5 and subsequent oxLDL-specific 
IgM antibody formation.117 Recently, Cardilo-Reis et al. showed that IL-13 deficiency 
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accelerates atherosclerosis in LDLr-/- mice and that IL-13 administration increased 
collagen content and reduced VCAM-1-dependent monocyte recruitment, resulting in 
decreased lesional macrophages.118 Moreover, IL-13 induced M2 macrophages, which 
exhibited increased clearance of oxLDL in comparison with M1 macrophages. 
In contrast, Th2 cells can also fulfill a pro-atherogenic role, since LDLr-/- mice and 
ApoE-/- mice deficient in IL-4 have reduced atherosclerosis.112, 119 In addition, van 
Wanrooij et al. showed that blockade of the costimulatory OX40-OX40L pathway 
reduces initial atherosclerosis in part via decreased IL-4 levels.120 Notably, IL-5 levels 
and oxLDL-specific IgM responses were increased in this study, which suggests a pro-
inflammatory role for IL-4 and an anti-inflammatory role for IL-5. In fact, IL-4 and IL-5 
are differentially regulated at the transcriptional level. Whereas differentiation of IL-
4-producing T cells is dependent on STAT6121 and GATA-3122, Kurowska et al. showed 
that IL-5-producing T cells differentiate independently of STAT6 and GATA-3.123 This 
shows that Th2 cells do not exclusively secrete the complete panel of typical Th2 
cytokines but may form specific subsets that secrete either IL-4 or IL-5, which might 
determine the pro- or anti-atherogenic fate of these cells.
Th17 cells
Another subset of CD4+ T cells are Th17 cells, which mainly produce the pro-
inflammatory cytokine IL-17. The differentiation of Th17 cells is mainly driven by the 
transcription factor RORγt and the cytokines TGF-β and IL-6.124-126 IL-17 induces tissue 
inflammation and is therefore commonly associated with autoimmune diseases.127, 128 
However, the role of Th17 cells in atherosclerosis has not been fully elucidated yet. 
In humans, IL-17 is upregulated in atherosclerotic plaques of symptomatic patients 
compared to plaques from asymptomatic patients.129-131 In mice, the expression of 
IL-17 and RORγt also correlated to plaque size132 and IL-17A-expressing T cells were 
significantly increased in the aorta and spleen of aged ApoE-/- mice compared with 
C57BL/6 mice.133 Furthermore, a deficiency in the IL-17R134 or blockade of IL-17 by 
using neutralizing antibodies132, 135 or by use of adenovirus-produced soluble IL17-
RA133 reduces atherosclerosis, while exogenous IL-17 promotes the formation of 
atherosclerotic lesions. Conversely, Madhur et al. showed that an IL-17A deficiency 
in ApoE-/- mice fed a Western-type diet for 12 weeks does not affect plaque burden, 
whereas it does decrease aortic CD3+ T cells and IFN-γ production by splenocytes.136 
Taleb et al. also did not observe an effect of IL-17 neutralization on atherosclerosis, 
although they do describe a protective role for IL-17 in a mouse model in which 
suppressor of cytokine signaling (SOCS) 3 was absent in T cells.137 These conflicting 
results show the need for more research to determine the exact role of Th17 cells in 
atherosclerosis. 
Regulatory T cells
Regulatory T cells (Tregs) play an important role in the regulation of immune responses 
through suppression of immune cell proliferation and cytokine production. Suppression 
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mainly occurs through secretion of the inhibitory cytokines IL-10 and TGF-β, and 
cell-cell contact, mediated by membrane-bound TGF-β, CTLA-4 and/or GITR.138, 139 
In mice, Tregs are characterized by the expression of the surface molecules CD4 and 
CD25, and expression of the transcription factor Forkhead box protein P3 (Foxp3).140 
Tregs can be divided into two subsets, natural occurring Tregs and adaptive Tregs. 
Natural occurring Tregs are derived from thymocytes during negative selection 
in the thymus as part of a tolerance mechanism.141, 142 The tolerance mechanism 
deletes unmatured T- or B cells in the thymus that recognize self antigens with a 
high affinity. However, some self-reactive lymphocytes escape from this mechanism 
and have to be controlled by peripheral tolerance.143 In the thymus, thymocytes with 
low affinity for self antigens are positively selected and released. Thymocytes with 
intermediate affinity for self antigens upregulate the transcription factor Foxp3 and 
become Tregs.144 In the secondary lymphoid tissues and at sites of inflammation these 
Tregs function by regulating self-reactive T cell responses.145 Naturally occurring Tregs 
express CD4, CD25 and Foxp3 and secrete IL-10 and TGF-β. Adaptive or induced 
Tregs are generated from naive T cells after stimulation by tolerogenic DCs and/or in 
the presence of IL-10 and TGF-β. Adaptive Tregs can be subdivided in T regulatory 
type 1 (Tr1) and Th3 cells. Tr1 cells suppress mainly through IL-10, whereas Th3 cells 
function via TGF-β production.146-151 
Foxp3 is crucial for the development and function of Tregs. The mechanism underlying 
the role of Foxp3 in the suppressive function of Tregs remains to be fully understood, 
but recently it is shown that Foxp3 is part of a large molecular complex that represses 
transcription of target genes, such as nuclear factor of activated T cells (NFAT) and 
nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB), that are involved 
in the TCR signaling pathway.152 Additionally, Foxp3 also upregulates the expression 
of genes such as IL-2Rα (CD25) and glucocorticoid-induced tumor necrosis factor 
receptor (GITR), which are essential for the function of Tregs.153, 154 
The delicate balance between the pro- and anti-inflammatory signals can be disturbed 
when Tregs are deficient or dysfunctional, ultimately leading to severe autoimmune 
diseases or pathogen-induced inflammation.142, 155 In atherosclerosis an imbalance 
between pro-inflammatory cells, such as Th1 cells, and anti-inflammatory cells 
(Tregs) exists, with increased numbers of the first. In addition, oxLDL attenuates the 
suppressive function of Tregs.156 Therefore, increased Treg numbers may be beneficial 
for patients suffering from atherosclerosis. The role of Tregs in atherosclerosis has 
been subject of intense investigation (Figure 6). Adoptive transfer of CD4+CD25+ T 
cells causes a reduction in atherosclerotic lesion development157 while a depletion of 
CD4+CD25+ T cells aggravates lesion development.157, 158 Furthermore, an increase in 
the number of antigen-specific Tregs via induction of oral tolerance to oxLDL and heat 
shock protein 60 (HSP60) was associated with reduced atherosclerosis.159, 160 IL-10 
produced by Tregs attenuates plaque formation6, 15, 161 and similarly Tr1 induced immune 
responses in ApoE-/- mice resulted in a decreased plaque size and inflammation.162 
Deficiencies in total or T cell specific TGF-β signaling accelerates atherosclerosis and 
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induces an unstable plaque phenotype in hypercholesterolemic mice.163, 164 
Whereas the atheroprotective role of Tregs in mice is well-established, the role of 
human Tregs in atherosclerosis remains to be clarified. Foxp3+ cells are found in human 
atherosclerotic plaques165, 166 and low levels of circulating human Tregs are associated 
with an increased risk for the development of myocardial infarction.167 Additionally, 
simvastatin significantly enhanced the quantity and suppressive function of Tregs in 
peripheral blood mononuclear cells (PBMCs) isolated from patients with acute coronary 
syndrome, which might contribute to the immunomodulatory mechanism of statins.168 
It must be noted that while Foxp3 is a commonly used marker for Treg identification, 
Foxp3 is also expressed in CD8+ T cells169 and macrophages.170 New markers for the 
characterization of Tregs are extensively investigated and the use of Tregs as a new 
immune therapy to modulate pro-inflammatory immune responses in atherosclerosis 
needs to be further explored. 
B cells
B cells are essential players in humoral immune responses and during atherosclerosis 
they are mainly present in the adventitia of lesions.171, 172  “Atherosclerotic” B cells  produce 
antibodies specific for self-antigens, such as oxLDL, HSP60 and β2-glycoprotein, and 
for bacterial antigens, such as Streptococcus and Chlamydia. Autoantibodies against 
many of these antigens have been found in humans with coronary heart disease 
Figure 6. Tregs regulate pro-inflammatory immune responses via several mechanisms in atherosclerosis. 
Tregs have an elevated expression of coinhibitory molecules, such as CTLA-4, through which they can 
directly inhibit pro-atherogenic T cells or dendritic cells. Indirectly, Tregs inhibit immune responses via 
the secretion of the anti-inflammatory cytokines IL-10, TGF-β and IL-35. These cytokines can skew 
macrophages towards an anti-inflammatory M2 phenotype and inhibit foam cell formation. Adapted from 
Lahoute et al. Nat. Rev. Cardiol. 2011;8:348.
Chapter 122
and in animal models of atherosclerosis, and titers of oxLDL-specific antibodies are 
directly correlated with the severity of disease. Initial studies showed that B cells are 
atheroprotective, since B cell deficiency aggravates atherosclerosis in LDLr-/- mice173 
and adoptive transfer of splenic B cells decreases atherosclerosis in ApoE-/- mice.174 In 
mice, several B cell subsets are identified: B1, B2 and B10 cells. B1 cells are a subset 
of B cells that are predominantly found in peritoneal cavities116, 175 and secrete oxLDL-
specific IgM antibodies upon IL-5 stimulation.176 OxLDL-specific IgM plays a protective 
role in atherosclerosis because it prevents foam cell formation by inhibiting oxLDL 
uptake by macrophages, helps to clear apoptotic cells and prevents inflammatory 
reactions towards oxLDL and other modified lipids.176, 177 Furthermore, IL-5 deficiency 
enhances atherosclerosis via decreased oxLDL-specific IgM titers and IL-33 protects 
against atherosclerosis through the induction of B1 cells.117, 178 In contrast to anti-
atherogenic B1 cells, B2 cells promote atherosclerotic lesion development.179, 180 B2 
cells are conventional B cells found in spleen and lymph nodes that produce low levels 
of IgM and high levels of IgD. Depletion of B2 cells using an anti-CD20 antibody 
ameliorated atherosclerosis, whereas adoptive transfer of B2 cells aggravates 
atherosclerosis. Therefore, future immune therapy to inhibit atherosclerosis may also 
focus on promoting B1 cells and inhibiting B2 cells. Recently, a third subset of B cells 
has been described; B10 cells or so-called IL-10 producing regulatory B cells (Bregs).181 
The exact role of Bregs in atherosclerosis has not been clarified yet, however, Bregs 
secrete IL-10 and thereby inhibit secretion of pro-inflammatory cytokines and support 
Treg differentiation, which indicates a protective role for Bregs in atherosclerosis. 
Mast cells
Another important key player in atherosclerosis is the mast cell. Activated mast cells 
are found in the adventitia of vulnerable and ruptured lesions of patients suffering 
from myocardial infarction182, 183, and mast cell numbers correlate with the incidence of 
plaque rupture and erosion.182 In addition, Bot et al. showed that mast cells also play 
a crucial role in plaque progression and destabilization.184 Mast cells are derived from 
bone marrow and circulate as precursors in the blood where they contribute to the 
first line of defense against pathogens, such as bacteria and parasites. Once recruited 
to specific tissues such as the skin, they mature into mast cells. Their most important 
function is the release of cytoplasmatic granules upon stimulation with various 
immunologic and nonimmunologic agents, such as IgE. In atherosclerotic lesions, 
mast cells can be activated by oxLDL-IgG immune complexes185 and neuropeptide 
substance P.186 The released granules contain inflammatory compounds, such as 
histamine, tryptase, chymase, TNFα, IL-6 and VEGF that promote lesion development 
and increase lesion instability.187, 188 The secretion of pro-inflammatory cytokines 
enables mast cells to act as so-called ‘non-professional’ APCs and to induce T cell 
responses.189 Mast cells can also secrete the cytokine IL-8 and the chemokine MCP-1, 
which attract immune cells to the site of inflammation and further promote the immune 
response.185 In addition, mast cells are directly involved in the lipid metabolism, as 
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several studies show that mast cell granules and their released compounds, such as 
heparin, can bind to LDL particles.190
Neutrophils
Neutrophils are classically described as the first cells to respond to pathogens, tissue 
damage or inflammation. Neutrophils are characterized by their surface expression 
of CD11b and Gr-1, Ly6G in particular. Upon activation, neutrophils release pro-
inflammatory mediators, such as myeloperoxidase (MPO), elastase, azurocidin and 
cathelicidin, from their granules. All these mediators are involved in atherosclerosis 
development. MPO for example promotes the formation of oxLDL191 and MPO serum 
levels are associated with a higher risk for the development of coronary artery 
disease.192, 193 
However, neutrophils are rarely detected in human and murine atherosclerotic lesions, 
which is possibly due to their life-span of approximately 5-8 hours and rapid apoptosis 
upon activation.194 Nonetheless, neutrophils have been found in subendothelial and 
intimal areas of early atherosclerotic lesions in mice195-197, as well as in plaque shoulder 
areas of rupture-prone lesions.196, 197 In humans, intraplaque neutrophils are mainly 
located in the fibrous cap, the shoulder, the interface to media and in areas with 
intraplaque bleeding.198 
Drechsler et al. showed that lesion sizes positively correlate with circulating neutrophils 
and depletion of neutrophils using the antibody 1A8 recognizing CD11b+Ly6G+ cells 
reduces early atherosclerosis in ApoE-/- mice.195 Additionally, Zernecke et al. show 
that administration of the anti-PMN antibody also reduced initial atherosclerosis.199 
However, the development of advanced lesions remained unaffected by neutropenia 
as depletion of neutrophils after 3 or 11 months of high-fat diet feeding did not reduce 
lesion formation.195 More specifically, neutrophils contribute in a variety of ways to 
the pathogenesis of atherosclerosis; neutrophils aggravate endothelial dysfunction, 
attract monocytes into atherosclerotic lesions, activate macrophages to produce 
pro-inflammatory cytokines, and can destabilize the lesion.200 Interestingly, statins 
have been shown to interfere with neutrophil function via the reduction of neutrophil 
recruitment and activation, and lowering of neutrophil-attracting chemokines.201, 202 
More research is needed to fully describe the role of neutrophils in atherosclerosis. 
MDSCs
Similar to neutrophils, myeloid-derived suppressor cells (MDSCs) express the myeloid 
cell markers Gr-1 and CD11b.203 MDSCs originate from the bone marrow and consist 
of early myeloid progenitor cells and immature myeloid cells. In healthy individuals 
these immature cells mature into granulocytes, dendritic cells and macrophages. In 
diseased individuals this maturation is blocked and the immature cells expand to a 
large population of MDSCs that migrate into lymphoid organs and inflamed tissues 
where they strongly suppress immune responses.
Two different subtypes of MDSCs are described: granulocytic-MDSCs (gr-MSDCs),
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which are CD11b+Ly6G+Ly6Clow, and monocytic-MDSCs (mo-MSDCs), which are 
CD11b+Ly6G-Ly6Chi.204  Although both subtypes can suppress T cell responses, it has 
been well documented that mo-MDSCs exhibit more potent suppressive activity than 
gr-MDSCs.204-206 Interestingly, whereas mo-MDSCs are driven by Th1 signals207, such 
as IFN-γ and LPS, gr-MDSCs are driven by Th2 cytokines, such as IL-4, IL-10 and IL-
13.208
MDSCs particularly suppress T cell function via upregulation of their expression of 
immune suppressive factors, such as inducible nitric oxide synthase (iNOS), arginase 
1 (arg-1), nitric oxide (NO) and reactive oxygen species (ROS) (Figure 7).209, 210 iNOS 
activity is mainly associated with mo-MDSCs as IFN-γ can induce iNOS expression and 
arg-1 is mostly linked to gr-MDSCs. Both iNOS and arg-1 compete for their common 
substrate L-arginine. iNOS consumes L-arginine to NO, which renders T cells non-
responsive to IL-2. In contrast, arg-1 converts L-arginine to urea and polyamines, 
which reduces the availability of L-arginine and subsequently impairs T cell function 
by loss of CD3ζ expression. Both arg-1 and iNOS can generate ROS, which inhibits 
T cell function via nitration of the T cell receptor that impairs the T cell-antigen-MHC 
interaction.209 Moreover, MDSCs can also promote de novo development of Foxp3, 
which results in elevated Tregs that also very efficiently suppress effector T cells.211 
Figure 7. MDSC-mediated T cell suppression. MDSCs can suppress T cells via different mechanisms. 
MDSCs can induce Tregs (A), suppress T cell proliferation in an L-arginine-mediated manner (B), render T 
cells unresponsive for IL-2 via iNOS and NO/reactive oxygen species (C), and can induce T cell apoptosis 






Besides regulating adaptive immune responses, MDSCs can also affect innate immune 
responses as they can stimulate macrophages to produce IL-10 and to reduce IL-12 
secretion.212
MDSCs have been extensively investigated in the context of cancer but their contribution 
to other diseases is only recently appreciated. MDSCs suppressed inflammation in 
obese mice213 and in a mouse model for MS214 and prevented type 1 diabetes215 and 
graft versus host disease.216 However, no studies describe the role or existence of 
MDSCs in atherosclerosis. 
Outline of the thesis
Patients suffering from cardiovascular disease are treated with statins to lower LDL 
cholesterol. However, these drugs have very little effect on established lesions, which 
emphasizes the requirement for novel experimental therapies to treat atherosclerosis. 
In this thesis, several therapeutic strategies are used to modulate the immune response 
in atherosclerosis. Pro-inflammatory responses responsible for atherosclerosis can be 
suppressed by modulation of costimulatory and coinhibitory pathways or induction 
of suppressor cells, such as regulatory T cells and myeloid-derived suppressor cells.
Costimulatory and coinhibitory molecules tightly control immune responses by 
providing positive signals that promote T cell activation or by transducing inhibitory 
signals that limit T cell responses. Chapter 2 provides an overview on the current 
status of research on costimulatory and coinhibitory pathways in atherosclerosis. 
In Chapter 3, a combined anti-inflammatory and lipid-lowering strategy was used to 
induce regression of atherosclerosis. Interruption of the costimulatory OX40-OX40L 
pathway reduces IgE serum levels and mast cell activation, induces atheroprotective 
IL-5 and oxLDL-specific IgM and in combination with dietary adjustments can induce 
regression of advanced lesions. 
Chapter 4 describes a study in which the role of the costimulatory pathway formed 
by CD30 and CD30L, members of the TNF(R) superfamily involved in activation and 
proliferation of T and B cells, is determined in atherosclerosis. Treatment with anti-
CD30L inhibits plaque development with 35% in LDLr-/- mice solely by modulation of 
T cell responses. 
Chapter 5 describes a study in which the role of the coinhibitory T cell immunoglobulin 
and mucin domain 3 (Tim-3) in atherosclerosis was investigated. Treatment of LDLr-/- 
mice with a Tim-3 blocking antibody increased atherosclerosis development with 35% 
in the aortic root and with 50% in the aortic arch compared with control treatment, by 
increasing circulating monocytes and lesional macrophages, and by decreasing IL-10 
producing regulatory T and B cells. 
In Chapter 6, the contribution of another new-emerging negative costimulatory 
pathway formed by T cell immunoreceptor with Ig and ITIM domains (TIGIT) and 
the poliovirus receptor (PVR) was determined in the pathogenesis of atherosclerosis. 
Signaling through the TIGIT-PVR pathway can inhibit T cell responses in a cell-intrinsic 
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manner as well as via the induction of IL-10 producing tolerogenic DCs. However, 
although agonistic TIGIT significantly affected T cell proliferation and activation in 
vitro and in vivo, agonistic TIGIT treatment did not significantly affect atherosclerosis 
development. 
Regulatory T cells are important regulators of immune responses and show great 
potential to be used as a therapeutic regime. In Chapter 7, the protective role of 
Foxp3+ Tregs in atherosclerosis was investigated. Vaccination using dendritic cells 
which were electroporated with mRNA encoding for Foxp3, decreased the number of 
Foxp3+ regulatory T cells leading to an increase in lesion formation in LDLr-/- mice. In 
addition, an increase in plaque cellularity and spleen cell proliferation was observed. 
In Chapter 8, administration of an IL-2-anti-IL-2 complex to Western-type diet fed 
LDLr-/- mice significantly expanded regulatory T cells up to 10-fold in the circulation and 
several (lymphoid) organs. This expansion of regulatory T cells potently suppressed 
effector T cells and reduced initial atherosclerotic lesion formation, whereas, in 
combination with a vigorous lowering of blood lipid levels, it enhanced lesion stability 
in LDLr-/- mice with pre-existing lesions.
Myeloid-derived suppressor cells (MDSCs) are potent suppressors of T cell responses 
in tumor immunology but their contribution to other diseases, such as EAE and type 
1 diabetes, is only recently appreciated. To investigate whether and how MDSCs 
contribute to the development of atherosclerosis, in Chapter 9, we isolated bone 
marrow-derived CD11b+Gr-1+ cells (MDSCs) from Western-type diet fed LDLr-/- mice 
and adoptively transferred them into LDLr-/- mice fed a Western-type diet for 6 weeks. 
Mice that received MDSCs showed a 35% reduction in atherosclerotic lesion formation 
with a concomitant reduction in T and B cell responses. 
Finally, all the results obtained in this thesis and future perspectives are summarized 
and discussed in Chapter 10.
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Abstract
Mortality from cardiovascular disease continues to increase worldwide despite the 
use of statins, anti-thrombotic drugs, and anti-hypertensive treatment. This indicates 
an urgent need for novel therapeutic strategies to inhibit atherosclerosis and to 
prevent cardiovascular complications and acute syndromes. T cells play a major role 
in the pathogenesis of atherosclerosis by promoting inflammation and destabilizing 
advanced lesions, and are regulated by a network of costimulatory and coinhibitory 
molecules. Costimulatory signals can promote T cell survival, cell cycle progression 
and differentiation of naive T cells to effector and memory T cells, whereas coinhibitory 
molecules can terminate these processes directly or indirectly via the induction of 
regulatory T cells. The immune system provides a large diversity of costimulatory and 
coinhibitory pathways and each pathway has its own unique effect on the behaviour of 
individual immune cells. This offers unique possibilities to regulate pro-inflammatory 
immune responses in atherosclerosis. In this review we provide an overview of 
costimulatory and coinhibitory pathways in atherosclerosis and their potential as 
therapeutic targets to treat or prevent cardiovascular disease.
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Atherosclerosis
Acute cardiovascular syndromes, such as myocardial infarction or stroke, are a 
major cause of death in Western society and are generally caused by rupture of 
an atherosclerotic plaque.1 Atherosclerosis is a chronic autoimmune-like disease 
resulting from endothelial damage and dysfunction, and cholesterol accumulation in 
the arterial wall. Atherosclerosis mostly occurs in medium- and large-sized arteries, 
already starts in early adolescence and progresses slowly.2, 3 Depending on exposure 
to risk factors including high fat intake, hypertension, smoking, stress and physical 
inactivity, and diseases such as obesity, diabetes and dyslipidemia, atherosclerotic 
lesions can lead to acute thrombotic complications and subsequent clinical events.
For many years it was believed that atherosclerosis was a ‘passive’ lipid disorder 
in which cholesterol accumulated in the arterial wall. However, the mechanism 
underlying the pathological process of atherosclerosis is much more complicated 
and the involvement of inflammatory cells in the development and progression of 
atherosclerosis was suggested after the discovery of T cells in atherosclerotic lesions 
in the 1980s.4 Patients suffering from cardiovascular disease are currently treated 
with statins to lower low-density lipoprotein (LDL) cholesterol. However, since these 
drugs lead to a 30% risk reduction in cardiovascular patients, there is an urgent need 
for new therapeutic strategies that target its inflammatory nature directly, to inhibit 
atherosclerosis and to prevent acute cardiovascular syndromes. 
The immune system in atherosclerosis
Besides lipid accumulation, inflammation is considered a key process in atherosclerotic 
plaque development and in the pathogenesis of plaque rupture.5, 6 Atherosclerosis 
involves both innate and adaptive immune responses. The innate immunity is 
the initial barrier against infections and several immune cells such as monocytes, 
macrophages, dendritic cells (DCs), neutrophils, natural killer (NK) cells and mast 
cells are programmed to detect foreign molecules of exogenous (eg lipopolysaccharide 
(LPS)) or endogenous (eg oxidized LDL (oxLDL) and heat shock protein (HSP) 60) 
origin.7 These foreign molecules are called pathogen-associated molecular patterns 
(PAMPs) and are recognized by the innate immune cells via pattern recognition 
receptors such as Toll-like receptors (TLRs) and Scavenger receptors (SRs).8 The 
pathogens are internalized and degraded by phagocytosis. Adaptive immune 
reactions are initiated when antigen-presenting cells (APCs), such as macrophages 
and DCs, display a surface complex consisting of an antigenic peptide bound to a 
major histocompatibility complex protein class I or class II (MHC I or MHC II) to a T 
or B cell. This leads to cytokine secretion, cytotoxicity, antibody production, memory 
formation and stimulation of many other components of an immune reaction.6 
T cells in atherosclerosis
To recognize antigens presented on MHC molecules of APCs, T cells express a T cell 
receptor (TCR). Depending on the composition of their TCR, T cells are divided in two 
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subsets; γδ T cells and αβ T cells. γδ T cells represent a minor subset of T cells that are 
mainly known for their role in innate immunity against pathogens.9 High numbers of 
γδ T cells are present in gut and lung mucosa and are triggered by antigens produced 
by stressed and damaged cells. Although γδ T cells also recognize lipid antigens, their 
role in atherosclerosis remains to be elucidated. The majority of T cells has a TCR 
consisting of an α- and β-chain and can be separated into CD4+ and CD8+ T cells. 
Whereas CD4+ T cells recognize antigens presented on MHC II molecules, CD8+ T cells 
recognize antigens presented on MHC I. 
For sustained and optimal T cell signaling, an immunological synapse is assembled at 
the interface of the T cell and an APC after the interaction of MHC-antigen complexes 
with the TCR. Initially, these MHC-antigen-TCR complexes are accumulated in a 
ring surrounding a central cluster of intercellular cell adhesion molecule-1 (ICAM-1) 
interactions with the integrin leukocyte function-associated molecule-1 (LFA-1).10, 11 
This immature immunological synapse transforms in a mature immunological synapse 
when the MHC-antigen-TCR complexes accumulate in the center via actin-mediated 
transport and are surrounded by a ring of ICAM-1/LFA-1 interactions. 
Besides the formation of the MHC-antigen-TCR complex (signal 1), two other signals 
are required for optimal T cell activation; costimulation (signal 2) and cytokines (signal 
3, Figure 1). Costimulatory molecules on both the APCs and T cells must interact and 
can either provide costimulatory or coinhibitory signals. Signaling via costimulatory 
ligand/receptor pairs results in the activation and proliferation of immune cells, 
whereas signaling through coinhibitory pairs blocks immune cell function. Naive 
T cells that only receive signal 1 without signal 2 become anergic or die through 












Figure 1. Schematic overview of optimal T cell activation. Three signals are required: (1) antigen 
presentation via MHC molecules on APCs to the TCR on T cells, (2) costimulatory or coinhibitory signaling, 
(3) environmental cytokines that can influence the T helper cell differentiation.
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receptor pairs triggers an accumulation of receptors and protein complexes at the 
center of the immunological synapse, which then amplifies and enhances the duration 
of TCR signaling.12 Strongly depending on signal 3, the cytokine environment, naive 
CD4+ T cells differentiate into various T cell subsets, such as Th1 cells, Th2 cells, Th17 
cells and Tregs, with each a distinct set of cytokines that is released upon activation. 
Thus, after exposure of antigens via APCs within the lesions or in lymphoid organs, this 
‘three signal model’ of T cell activation ensures the clonal expansion and differentiation 
of effector T cells. Upon activation T cells produce large amounts of pro-atherogenic 
cytokines that contribute to both the growth and destabilization of lesions, which can 
result in rupture of the lesion.
Costimulation and coinhibition of T cells
The immune system provides a large diversity of costimulatory and coinhibitory 
pathways (signal 2) and each pathway has its own unique effect on the fate of individual 
immune cells. Depending on the activation status of the cell, each costimulatory and 
coinhibitory molecule has its own expression pattern and thereby tightly regulates T 
cell function. Costimulatory signals can promote T cell survival, cell cycle progression 
and differentiation to effector and memory T cells, whereas coinhibitory molecules can 
terminate these processes directly or indirectly via the induction of regulatory T cells 
(Tregs). Tregs play an important role in the regulation of immune responses through 
suppression of immune cell proliferation and cytokine production.13, 14 
Costimulation can be provided in cis, meaning that both signal 1 and 2 are provided 
by the same APC, or in trans, in which signal 2 is provided by a different or so-called 
‘bystander’ APC than signal 1. During cis-costimulation both signal 1 and 2 are in close 
proximity, which results in a rapid and more efficient activation of the T cell compared 
with trans-costimulation.15 However, some studies suggest that trans-costimulation is 
as effective as cis-costimulation in the activation of T cells.16, 17 
Furthermore, several studies suggest that costimulatory molecules can elicit 
bidirectional signals that benefit both the interacting T cell and APC.18, 19 This ‘reverse 
signaling’ can provide costimulatory signals or cause anergy. Bidirectional signal 
transduction has been described for CD40L, CD137, OX40L, CD30L and LIGHT but the 
exact mechanism remains to be elucidated.19 
Most of the costimulatory and coinhibitory molecules belong to either the B720 or 
tumor necrosis factor (TNF)21 superfamilies. The B7 superfamily plays an important 
role in regulating T cell function and its members such as CD28, CTLA-4 and PD-1 are 
promising therapeutic targets. Members of the TNF superfamily, such as CD40L and 
OX40, also provide costimulation but additionally comprise molecules with cytoplasmic 
death domains which are involved in apoptosis. Not surprisingly, many of the known 
costimulatory and coinhibitory receptor-ligand pairs are expressed in atherosclerotic 
lesions22, 23 and all affect atherogenesis in various ways. In the next section, we will 
provide an overview of the different costimulatory and coinhibitory pathways and their 
role in the pathogenesis of atherosclerosis.
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Costimulatory pathways in atherosclerosis
Figure 2 provides an overview of costimulatory molecules of both the B7 and TNF(R) 
family that upon interaction contribute to the development of atherosclerosis. Each 
costimulatory molecule pair results in the proliferation and differentiation of T cells in 
a unique manner, which will be described in more detail.
The CD28-CD80/86 pathway 
The first identified and best characterized costimulatory molecules belonging to the 
B7 superfamily are CD80 (B7.1) and CD86 (B7.2) expressed on APCs, which bind to 
their receptor CD28 expressed on T cells, B cells, thymocytes and macrophages.24 
CD28 colocalizes with the TCR to form a TCR-CD28 microcluster which amplifies the 
phosphorylation of several molecules that play a role in T cell activation.25 CD28-
CD80/CD86 signaling is essential for the activation, proliferation, cytokine secretion 
and survival of T cells and in absence of CD28 costimulation, T cells become anergic 
and may eventually die.26 Several costimulatory molecules, such as OX40, ICOS and 
CD27, only exhibit low expression on naive T cells but are upregulated following TCR 
and CD28 signaling. To maintain homeostasis, CD28 can also bind CTLA-4, which 
in contrast to CD80/CD86 ligation can inhibit T cell responses. This pathway will be 
further discussed in another section. 
CD28, CD80 and CD86 are expressed on macrophages in human atherosclerotic 
lesions.22 Additionally, 5-15% of CD3+ T cells present in atherosclerotic lesions 
expressed CD80 and CD28. Furthermore, Dopheide et al. showed that monocyte-
derived DCs from patients with coronary artery disease have elevated expression of 
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Figure 2. Signaling via costimulatory pathways in atherosclerosis promotes T cell proliferation, 
differentiation and survival.
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CD80 and CD86 compared with DCs from healthy controls.27 
In experimental atherosclerosis it was shown that LDLr-/- mice deficient in CD80/CD86 
develop smaller atherosclerotic lesions in both initial and progressed atherosclerosis 
models compared with wild-type LDLr-/- mice.28 In initial lesions of LDLr-/-CD80-/-
CD86-/- mice reduced MHC II expression was found, whereas advanced lesions of 
these mice had reduced smooth muscle cell and collagen content compared with 
lesions from wild-type LDLr-/- mice. Additionally, Buono et al. showed that CD4+ T 
cells from LDLr-/-CD80-/-CD86-/- mice produced lower amounts of IFN-γ compared with 
LDLr-/- mice upon restimulation with HSP60. Interestingly, a two-fold increase in lesion 
size was observed in chimeric LDLr-/-CD80-/-CD86-/- and LDLr-/-CD28-/- mice due to 
decreased Tregs.29 This remarkable difference between a CD80/CD86 deficiency from 
birth and bone marrow chimeras of CD80 and CD86 was explained by the fact that 
in the bone marrow transplantation model CD80 and CD86 could still be expressed 
on nonhematopoietic cells after irradiation. Moreover, a deficiency in CD80 and CD86 
from birth could affect proliferation and activation of naive T cells, while T cells in 
chimeric LDLr-/-CD80-/-CD86-/- are less dependent on costimulation. 
The CD40-CD40L pathway 
CD40 (TNFRSF5) and CD40L (TNFSF5, CD154) form a special costimulatory dyad 
that not strictly mediate T cell costimulation, but mainly functions to activate APCs 
which subsequently upregulate the expression of other costimulatory molecules.30, 31 
Moreover, the expression of CD40L is not restricted to T cells and the expression of 
CD40 is not confined to the APC, suggesting functions of the CD40L-CD40 dyad other 
than mere costimulation.32, 33
The CD40L-CD40 pathway is one of the best-described costimulatory molecule pairs in 
the pathogenesis of atherosclerosis. In the mid ‘90s, it was found that both CD40L and 
CD40 are expressed on the vast majority of immune cells (T and B cells, monocytes, 
macrophages, DCs, neutrophils and mast cells) and non-immune cells (eg endothelial 
cells and vascular smooth muscle cells) present in the plaque, as well as on platelets 
in the circulation.33-35 Both CD40L and CD40 are already expressed in early stages of 
atherosclerosis. Their expression increases with plaque progression and is the highest 
in lesions with a thin fibrous cap and in ruptured plaques.35 
In 1998, Mach et al. showed in hyperlipidemic LDLr-/- mice that treatment with 
an anti-CD40L antibody significantly reduced the size and lipid content of aortic 
atherosclerotic lesions.36 In 1999, it was shown that CD40L-/-ApoE-/- mice exhibited 
a 5.5 fold decrease in plaque area37, and these mice displayed a remarkable plaque 
phenotype. Advanced atherosclerotic plaques of CD40L-/-ApoE-/- mice contained 
increased amounts of collagen and smooth muscle cells, while plaque lipid levels and 
the number of inflammatory cells were strongly reduced.37 These plaques resemble 
clinically favorable, stable plaques in humans. In a follow-up study an antagonizing 
anti-CD40L antibody was administered to ApoE-/- mice on chow diet, either at the 
onset of atherosclerosis or when established atherosclerotic lesions were present, 
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as the equivalent for the situation in patients. In both treatment groups, anti-CD40L 
antibody treatment did not result in a decrease in plaque area but resulted in the 
development of lipid-poor, collagen-rich, stable plaques.38 Schonbeck et al. showed 
similar results with a different anti-CD40L antibody (M158, Immunex) in high-fat 
diet fed LDLr-/- mice.39 Transplantation of CD40L-/- bone marrow into LDLr-/- mice 
did not significantly alter atherosclerosis.40,41 Interestingly, repeated administration 
of CD40L-/- platelets in ApoE-/- mice did prevent accelerated atherosclerosis that is 
induced by administration of wild type platelets.42
Besides the membrane-associated form, CD40L also exists in a truncated soluble 
form, sCD40L. sCD40L is cleaved from the CD40L protein upon activation, especially 
in platelets.43 Numerous studies have proven sCD40L to be a useful biomarker for 
cardiovascular disease severity. Elevated levels of sCD40L have been associated with 
hypercholesterolemia, diabetes, ischemic stroke and acute coronary syndromes and 
predict increased restenosis after percutaneous coronary and carotid interventions.44-49 
For CD40, the receptor for CD40L, the results are contradictory. In CD40-/-ApoE-/- mice, 
atherosclerosis was decreased, and plaques contained only few inflammatory cells 
and showed increased levels of fibrosis. This phenotype was due to CD40 expressing 
hematopoietic cells, since bone marrow transplantation of CD40-/- bone marrow into 
irradiated LDLr/- recipients resulted in similar results.50 Zirlik et al. reported that 
atherosclerosis development is not affected in CD40-/-LDLr-/- mice and claims that 
CD40 is not the only receptor for CD40L, but that CD40L can interact with the integrin 
Mac-1.51 
The mechanisms and pathways, as well as the interacting cell-types that modulate 
CD40L-CD40 signaling in vascular biology, are still under investigation, but many 
in vitro studies have provided insights how CD40L-CD40 interactions affect 
atherosclerosis.52 CD40L-CD40 endothelial-leukocyte interactions mediate expression 
of chemokines and adhesion molecules, thereby affecting leukocyte adhesion and 
diapedesis.53, 54 Platelet-monocyte CD40L-CD40 interactions facilitates leukocyte 
recruitment and induces the expression of cytokines, whereas platelet CD40L affects 
platelet aggregation.42 Activation of CD40-CD40L interactions seems to polarize T 
cells towards the pro-atherogenic Th1 phenotype, and CD40 is an important player 
in the activation of classically activated macrophages and DCs, which upon activation 
release a plethora of pro-atherogenic chemokines and cytokines.50 
CD40-CD40L interactions thus play a crucial role in the development and progression 
of atherosclerosis, are involved in the many different aspects of the disease, and 
constitute promising biomarkers for cardiovascular disease.
The OX40-OX40L pathway 
OX40 (TNFRSF4, CD134) and OX40L (TNFSF4, CD252) are members of the TNF/TNF 
receptor family, respectively.55, 56 In contrast to other costimulatory molecules, OX40 
and OX40L are expressed 2-3 days after activation. OX40 is present on activated T 
cells, Tregs and NKT cells, whereas OX40L is mainly expressed on APCs but is also 
Regulating atherosclerosis via costimulatory and coinhibitory pathways 45
2  
found on vascular endothelial cells. The OX40-OX40L interaction is important for T cell 
proliferation, in particular Th2 cells57, 58, and mediates crosstalk between APCs, mast 
cells, smooth muscle cells and endothelial cells.59 The OX40-OX40L axis also plays 
a key role in the survival of effector and memory T cells. OX40 deficient mice have 
reduced CD44hiCD62Llo memory CD4+ T cells, whereas OX40L transgenic mice have 
increased levels of memory CD4+ T cells.60, 61 Furthermore, activated OX40+ T cells 
drive isotype switching of B cells via interaction with OX40L and interruption of the 
OX40-OX40L pathway.62 
Modulation of the OX40-OX40L pathway potently ameliorates autoimmune-like 
diseases, such as EAE63, GVHD64, asthma65 and arthritis.66 The role of the OX40-
OX40L pathway in cardiovascular disease was first discovered in the 1980s, when 
Wang and Paigen et al. showed that OX40L is located in Ath-1 on chromosome 
1, a quantitative trait locus (QTL) that affects the differences in atherosclerosis 
susceptibility in Bl6 mice versus C3H/He and BALB/C mice.67, 68 In humans, single 
nucleotide polymorphisms (SNPs) in both the OX40 and OX40L genes have shown to 
affect the incidence of cardiovascular disease.67, 69, 70 Furthermore, patients suffering 
from acute coronary syndrome have increased expression of OX40 and OX40L on 
CD4+ T cells.71 Interestingly, elevated soluble OX40L levels in serum were associated 
with higher risk for cardiovascular events such as acute coronary syndrome, sudden 
death and recurrent angina. In addition, serum soluble OX40L correlated with carotid 
intima-media thickness72, indicating sOX40L is a promising biomarker to predict 
occurrence of cardiovascular disease.  
The role of the OX40-OX40L pathway has also been established in several mouse 
models of atherosclerosis. OX40L deficiency renders mice less susceptible to 
atherosclerosis, whereas OX40L overexpression enhances the development of 
atherosclerosis.67 In addition, cholesterol levels are correlated to upregulation of 
OX40 expression on T cells and interruption of the OX40-OX40L interaction using 
an OX40L-blocking antibody leads to a 53% reduction in initial atherosclerotic lesion 
development.73 Another study showed that ApoE-/-OX40L-/- mice have, in addition to 
a reduction in atherosclerotic lesion formation, a reduced vascular endothelial growth 
factor-induced angiogenesis compared with ApoE-/- mice.74 Recently, we showed 
that interference in the OX40-OX40L signaling pathway combined with decreases in 
dietary cholesterol induces regression of atherosclerosis through induction of IL-5-
producing T cells and oxLDL-specific IgM and reduction in Th2 responses and mast cell 
numbers (unpublished data). These data demonstrate that OX40 and OX40L are not 
only promising biomarkers to predict cardiovascular events, they are also potential 
therapeutic targets to reduce well-established atherosclerotic lesions.
The CD27-CD70 pathway
Another costimulatory pair of the TNF(R) family involved in T cell activation is formed 
by CD27 and CD70 (TNFSF7). CD27 is a transmembrane homodimer constitutively 
expressed on naive CD4+ and CD8+ T cells, early thymocytes, B cells and NK cells.75, 
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76 CD27 is upregulated on T cells following TCR stimulation and is downregulated 
when T cells differentiate towards effector T cells.77 Additionally, binding of CD70 to 
CD27 can result in proteolytic cleavage of a truncated form of CD27.78 CD70 is a type 
II transmembrane glycoprotein expressed on activated DCs, macrophages, B cells 
and activated T cells.22, 79, 80 Interaction of CD27 with CD70 activates the NF-κB and 
JNK pathways81 and enhances the proliferation and survival of effector and memory 
T cells.82 Signaling through CD27-CD70 especially induces IFN-γ and IL-2 producing 
CD4+ T cells which in turn may promote the accumulation of CD8+ memory T cells.83 
Furthermore, CD27-CD70 signaling is also involved in humoral responses as CD27 
signaling enhances plasma cell formation and promotes IgG production75, whereas 
CD70 engagement inhibits IgG secretion.84
In humans, CD4+CD25+ T cells expressing CD27 represent a highly suppressive Treg 
subset.85, 86 Sardella et al. reported that patients with myocardial infarction have 
decreased CD27+ Tregs compared with healthy individuals.87 Both CD27 and CD70 are 
expressed on T cells and macrophages in human atherosclerotic lesions.22 The role of 
the CD27-CD70 pathway in atherosclerosis has been investigated by Olffen et al. who 
constitutively triggered CD27 signaling on T cells through transgenic overexpression 
of CD70 on B cells in ApoE*3-Leiden mice.88 Previously, they showed that B cell-
specific CD70 transgenic mice have increased numbers of IFN-γ producing T cells 
which subsequently deplete B cells.89 Surprisingly, B cell-specific CD70 transgenic 
ApoE*3-Leiden mice are protected against atherosclerosis despite enhanced numbers 
of IFN-γ producing effector T cells and inflammatory Ly6Chi monocytes. This anti-
atherogenic effect of excessive CD27-CD70 signaling was ascribed to the increased 
susceptibility of monocytes to undergo apoptosis. In addition, B cell-specific CD70 
transgenic ApoE*3-Leiden mice show extremely reduced oxLDL-specific antibodies as 
a consequence of B cell loss, which might also contribute to reduced atherosclerosis. 
No atherosclerosis studies have been performed using blocking or agonistic CD27 or 
CD70 antibodies. 
The CD137–CD137L pathway
CD137 (4-1BB, TNFRSF9) and CD137L (4-1BBL, TNFSF9) are also members of the 
TNF(R) superfamily. CD137 is a glycoprotein and exists as a monomer or dimer 
on activated CD4+ and CD8+ T cells, NK cells, NKT cells and mast cells, and is 
constitutively expressed on resting monocytes, DCs, neutrophils and Tregs.90-94 Upon 
activation, CD137 expression is slowly increased within hours, peaks round 60 hours, 
and remains stably expressed.91 CD137 binds to its ligand CD137, which is a type II 
membrane glycoprotein and expressed on monocytes, macrophages, dendritic cells, 
activated B cells and T cells.95, 96 Similar to other costimulatory molecules, CD137 
can also be secreted in a soluble form.97 Interaction of CD137 with CD137L initiates 
costimulatory responses via downstream signaling through TNF receptor-associated 
factor-2 and activation of NF-κB, which results in enhanced T cell proliferation 
and IL-2 production.98 Interestingly, CD137-CD137L signaling affects CD8+ T cell 
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proliferation more vigorously than CD4+ T cell proliferation.99 Moreover, CD137-CD137 
signaling also affects humoral responses since engagement of CD137L induces B cell 
proliferation and immunoglobulin synthesis.100 
Agonistic CD137 antibodies have been extensively used in several autoimmune 
diseases. Surprisingly, agonistic CD137 greatly reduced EAE101, systemic lupus 
erythematosus102 and collagen-induced arthritis103 in mice. This rather unexpected 
protective effect was attributed to elevated activation-induced cell death of CD4+ T 
cells with a subsequent suppression of autoantibody production. 
A possible role for the CD137-CD137L pathway in the pathogenesis of cardiovascular 
disease was first shown by Drenkard et al. who showed that CD137 is expressed on 
endothelial cells at sites of inflammation in the arterial wall and enhances the migration 
of monocytes into the intima.104 Both CD137 and CD137L are also expressed on 
smooth muscle cells and cardiac myocytes, which are also involved in cardiovascular 
disease.105, 106 Olofsson et al. showed that human atherosclerotic arteries contain 17 
times higher levels of CD137 mRNA in comparison with healthy arteries and that 
CD137 is mainly colocalized with endothelial cells and CD8+ T cells.107 Additionally, 
atherosclerotic lesions of ApoE-/- mice showed a 10-fold increase in CD137 mRNA 
expression compared with C57BL/6 mice. In vitro experiments demonstrated that 
pro-atherogenic cytokines induce CD137 expression on endothelial and smooth 
muscle cells and that activation of the CD137-CD137L pathway upregulates adhesion 
molecules on endothelial cells and reduces proliferation of smooth muscle cells. Despite 
the protective effect of an agonist for CD137 described in numerous autoimmune 
diseases, treatment with agonistic CD137 enhanced atherosclerosis development in 
ApoE-/- mice via increased inflammation, CD8+ T cell infiltration and MHC II expression 
in lesions. Aortic expression of pro-inflammatory molecules, such as ICAM-1, IL-1β 
and TNFα was also increased. In another study, CD137 deficiency in hyperlipidemic 
LDLr-/- and ApoE-/- mice attenuated atherosclerosis, which was attributed to reduced 
pro-inflammatory cytokines, such as IFN-γ, MCP-1 and TNFα, released by endothelial 
cells and monocytes/macrophages.108 
Furthermore, CD137 expression, either soluble or membrane-bound, is elevated in 
patients with acute coronary syndromes (ACS) compared with healthy controls.109 
Recently, Dumitriu et al. showed that patients with ACS have elevated levels of CD137 
and OX40 on CD4+CD28null T cells, a distinct subset of T cells known to expand in 
the circulation and atherosclerotic plaques of these patients.110 Blockade of CD137 
reduced the IFN-γ, TNFα and perforin secretion of CD4+CD28null T cells isolated from 
PBMCs from patients with ACS. Additionally, CD137L is highly present in human 
atherosclerotic lesions. 
These studies show an important role for CD137-CD137L signaling in atherosclerosis 
and future studies should identify approaches to interfere in the CD137-CD137L 
pathway to prevent atherosclerosis. 
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The CD30-CD30L pathway
CD30 (TNFRSF8) and CD30L (TNFSF8, CD153) also belong to the TNF(R) superfamily 
and similar to OX40 and OX40L, are mainly expressed on activated immune cells. 
Whereas CD30 and CD30L are both present on activated B and T cells, and especially 
CD4+ T cells of both Th1 and Th2 phenotypes, CD30L is also expressed on other cell 
types, such as mature DCs, macrophages and mast cells. Signal transduction via 
CD30-CD30L induces activation and proliferation of T cells via TRAF1- and TRAF2-
mediated NF-κB activation.111, 112 However, under certain circumstances CD30-CD30L 
signaling can also promote cell cycle growth arrest and apoptosis.113, 114 Furthermore, 
the CD30-CD30L pathway plays a major role in secondary humoral immune 
responses. Mice deficient in CD30 have impaired follicular germinal center responses 
and reduced secondary antibody responses.115, 116 In addition, CD30L transgenic mice 
show increased numbers and activity of splenic germinal centers and have elevated 
serum antibody levels, such as IgG2b and IgE.117 
The in vivo role of the interaction between CD30 and CD30L can be investigated using 
anti-CD30L antibodies, which interrupt the CD30-CD30L pathway. CD30 deficiency 
or treatment with a CD30L blocking antibody (RM153) significantly reduced airway 
inflammation in a murine asthma model by inhibition of splenocyte proliferation, 
reducing serum IgE levels and diminishing the Th2 cytokines IL-5 and IL-13.118 Blazar 
et al. showed that anti-CD30L prolongs survival of mice in graft versus host disease.119 
Furthermore, administration of anti-CD30L completely suppressed the development 
of spontaneous/type I diabetes in NOD mice.120 Interestingly, CD30 and CD30L can 
also be cleaved by metalloproteinases and circulate as a soluble form.121, 122 Elevated 
concentrations of serum CD30 correlate with disease activity in cancer123, systemic 
lupus erythematosus124, rheumatoid arthritis125, and HIV.126 
Only limited research is performed to establish the CD30-CD30L pathway in 
cardiovascular diseases. Macrophages bearing CD30 have been identified in ruptured 
plaques of patients with coronary artery disease127 and recently, we showed that 
treatment with a blocking anti-CD30L antibody reduced atherosclerosis with 35% in 
LDLr-/- mice fed a Western-type diet for 8 weeks, independent of plasma cholesterol 
levels and plaque macrophage and collagen content.128 This reduction in atherosclerosis 
coincided with reduced adventitial T cell numbers, reduced percentages of CD4+ T cells 
in the spleen and lymph nodes and with strongly reduced splenocyte proliferation. 
In particular, CD4+ T cells isolated from anti-CD30L-treated mice proliferated less 
vigorously after αCD3/CD28 stimulation than CD4+ T cells from control mice, whereas 
their adhesion and migration capacity remained unaffected. This identifies anti-CD30L 
treatment as a novel therapeutic modality in the inhibition of atherosclerotic lesion 
development and the prevention of acute cardiovascular syndromes.
The TL1A-DR3 pathway
Another costimulatory pair of the TNF-TNFR family is formed by TNF-like protein A 
(TL1A, VEGI, TNFSF15) and Death receptor 3 (DR3, TNFRSF12).196 TL1A is mainly 
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expressed on endothelial cells and is induced on APCs196-198 after stimulation with 
for example FcyR or microbial antigens.199, 200 DR3 is expressed on a variety of cells 
involved in atherosclerosis such as macrophages, T cells, NK cells and endothelial 
cells, and regulates cell apoptosis and activation by NF-κB.198, 201-203 Signaling via TL1A 
and DR3 can enhance Th1, Th2 and Th17 effector functions.203-205 
Both TL1A and DR3 are present in macrophage/foam cell rich regions of human 
atherosclerotic lesions and exposure of IFN-y-stimulated human monocytes to anti-
DR3 or recombinant TL1A induces the release of pro-atherogenic mediators, such 
as MMP-9 and IL-8.198, 206 Furthermore, activation of human PBMCs with TNFα and 
LPS induced DR3 expression. More recently, McLaren et al. showed that TL1A and 
DR3 regulate foam cell formation by increasing cholesterol uptake via upregulation 
of SR-A, SR-B1, CD36 and LPL, and by reducing cholesterol efflux via ApoE, ABCA1 
and ABCG1.207 These data suggest that the TL1A-DR3 pathway might be involved in 
atherosclerosis via the induction of pro-inflammatory mediators, by promoting foam 
cell formation and by decreasing plaque stability through the induction of extracellular 
matrix degrading enzymes but the exact role of TL1A and DR3 in atherosclerosis 
remains to be elucidated. 
Coinhibitory pathways in atherosclerosis
Figure 3 provides an overview of coinhibitory molecules of both the B7 and TNF(R) 
family that upon interaction suppress the development of atherosclerosis. Their 
specific contribution to the suppression of pro-atherogenic immune responses will be 
discussed in more detail. 























Figure 3. Signaling via coinhibitory molecules in atherosclerosis inhibits T cell function, induces tolerance 
and can induce apoptosis. 
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The CTLA-4-CD80/CD86 pathway
Similar to CD28, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4, CD152), a 
member of the B7-family, binds to the costimulatory molecules CD80 and CD86. 
Whereas the interaction between CD80/CD86 and CD28 promotes T cell responses, 
CTLA-4 binding to CD80/CD86 inhibits T cell activation and proliferation.129, 130 CTLA-
4 is a type 1 transmembrane glycoprotein of the immunoglobulin superfamily131 
and is mainly expressed on Tregs and on activated CD4+ and CD8+ T cells130, 132, 133 
but can also be found on a variety of other cells such as monocytes134, activated B 
cells135 and embryonic stem cells.136 CTLA-4 is predominantly an intracellular antigen 
whose surface expression is not detected until 24-48 hours after activation.132 The 
importance of CTLA-4 in the regulation of lymphocyte homeostasis became evident 
when Waterhouse et al. showed that CTLA-4 deficient mice die already at 3-4 weeks 
of age due to severe lymphoproliferative disease.137 Peripheral lymphoid organs of 
CTLA-4 deficient mice contain 5-10 times the normal amount of lymphocytes, and 
immunoglobulin levels, such as IgE and IgG1, are highly increased as a consequence 
of enhanced B cell activation. Two mechanisms are described for CTLA-4-mediated T 
cell inhibition. A number of studies showed that CTLA-4 competes with CD28 for the 
ligands CD80 and CD86 and since CTLA-4 has a 10 times greater affinity for CD80/
CD86 than CD28, this limits CD28-mediated signaling and induces T cell anergy.138, 139 
CTLA-4 can also directly inhibit T cell proliferation through negative signaling via for 
example phosphorylation of tyrosine motifs on the cytoplasmic tail.138, 140 However, the 
exact mechanism of this direct T cell inhibition remains to be elucidated.
Since CTLA-4 plays a dominant role in T cell homeostasis, CTLA-4 provides a promising 
therapeutic target to inhibit autoimmune diseases. Two recombinant CTLA-4-Ig soluble 
fusion proteins, abatacept and belatacept, are approved by the FDA for the treatment 
of rheumatoid arthritis and renal allograft rejection.141 These fusion proteins consist of 
the extracellular CD80/CD86 binding portion of CTLA-4 coupled to IgG1 to elongate 
the circulating half-life, and disrupt the CD28-CD80/CD86 signaling pathway. However, 
limited information is available on the role of CTLA-4 in atherosclerosis. CTLA-4-Ig 
treatment has been shown to prevent experimental hypertension by reducing the 
activation and cytokine production of T cells and by abrogation of vascular T cell 
accumulation.142 Increased mRNA levels of CTLA-4 have been associated with reduced 
atherosclerotic lesions and increased Tregs in several studies.143-145 Ma et al. showed 
that CTLA-4 IgG (abatacept) ameliorates homocysteine-accelerated atherosclerosis by 
inhibiting T cell overactivation in ApoE-/- mice.146 Abatacept treatment alone, for 2 or 4 
weeks, did not reduce atherosclerosis. However, it must be noted that homocysteine 
induces very small atherosclerotic lesions whereas for example Western-type diet 
induced atherosclerosis results in much greater lesion sizes. Recently, Ewing et 
al. showed that abatacept treatment of hypercholesterolemic ApoE3*Leiden mice 
prevents intimal thickening by 59% in a femoral artery cuff mouse model for post-
interventional remodeling.147 Furthermore, treatment with abatacept resulted in a 
78% reduction in accelerated atherosclerosis development, whereas treatment with a 
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CTLA-4 blocking antibody strongly increased lesion size by 67%. The atheroprotective 
effect of abatacept was attributed to a reduction in the activation of Th1 and elevated 
Tregs, with concomitant reduced IFN-γ and elevated IL-10 serum levels. In contrast, 
our group treated 30 week old or Western-type diet fed ApoE-/- mice with abatacept 
and we did not observe any effect on atherosclerotic lesion size in comparison with 
control IgG treatment (unpublished data). In conclusion, promoting CTLA-4 activity 
has the potential to be a useful strategy for prevention of atherosclerosis, but the 
mechanism-of-action in different stages of atherosclerosis is still unclear and needs 
to be further investigated.
The PD-1-PD-L1/2 pathway
Another coinhibitory pair in the B7-CD28 family is formed by programmed death 1 (PD-
1, CD279)148, which binds to programmed death-ligand 1 (PD-L1, B7-H1, CD274)149, 
150 and 2 (PD-L2, B7-DC, CD273).151, 152 PD-1 is mainly expressed on activated T cells, 
including CD4+ T cells, CD8+ T cells, NKT cells and NK cells, but is also expressed on 
B cells and activated monocytes.153, 154 PD-L1 is constitutively expressed on T cells, B 
cells, DCs, macrophages and bone-marrow derived mast cells and can also be found 
on non-hematopoietic cell types, such as vascular endothelial cells, epithelial cells 
and muscle cells.154, 155 In contrast, expression of PD-L2 is highly restricted to DCs 
and activated macrophages.151, 156 While PD-L1 and PD-L2 bind with a similar affinity 
to PD-1, they do cross-compete for binding to PD-1.157 Interestingly, PD-L1 has also 
been shown to bind to CD80 in both mice and humans.158, 159 
The exact mechanism by which the interaction between PD-1 and PD-L1/2 inhibits 
costimulation-mediated T cell proliferation and cytokine secretion remains to be 
fully understood. PD-1 engagement has shown to inhibit ZAP70/CD3ζ signaling 
and decreases the phosphorylation of ERK and PKCΘ, eventually resulting in 
downmodulation of TCR signaling and IL-2 secretion.160 In addition, association of 
protein tyrosine phosphatases, SHP-1 and 2, to immunoreceptor tyrosine-based 
motifs (ITSM and ITIM) present on the cytoplasmic tail of PD-1, may inhibit T cell 
responses. Furthermore, PD-1 has shown to upregulate a basic leucine transcription 
factor, ATF-like (BATF), which impairs T cell responses.161 In contrast, some studies 
report a pro-inflammatory role of PD-L1/2; PD-L2 induces IL-12 producing DCs and 
subsequent T cell activation.162 
Modulation of the PD-1/PD-L1/2 pathway may be a potent approach to regulate T 
cell responses in autoimmune diseases such as atherosclerosis. Previously, it has 
been shown that PD-1 is upregulated on aortic T cells in hypercholesterolemic LDLr-/- 
mice163, whereas PD-L1 and PD-L2 are present on macrophages and dendritic cells in 
aortic lesions.164 Combined deficiency of PD-L1 and PD-L2 in LDLr-/- mice aggravated 
atherosclerosis and increased numbers of lesional CD4+ and CD8+ T cells.164 In addition, 
LDLr-/-PD-L1/2-/- mice showed increased numbers of activated CD4+ T cells in lymphoid 
organs and serum TNFα was elevated. Both in vitro and in vivo, PD-L1/2 deficient 
APCs showed increased capability to activate CD4+ T cells under hypercholesterolemic 
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conditions. Furthermore, LDLr-/- mice deficient in PD-1 or LDLr-/- mice treated with a 
blocking anti-PD-1 antibody also showed increased atherosclerosis development.163 
Similar to PD-L1 and PD-L2 deficiency, lesions of LDLr-/-PD1-/- mice contained high 
numbers of CD4+ T cells, CD8+ T cells and macrophages, and TNFα levels in serum 
were increased. Interestingly, both PD-L1/2 and PD-1 deficiencies induced CD8+ T 
cells, which are rarely present in lesions of LDLr-/- mice. Bu et al. showed that CD8+ 
T cells of LDLr-/-PD1-/- mice have increased cytotoxic capacity. Moreover, PD1-/-CD8+ 
T cells are potent killers of SMC in vitro and could thereby play an important role in 
lesion stability. 
There are also indications that this coinhibitory pathway regulates T cell responses in 
humans with cardiovascular disease. Patients suffering from coronary artery disease 
showed significantly decreased expression of PD-1 and PD-L1 on T cells and myeloid 
DCs. As a result, CD4+ and CD8+ T cell proliferation and production of pro-inflammatory 
cytokines was enhanced.165 
Stimulation of the PD-1/PD-L1/2 pathway by using agonistic antibodies could be a 
successful approach to inhibit atherosclerosis and to further unravel the role of PD-
L1 and PD-L2 in atherosclerosis, since the differential roles of PD-L1 and PD-L2 in 
atherosclerosis remain unclear. 
The ICOS-ICOSL pathway
CD28/B7 family member inducible costimulatory molecule (ICOS) is rapidly induced 
on activated T cells and resting memory T cells, and its ligand ICOSL (B7h) is 
expressed on B cells, a small subset of T cells, monocytes, macrophages, dendritic 
cells and in non-lymphoid tissues, such as the lung.166-168 ICOS-/- mice show impaired 
humoral immune responses and germinal center reactions169, 170 and both ICOS- and 
ICOSL-deficient T cells show impaired proliferative capacity and IL-2 production.170, 171 
Furthermore, IL-4 production by these T cells was greatly reduced upon restimulation, 
which is in line with several studies that report a role for ICOS-ICOSL in Th2 
differentiation.171-173 Stimulation of ICOS-ICOSL signaling in CD4+ T cells cultured with 
αCD3 increased not only the production of IL-4 but also of IFN-γ, the hallmark cytokine 
of Th1 responses.174 In line with this finding, ICOS-ICOSL interruption enhances Th1 
differentiation. Moreover, CD4+ T cells expressing ICOS are shown to produce a great 
amount of anti-inflammatory IL-10.174, 175 
The role of the ICOS-ICOSL pathway in autoimmune diseases remains controversial. 
ICOS-/- mice do not develop collagen induced arthritis, with great reductions in anti-
collagen IgM and IgG2A antibodies and reduced T cell proliferation.171 In an EAE model, 
ICOS deficiency or ICOS blockade during disease onset greatly exacerbated EAE, 
which was associated with enhanced IFN-γ production.176 In contrast, ICOS blockade 
after the manifestation of EAE is protective.177  
Afek et al. showed that ICOS and ICOSL are present in murine atherosclerotic 
plaques.178 Spleens from ApoE-/- mice contained reduced percentages of CD3+ICOS+ 
cells but surprisingly when the splenocytes were cultured in the presence of 0-50 μg/
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mL oxLDL, CD3+ICOS+ cells increase dose-dependently. Subsequently, blockade of 
the ICOS-ICOSL interaction by immunization with a human ICOS-Ig fusion protein 
increased early/spontaneous atherosclerosis with 77% in ApoE-/- mice and increased 
atherosclerosis with 36% in ApoE-/- mice fed a high-fat diet for 8 weeks. They observed 
increased splenocyte proliferation after stimulation with oxLDL with concomitant 
increased levels of IFN-γ and reduced IL-10. However, a mechanism for this ICOS-
mediated atherosclerosis induction was provided in another study by Gotsman et al. 
who showed that ICOS deficiency on bone marrow-derived cells significantly increased 
atherosclerotic lesion development with 53% in the aortic root.179 A 3-fold increase 
in CD4+ T cells was observed in the intima and in line with this finding, CD4+ T 
cells isolated from ICOS-/- mice showed enhanced proliferation, which was ascribed to 
reduced Treg numbers with reduced suppressive capacity. Furthermore, ICOS-/-CD4+ 
T cells produced more Th1 and Th2 cytokines, whereas the anti-inflammatory TGF-β 
was decreased. In addition, Tregs and ICOS+-Treg subsets are decreased in patients 
with myocardial infarction and stable angina.180 
All together, these data suggest a coinhibitory role for the ICOS-ICOSL pathway in 
atherosclerosis through its effect on Tregs. Modulation of the ICOS-ICOSL pathway 
with agonistic antibodies might have a therapeutic potential to prevent cardiovascular 
diseases.
Tims 
T cell immunoglobulin and mucin domain (Tim) proteins are type 1 transmembrane 
proteins expressed on various immune cells and are similar to PD-1/PD-L1/2 negative 
regulators of immune responses. Four functional TIM genes have been identified 
in the murine genome (TIM-1-4), whereas the human genome only contains three 
TIM genes (TIM-1,3 and 4).181 The genes encoding Tim proteins are located on 
chromosome 11 (mouse) and chromosome 5 (human), which are associated with 
enhanced susceptibility to allergy and several autoimmune diseases, such as EAE and 
diabetes.181
Tim-1 ligation can costimulate T cell proliferation and cytokine production, and is present 
at very low levels on naive T cells.182 Tim-1 is upregulated upon activation and interacts 
either with Tim-4 or can homodimerize with itself. Besides the direct effect on T cell 
proliferation, Tim-1 is also involved in Treg function. Tim-4 is preferentially expressed 
by APCs and upregulated upon activation.183 Tim-4 specifically phosphorylates Tim-
1 and induces T cell expansion by enhancing cell division and reducing apoptosis.183 
Although Tim-1 and Tim-4 are interesting candidates to modulate pro-atherogenic 
immune responses in atherosclerosis, their contribution to atherosclerosis remains to 
be elucidated.
Tim-3 was first discovered as a specific marker for Th1 cells184 but is also expressed on 
a variety of immune cells such as NK cells, monocytes, macrophages and mast cells.185 
During innate immune responses, Tim-3 promotes inflammation via TNFα secretion 
by monocytes and APCs186 and enhances macrophage clearance of intracellular 
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pathogens.187 However, in adaptive immune responses, Tim-3 terminates IFN-γ driven 
inflammation by inducing cell death of T cells after binding to its ligand galectin-9, a 
soluble molecule that is upregulated by IFN-γ.188 In addition, Tim-3 can induce Treg 
activity189 and induce expansion of myeloid-derived suppressor cells, which play an 
important role in tumor immunology.190 Recently, Zhang et al. showed that Tim-3 can 
also negatively regulate innate immune responses, since reduced Tim-3 signaling by 
antibody blockade or knock-down with siRNA increases the activation of monocytes.191 
The in vivo role of Tim-3 can be investigated using anti-Tim-3 antibodies, which 
interrupt the Tim-3-galectin-9 interactions. Previously, it was shown that blocking 
Tim-3 with either a Tim-3 blocking antibody or a Tim-3-Ig fusion protein, enhances 
type 1 diabetes in NOD-mice and prevents the generation of immunological tolerance 
in a transplantation model, by dampening the function of Tregs.192 Furthermore, in vivo 
administration of a Tim-3 blocking antibody enhances inflammation and demyelination 
in a mouse model of EAE by increasing the number and activation of macrophages.184 
Blockade of the Tim-3-galectin-9 interaction also accelerates graft versus host disease 
via enhanced activation of Th1 cells and cytotoxic T cells.193 In addition, blocking 
Tim-3 signaling aggravates inflammatory heart disease in BALB/c mice by decreasing 
CD80 expression on macrophages and mast cells and by reducing Tregs.194 
Hou et al. showed that patients with atherosclerosis have augmented Tim-3 expression 
on NK cells, which might affect NK cell function during atherosclerosis.195 Recently, 
we showed that Tim-3 acts as a negative regulator of atherosclerosis, since blockade 
of Tim-3 augmented atherosclerotic lesion development and enhances immune 
responses by increasing circulating monocytes and plaque macrophages. Additionally, 
Tim-3 blockade decreased IL-10 producing Tregs and Bregs (unpublished data). In the 
future, approaches to promote the Tim-3 pathway, such as treatment with agonistic 
Tim-3 antibodies or galectin-9, may represent novel therapeutic strategies to inhibit 
atherosclerotic lesion development and prevent cardiovascular diseases. 
The GITR-GITRL pathway
Glucocorticoid-induced TNF receptor family related protein (GITR, TNFRSF18) and its 
ligand GITRL (TNFSF18) are members of the TNFR superfamily. GITR is expressed 
at low levels on a range of cell types such as CD4+ and CD8+ T cells, NK cells, B 
cells, macrophages, DCs, endothelial cells and smooth muscle cells, whereas Tregs 
constitutively express high levels of GITR.208, 209 GITR is upregulated after T cell 
activation, with a peak expression after 24 hours, and induces T cell proliferation 
and cytokine production.210, 211 GITR-GITRL signaling also inhibits TCR-induced 
apoptosis and promotes T cell survival in a MAPK and NF-κB-dependent manner.211, 212 
Additionally, GITR signaling in Tregs abrogates the suppressive capacity of Tregs.208, 213 
GITRL is mainly expressed on APCs and endothelial cells210, 214, 215 and after activation 
with pro-inflammatory stimuli induces the production of IL-1β, IL-8, TNFα, MCP-1, 
iNOS and MMP-9.216, 217
Similar to the TL1A-DR3 pathway, the GITR-GITRL pathway has not been extensively 
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investigated in atherosclerosis. GITR and GITRL are mainly expressed in macrophage 
rich areas of human atherosclerotic lesions and human and mouse monocytes/
macrophages produce MMP-9 and TNFα upon GITR/GITRL signaling in a NF-κB and 
MAPK-dependent manner.217, 218 Furthermore, GITR positive cells are found in human 
atherosclerotic lesions and overlap with Foxp3+ T cells.219 Notably, the frequency of 
GITR and Foxp3+ T cells was significantly higher in healthy arterial walls compared 
with atherosclerotic lesions, which is in line with the general consensus that 
atherosclerosis is a chronic autoimmune disease resulting from an imbalance between 
pro-inflammatory cell types and anti-inflammatory Tregs. 
Clinical implications
In cardiovascular disease, modulation of costimulatory and coinhibitory molecules 
can be a powerful tool to target specific stages of atherosclerosis or specific cell 
types involved in the pathogenesis of atherosclerosis. A highly relevant feature of 
costimulatory and coinhibitory pathways is that they individually have their unique 
effect on the behaviour of specific immune cells and thus on the outcome of 
disease. For example, interference in OX40-OX40L and CD30-CD30L signaling both 
reduce atherosclerosis via different pathways; anti-OX40L specifically targets Th2 
responses and mast cell activity, whereas anti-CD30L limits all CD4+ T cell responses 
without affecting a specific T cell subset or other immune cells. In addition, several 
costimulatory and coinhibitory molecules are involved in the induction and function of 
Tregs. This enables the development of a treatment that particularly targets different 
subsets of T cells. Ultimately, it would be ideal to modulate antigen-specific pro-
atherogenic T cells using blocking costimulatory antibodies and agonistic coinhibitory 
antibodies without affecting the general T cell population and other immune cells 
to limit any adverse effects on the immune system. Although several candidates of 
atherosclerosis specific antigens have been investigated, such as oxLDL, HSP60 and 
ApoB100, to date the exclusively atherosclerosis-associated antigen is not identified 
yet, which complicates the approach to specifically target the pro-atherogenic T cells. 
However, some costimulatory molecules, such as OX40, are virtually absent on naive T 
cells but are upregulated on activated T cells. Targeting these costimulatory molecules 
with blocking antibodies could specifically eliminate the pathogenic T cells without 
causing any side effects. Furthermore, the ligand of OX40, OX40L, is expressed on 
endothelial cells which upon blockade can also reduce the attraction of OX40+ T cells 
to the site of inflammation. 
Blocking and agonistic antibodies for costimulatory and coinhibitory molecules 
have already been extensively explored in cancer and allograft rejections. Blocking 
antibodies for CTLA-4 and PD-1 to boost T cell responses are approved for treatment 
of patients with several types of cancer.220 In contrast to cancer where T cell activity 
is highly appreciated, the unwanted activation of the immune system needs to be 
suppressed in atherosclerosis. Therefore, whereas in cancer for example a blocking 
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PD-1 antibody to promote T cell activity is beneficial, in atherosclerosis an agonistic 
PD-1 antibody is needed to suppress T cells. CTLA-4-Ig has already been established 
as an effective treatment for human autoimmune diseases including rheumatoid 
arthritis221 and psoriasis.222 At present, one clinical trial has been completed using 
anti-OX40L in the prevention of allergen-induced airway obstruction in adults with 
mild asthma.223 However, no study results are reported yet. 
Although many antibodies against costimulatory and coihibitory molecules have been 
approved and are used in clinical settings, caution is needed when translating animal 
experiments to the clinic, as a Phase I clinical trial with an agonistic monoclonal anti-
CD28 antibody induced a strong cytokine storm (IFN-γ, TNFα, IL-2) several hours 
after drug infusion, which caused multiorgan failure in six human volunteers who 
ended up on the intensive care unit.224 Moreover, blocking costimulatory pathways 
and stimulating coinhibitory pathways may enable opportunistic infections to emerge. 
However, treatment can be adjusted in a way that patients will only receive blocking 
antibodies for costimulatory molecules or agonistic antibodies for coinhibitory 
molecules temporarily until the lesion is stabilized.  
No clinical trials investigating blocking antibodies for costimulatory molecules 
and agonistic antibodies for coinhibitory molecules in cardiovascular disease have 
been started yet. In fact, only recently the first clinical trial involving interference 
of inflammatory pathways to reduce major cardiovascular events in persons with 
preexisting coronary artery disease was launched.225, 226 This CANTOS trial is a large-
scaled study in which over 17.000 subjects will be included to test three different doses 
of Canakinumab, a humanized monoclonal antibody specific for IL-1β, compared with 
placebo. Canakinumab is already approved in other autoimmune diseases where IL-1β 
plays a major role, such as Muckle-Wells syndrome and familial cold autoinflammatory 
syndrome.227 This study will provide the first evidence whether interference in 
inflammatory pathways can reduce clinical events in cardiovascular patients and will 
possibly initiate numerous clinical trials focused on modulating immune responses in 
atherosclerosis. 
Interestingly, some anti-tumor therapy trials have indicated that treatment with only 
a single costimulatory agonist, in addition to existing cytostatic therapy or cancer-
antigen vaccination, is not effective or induces adverse immunological events. The co-
administration of a second agonist or another factor that stimulates T cell function is 
necessary to achieve a greater anti-tumor reactivity. For example, a clinical trial with an 
anti-CTLA-4 antibody (MDX-010) in conjunction with anti-cancer antigen vaccination 
resulted in regression of cancer but unfortunately also induced severe autoimmune 
diseases in melanoma patients.228 Kocak et al. showed that a combination therapy in 
mice with pre-existing tumors with anti-CTLA-4 and anti-4-1BB enhances anti-tumor 
immunity without any adverse effects on the immune system.229 The mechanism 
through which the combination of anti-CTLA-4 and anti-41BB reduce each other’s 
side effects is not fully explained but it is shown that they synergistically enhance the 
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suppressive capacity of regulatory T cells. Currently, a phase I clinical trial is carried 
out in which anti-CTLA-4 (Ipilimumab) is combined with anti-PD-1 (BMS-936558) to 
treat melanoma patients.230
It may be very likely that a combinatorial therapy may also be very effective in 
atherosclerosis. For example, previous studies reported a synergistic effect of OX40L 
and CD30L on T cell responses. Blocking CD30 together with OX40 signaling prevented 
lethal X-linked CD4 T cell-dependent Th1- and Th2-driven autoimmune disease in 
mice lacking regulatory T cells231 and affected effector and memory T cell formation 
and function.115 Moreover, a combined blockade of costimulatory signals, e.g. anti-
OX40L or anti-CD30L, with activation of coinhibitory signals, e.g. PD-1 or Tim-3 
agonists, could be explored to suppress for example pro-atherogenic T cells while 
stimulating athero-protective Tregs. More research should be performed to identify 
the most relevant combinations of blocking and agonistic antibodies for costimulatory 
and coinhibitory molecules respectively, which could be used as an immunotherapy to 
inhibit atherosclerosis.  
Costimulatory and coinhibitory molecules are also essential for the establishment 
and maintenance of immunological tolerance via the induction of tolerogenic DCs 
and Tregs. A frequently used method to induce tolerance is by oral immunization. In 
atherosclerosis, oral tolerance induction to oxLDL144, HSP60143, β2-glycoprotein I232 
and ApoB100 peptide233 has been shown to suppress atherosclerosis. Van Puijvelde et 
al. showed that oral tolerance induction against oxLDL and HSP60 increased Tregs and 
their CTLA-4 expression.143, 144 Possibly, oral tolerance induction against auto-antigens 
such as oxLDL, can be combined with blocking antibodies against costimulatory 
molecules or agonists for coinhibitory molecules to achieve T cell non-responsiveness 
against these auto-antigens and to promote the induction of antigen-specific Tregs. 
In conclusion, modulation of costimulatory and coinhibitory molecules provides novel 
approaches to dampen the immune response in atherosclerosis. However, further 
characterization of these potential new drug targets are necessary before they can be 
applied in clinical research.
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Abstract 
Objective: Patients suffering from cardiovascular disease have well-established 
atherosclerotic lesions, rendering lesion regression of therapeutic interest. The OX40 
(TNFRSF4)-OX40L (TNFSF4) pathway is important for the proliferation and survival 
of T cells, stimulates B cells, and is associated with cardiovascular disease. We 
hypothesized that interference with the OX40-OX40L pathway, in combination with 
decreases in cholesterol, may induce regression of atherosclerosis. 
Methods and Results: LDLr-/- mice were fed a Western-type diet for 10 weeks, after 
which they received chow diet and were treated with anti-OX40L or PBS for 10 weeks. 
A significant regression of lesions was observed in the aorta and aortic arch of anti-
OX40L-treated mice compared with control mice. Interference of the OX40-OX40L 
pathway reduced Th2 responses, as shown by decreases in GATA-3 and IL-4 levels. 
Also, IgE levels were decreased, as demonstrated by reduced mast cell presence 
and activation. Notably, IL-5 production by T cells and B1 cells was increased, thus 
enhancing atheroprotective oxLDL-specific IgM production. The increase in IL-5 
production and IgM was mediated by IL-33 production by APCs upon OX40L blockade.
Conclusions: We conclude that interruption of the OX40-OX40L signaling 
pathway, combined with decreases in dietary cholesterol, induces the regression of 
atherosclerosis through induction of IL-5-producing T cells and oxLDL-specific IgM and 
reductions in Th2 and mast cell numbers. 
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Introduction 
Atherosclerosis is a chronic autoimmune-like disease resulting from endothelial 
damage, subsequent vascular dysfunction, and cholesterol accumulation in the arterial 
wall. The development of experimental therapies for the treatment of atherosclerosis 
has focused mainly on preventing the initiation and, to a lesser degree, the progression 
of atherosclerosis. Patients suffering from cardiovascular disease, however, have well-
established lesions and could benefit from a therapy that decreases the extent of 
disease. Currently, patients are usually treated with statins to lower LDL cholesterol, 
but these drugs have very little effect on established lesions.1, 2 Several strategies 
to induce regression via modulation of lipid homeostasis have been tested in mouse 
models of atherosclerosis. Reintroducing apolipoprotein E (ApoE) into ApoE-/- mice 
via ApoE gene transfer induces regression.3, 4 Furthermore, LXR compounds induce 
atherosclerotic regression by promoting reverse cholesterol transport in macrophages.5 
Another approach to study regression was introduced by Feig et al., who used a 
model in which atherosclerosis-containing aortic segments from ApoE-/- mice were 
transplanted into wild-type recipient mice.6 However, the mechanisms underlying 
regression of atherosclerosis are not completely understood. While Feig et al. argued 
that promoting the emigration of CCR7-dependent monocytes/macrophages (CD68+ 
cells) is required for maximal regression, Potteaux et al. hypothesized that enhanced 
suppression of monocyte recruitment and increased macrophage apoptosis is essential 
for regression of atherosclerosis.7 
In addition to lipids, immune responses play a pivotal role in the pathogenesis of 
atherosclerosis. Oxidized LDL-cholesterol (oxLDL) is generally accepted as an 
antigen that activates the adaptive immune system after recognition by APCs such 
as macrophages and dendritic cells (DCs).8 Although antibody treatment against 
a specific epitope of oxLDL, ApoB100, has been shown to induce regression of 
atherosclerosis, the effect of modulating immune responses on regression has not 
been explored.9 T cells are important in the process of atherosclerosis and affect all 
stages of the disease process. For maximal activation, T cells require T cell receptor-
mediated antigen stimulation and costimulatory signals provided by costimulatory 
molecules on APCs. OX40 and OX40L are costimulatory molecules and belong to the 
TNF/TNF receptor family, respectively. OX40 is mainly present on activated T cells, 
whereas OX40L is mostly expressed on APCs but is also found on vascular endothelial 
cells. The OX40-OX40L interaction is important for T cell proliferation and survival; 
in particular, it promotes Th2 responses.10 Furthermore, activated OX40+ T cells drive 
isotype switching of B cells via interaction with OX40L.11
Modulation of the OX40-OX40L pathway potently ameliorates autoimmune-like 
diseases, such as EAE12, GVHD13, asthma10, and arthritis.14 We have previously linked 
increased levels of cholesterol to upregulation of OX40 expression on T cells and 
showed that interruption of the OX40-OX40L interaction using an OX40L-blocking 
antibody leads to a reduction in the initiation of atherosclerosis.15 In addition, Nakano 
et al. showed that the OX40-OX40L pathway plays an important role in vasa vasorum 
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formation.16 OX40L is located in Ath-1 on chromosome 1, a QTL that affects the 
differences in atherosclerosis susceptibility in Bl6 mice versus C3H/He and BALB/C 
mice.17, 18 OX40L deficiency renders mice less susceptible to atherosclerosis, whereas 
OX40L overexpression enhances the development of atherosclerosis.17 In humans, 
SNPs in both the OX40 and OX40L genes affect the incidence of cardiovascular 
disease.17, 19, 20
In the present study, we aimed to induce the regression of atherosclerotic lesions by 
a combined anti-inflammatory and lipid-lowering strategy. Atherosclerosis-prone LDL 
receptor-deficient (LDLr-/-) mice that had previously been fed a Western-type diet for 
10 weeks were placed back on a chow diet to lower plasma cholesterol levels and 
given anti-OX40L treatment, after which the degree of atherosclerosis was quantified. 
Materials and Methods
Animals
Male LDLr-/- mice, 10-12 weeks old, were obtained from Jackson Laboratories and 
male C57BL/6J mice were obtained from Charles River Laboratories. The animals 
were kept under standard laboratory conditions and were fed a normal chow diet or a 
Western-type diet containing 0.25% cholesterol and 15% cocoa butter (Special Diet 
Services, Witham, Essex, UK). Diet and water were provided ad libitum. All animal 
work was approved by the regulatory authority of Leiden University and performed in 
compliance with the Dutch government guidelines.
Regression of atherosclerosis
To study regression of atherosclerosis, mice were initially fed a Western-type diet for 
10 weeks. At week 10, a baseline group (n=13) was sacrificed to determine disease 
extent at the beginning of the treatment. Subsequently, mice were put on a chow 
diet and simultaneously treated intraperitoneally with 300 µg of anti-OX40L antibody 
(RM134L) in 150 µl of sterile PBS twice a week during 10 weeks (n=14). As a control, 
mice were treated with sterile PBS (n=14). At week 20, mice were sacrificed and 
tissues were harvested after in situ perfusion using PBS and subsequent perfusion 
using Zinc Formal-Fixx (Shandon Inc. Pittsburg, USA). Tissues were snap frozen in 
liquid nitrogen and stored at -80 °C until further use. 
Serum cholesterol levels
During the experiment, mice were weighed and blood samples were obtained by tail 
vein bleeding. The total cholesterol levels in the serum were determined at week 0, 
5, 10, 14, 18 and 20 after the start of the experiment. The concentrations of serum 
cholesterol were determined using enzymatic colorimetric procedures (Roche/Hitachi, 
Mannheim, Germany). Precipath (Roche/Hitachi) was used as an internal standard. 
Histological analysis and morphometry
Cryosections of the aortic root (10 µm) were collected and stained with Oil-Red-O. 
Interruption of the OX40-OX40L pathway causes regression of atherosclerosis 73
3  
Lesion size was determined in 5 subsequent sections of the heart within the three 
aortic valves. Lesion collagen content was determined with a Masson trichrome 
staining (Sigma-Aldrich, Zwijndrecht, The Netherlands). Corresponding sections 
on separate slides were stained immunohistochemically with an antibody directed 
against a macrophage specific antigen (Moma-2, monoclonal rat IgG2b, diluted 
1:1000, Serotec). Goat anti-rat IgG alkaline phosphatase conjugate (dilution 1:100) 
was used as a secondary antibody and nitro blue tetrazolium and 5-bromo-4-chloro-
3-indolyl phosphate as enzyme substrates. To determine the number of adventitial 
T cells, a CD3 staining was performed using anti-mouse CD3 (1:50, BD Biosciences 
Pharmingen, San Diego. CA). Mast cells were visualized by staining with Chloro-
Acetate Esterase (CAE, Sigma-Aldrich) according to manufacturer’s protocol. Mast 
cell numbers and the extent of mast cell degranulation were assessed manually. In 
addition, the aortic arch and its main branch points were excised (4 µm), fixed, and 
embedded in paraffin. Longitudinal sections of the aortic arch were analyzed for lesion 
extent with a hematoxylin and eosin staining. Collagen content was determined with a 
Masson trichrome staining. Morphology was studied using a Leica DM-RE microscope 
and LeicaQwin software (Leica imaging systems, Cambridge, UK). 
Flow cytometry
After sacrificing the mice, blood, spleen and peritoneal cells were isolated (n=5 per 
group). Single cell suspensions were obtained by squeezing the cells through a 70 
µm cell strainer. Red blood cells were lysed using erythrocyte lysis buffer (0.15 M 
NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA, pH 7.3). Subsequently, cells were stained 
for the following surface markers: CD4, OX40, CD5, IgM, CD3 and NK1.1 (0.20 
µg Ab/200.000 cells). For intracellular staining, cells were fixed and permeabilized 
according to manufacturer’s protocol (eBioscience, Belgium). Subsequently, the cells 
were stained for IL-5, GATA-3, Foxp3, T-bet or RORγt. All antibodies were purchased 
from eBioscience (Belgium) or Beckton Dickinson (Mountain View, CA). FACS analysis 
was performed on a FACSCantoII (Beckton Dickinson). Data were analyzed using 
FACSDiva software. 
Serum antibody detection
IgM levels against oxLDL were detected in serum using Abs recognizing mouse IgM 
and HRP-labeled goat anti-rat Ig (BD Pharmingen). OxLDL (5 µg/mL) was dissolved 
in NaHCO3/Na2CO3 buffer (pH 9.6) and was coated o/n onto a flat-bottom 96-well 
high binding plate (Corning, NY). Serum samples were 1:1 diluted in PBS and 
absorbance was detected at 450 nm. Total IgE in serum was determined by a mouse 
IgE quantitative ELISA according to manufacturer’s protocol (Bethyl Laboratories, 
Montgomery TX, USA). 
Cytokine determination in serum and supernatant of splenocytes
To detect IL-5 in serum an ELISA was performed according to manufacturer’s protocol 
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(eBioscience, Belgium). Serum samples were 1:1 diluted in assay diluent and 
absorbance was detected at 450 nm. Eotaxin levels were measured with an eotaxin 
ELISA kit (R&D Systems) and used according to manufacturer’s protocol. Absorbance 
was measured at 450 nm. For the detection of IL-4, IL-5 and IL-10, splenocytes isolated 
from mice at sacrifice (n=5 per group) were cultured for 48 hours in triplicate at 2x105 
cells/well in the presence of 2 μg/mL αCD3 and αCD28. Supernatant was collected 
and cytokine concentrations were determined by ELISA (eBioscience, Belgium). 
Real-time PCR assays
Spleens from baseline mice (n=13), control mice (n=14) and anti-OX40L mice 
(n=14) were isolated and mRNA was extracted using the guanidium isothiocyanate 
(GTC) method and reverse transcribed (RevertAid M-MuLV reverese transcriptase). 
Quantitative gene expression analysis was performed on a 7500 Fast Real-Time PCR 
system (Applied Biosystems, CA) using SYBR green technology. The following primer pair 
was used: 5’-GATGGGAAGAAGGTGATGGGTG-3’ and 5‘-TTGTGAAGGACGAAGAAGGC-3’ 
for IL-33. Acidic ribosomal phosphoprotein PO (36B4) and hypoxanthine phospho-
ribosyltransferase (HPRT) were used as the endogenous references.
Cell culture 
Bone marrow cells were harvested from the femora and tibia of C57BL/6J mice 
and were cultured for 10 days in complete IMDM supplemented with granulocyte-
macrophage colony-stimulating factor (GM-CSF) to obtain immature DCs. To obtain 
immature macrophages, bone marrow cells were cultured for 7 days in complete RPMI 
supplemented with M-CSF (L929 supernatant). Immature DCs and macrophages were 
stimulated with copper-oxidized LDL in the absence or presence of 1, 5 or 10 µg/mL 
anti-OX40L (RM134L). IL-33 production was analyzed with flow cytometry by using 
IL-33-PE (R&D Systems). 
Statistical analysis
All data are expressed as mean±SEM. An unpaired two-tailed student’s T-test was 
used to compare normally distributed data between two groups of animals. Probability 
values of P<0.05 were considered significant. 
Results
Interruption of the OX40-OX40L pathway induces regression of atherosclerosis
To study the regression of atherosclerotic lesions, we investigated the effect of 
lowering cholesterol combined with an immunomodulatory treatment on pre-formed 
atherosclerotic lesions. To this end, we put LDLr-/- mice that had been fed a Western-
type-type diet for 10 weeks on a chow diet for another 10 weeks, combined with 
simultaneous administration of anti-OX40L or PBS. A baseline group was sacrificed 
after 10 weeks on the Western-type diet to determine the effect of treatment on 
atherosclerotic lesion size. No significant differences in weight and cholesterol levels 






















































Figure 1. Anti-OX40L treatment induces regression of atherosclerosis. LDLr-/- mice received Western-
type diet for 10 weeks and were subsequently put on chow diet for 10 weeks and simultaneously treated 
with anti-OX40L (n=14) or PBS (n=14). A baseline group was sacrificed after 10 weeks of Western-
type diet (n=13). Sections of the aortic root were stained with Oil-Red-O and hematoxylin (A) and 
subsequently lesion size was determined (B). Corresponding sections on separate slides were also stained 
for collagen using Masson’s trichrome staining (C). The percentage of collagen relative to the lesion size 
was determined (D). Furthermore, relative macrophage content was determined with a MOMA-2 staining 
(E) and quantified (F). *P<0.05, ***P<0.001 
were found between baseline, control and anti-OX40L-treated mice after 10 weeks 
of Western-type diet (data not shown). In addition, no differences in weight and 
cholesterol levels were observed between the control and anti-OX40L-treated mice 10 
weeks after switching to chow diet. After 10 weeks on the chow diet, the mice were 
sacrificed, and the degree of atherosclerosis was analyzed at a number of sites in the 
vascular bed. Figure 1A shows representative cross-sections of lesions in the three-
valve area of the aortic root. We observed a significant 29% reduction in the aortic 
root lesion size in anti-OX40L-treated mice (2.18×105±0.22×105 µm2) compared with 
control mice (3.06×105±0.25×105 µm2, P<0.05) and a 20% reduction compared 
to baseline mice (2.74×105±0.10×105 µm2, P<0.05, Figure 1B). With respect to 
the composition of the lesion, no differences were found in lesion collagen content 
between anti-OX40L-treated mice (31.5±3.5%) and control mice (31.6±1.8%). We 
did observe a significant increase in the relative collagen content (P<0.001) in both 
groups of mice that were put on a low-fat diet compared to baseline-sacrificed mice 
(collagen content 12.2±1.2%, Figure 1C-D). Furthermore, the relative macrophage 
content did not significantly differ in the anti-OX40L-treated group (13.4±2.3%) 
versus the control group (14.3±1.6%, Figure 1E-F). Both groups, however, showed 
a significant 60% reduction in the relative macrophage content compared to the 
baseline group (36.7±2.6%, P<0.001). 
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Analysis of lesion formation in the aortic arch showed an even greater capacity of anti-
OX40L to induce regression when administered in combination with cholesterol lowering 
(Figure 2A-B). The lesion size in anti-OX40L-treated mice (1.73×105±0.22×105 
µm2) was reduced by 38% in comparison with control mice (2.78×105±0.39×105 
µm2, P<0.05) and by 27% compared with baseline mice (2.38×105±0.22×105 µm2, 
P<0.05). 
 
Anti-OX40L treatment reduces OX40 expression and adventitial T cell 
numbers
To determine whether anti-OX40L treatment effectively interrupted the OX40-OX40L 
pathway, OX40 expression on T cells in the blood was determined using flow cytometry. 
As shown in Figure 3A, a 47% decrease in CD4+OX40+ T cells within the CD4+ T cell 
population was observed in the blood of mice treated with anti-OX40L (9.9±0.8%) 
compared with control mice (18.5±1.3%, P<0.001). Furthermore, we analyzed the 
aortic root to identify CD3+ T cells within lesions and found almost no T cells in the 
lesions of the baseline, control and anti-OX40L-treated mice. However, we observed a 
significant 56% reduction in the number of CD3+ T cells within the adventitia of anti-
OX40L-treated mice (17.6±1.4 T cells/section) compared with control mice (40.3±6.3 
T cells/section, P<0.05, Figure 3B-C). Notably, both groups showed an accumulation 
of adventitial CD3+ T cells compared with baseline mice (7.7±1.8 T cells, P<0.01) 
after the switch to the chow diet. 
Interruption of the OX40-OX40L pathway reduces Th2 responses
OX40/OX40L costimulatory molecules modify T cell polarization; in particular, they 























Figure 2. Anti-OX40L treatment induces regression of atherosclerosis in the aortic arch. LDLr-/- mice 
received Western-type diet for 10 weeks and were subsequently put on chow diet for 10 weeks and 
simultaneously treated with anti-OX40L (n=14) or PBS (n=14). A baseline group was sacrificed after 10 
weeks of Western-type diet (n=13). The aortic arch and its main branch points were excised, fixed, and 
embedded in paraffin. Longitudinal sections of the aortic arch were stained with hematoxylin and eosin 
(A) to analyze lesion extent (B). *P<0.05
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Figure 3. Decreased OX40 expression and adventitial CD3+ T cell infiltration in anti-OX40L-treated mice. 
LDLr-/- mice received 10 weeks Western-type diet and were subsequently put on chow diet for 10 weeks 
and treated with anti-OX40L (n=14) or PBS (n=14). A baseline group was sacrificed after 10 weeks 
of Western-type diet (n=13). At sacrifice, OX40 expression on T cells in the blood was determined by 
flow cytometry (A). Sections of the aortic root were stained for CD3 (red) to determine the number of 
infiltrating T cells (B-C). *P<0.05, **P<0.01, ***P<0.001
on T cells inhibits Treg differentiation and may thus enhance inflammation.21 The 
differentiation of naive T cells into Th1, Th2, Th17 or Treg cells following anti-
OX40L treatment was analyzed using flow cytometry. Anti-OX40L-treated mice had 
a significantly reduced number of GATA-3+ cells within the CD4+ T cell population 
of the blood (5.0±0.6% versus 7.0±0.4% (control), P<0.05, Figure 4A) and spleen 
(3.6±0.4% versus 5.3±0.4% (control), P<0.05). The other T cell subsets, Th1, Th17 
and Tregs, remained unaffected under hypercholesterolemic conditions following anti-
OX40L treatment (data not shown). To further define the reduced Th2 response, 
splenocytes isolated from anti-OX40L-treated mice and control mice were cultured for 
48 hours in the presence of αCD3/CD28 stimulation. Secretion of the Th2 cytokines 
IL-4 and IL-10 was significantly (P<0.05) decreased by splenocytes from anti-OX40L-
treated mice, whereas IL-5 secretion was unexpectedly increased in these mice, 
compared with IL-5 production by splenocytes from control mice (Figure 4B).
Anti-OX40L treatment increases the production of atheroprotective oxLDL-
specific IgM via IL-5
Previous studies have shown that IL-5 exerts its atheroprotective functions in part 
by promoting oxLDL-specific IgM secretion by B1 cells, a subset of B cells that is 
predominantly found in peritoneal cavities.22, 23 To determine whether the increased 
IL-5 levels observed in anti-OX40L-treated mice induced oxLDL-specific IgM production 
in B1 cells, we quantified the serum IL-5 levels. As shown in Figure 4C, IL-5 was 
elevated in the serum of anti-OX40L-treated mice (229.5±52.6 pg/mL) compared 
with control mice (123.7±4.1 pg/mL, P<0.05), which is in agreement with our 
previous findings on OX40L inhibition.15 In addition, increased percentages of IL-5-
producing cells were found in the blood of anti-OX40L-treated mice (3.0±0.7% versus 
0.8±0.1% (control), P<0.05, Figure 4D). Most importantly, IL-5 production was 
increased in the peritoneum of anti-OX40L-treated mice (17.4±3.2%) compared with 




































































































Figure 4. Reduced Th2 response and increased oxLDL-specific IgM production by B1 cells in anti-OX40L 
treated mice. LDLr-/- mice received 10 weeks Western-type diet and were subsequently put on chow diet 
for 10 weeks and treated with anti-OX40L (n=14) or PBS (n=14). The treated mice were sacrificed 20 
weeks after initiation of the experiment. At sacrifice, GATA-3 expression in CD4+ T cells from the blood 
and spleen was determined by flow cytometry (A). Detection of IL-4, IL-5 and IL-10 was determined by 
ELISA in the supernatant of splenocytes stimulated with αCD3 and αCD28 for 48 hours (B). IL-5 present 
in serum of treated mice was determined by ELISA (C). At sacrifice, IL-5 production by cells in blood and 
the peritoneum was determined by flow cytometry (n=5 per group) (D). In the peritoneum B1 cells (CD4-
CD5+IgM+) were stained (E). oxLDL-specific IgM production was detected in serum of control (n=9) and 
anti-OX40L treated mice (n=8) (F). *P<0.05, **P<0.01
CD5+IgM+) were found in the peritoneum of anti-OX40L-treated mice (13.1±1.3% 
versus 8.9±0.5% in control mice, P<0.05, Figure 4E). Furthermore, a significant 51% 
increase in oxLDL-specific IgM was found in the serum of anti-OX40L-treated mice, as 
shown in Figure 4F (P<0.01). We previously showed that the OX40-OX40L interaction 
also affects T cell-dependent humoral responses.15
Anti-OX40L treatment induces IL-5-producing T helper cells 
Most researchers agree that a single T cell population secretes a complete panel of 
typical Th2 cytokines. However, splenocytes from anti-OX40L-treated mice produced 
increased levels of IL-5 but had a vast decrease in IL-4 secretion (Figure 4B), which 
may indicate that a specific subset of T cells is responsible for the production of IL-5. 
Therefore, we investigated which cells produced IL-5, independent of IL-4, in anti-
OX40L-treated mice. Notably, we observed increased levels of IL-5-producing CD4+ 
T cells in the peritoneum of anti-OX40L-treated mice compared with control mice 
(1.1±0.2% versus 2.9±0.4%, respectively, P<0.01, Figure 5A). A newly described 
IL-1 family member, IL-33, induces antigen-specific IL-5+ T cells and oxLDL antibody 
production.24 We therefore analyzed IL-33 production in anti-OX40L-treated mice; 
quantitative PCR demonstrated a 4-fold higher relative expression of IL-33 in the 
spleen of anti-OX40L-treated mice compared with control mice (P<0.05, Figure 5B). 
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IL-33 is produced by a variety of cells, including macrophages and dendritic cells.25 
We determined the effect of anti-OX40L on cultured, oxLDL-stimulated macrophages 
and dendritic cells; anti-OX40L dose-dependently increased IL-33 secretion by both 
macrophages (Figure 5C) and DCs (Figure 5D), as measured using flow cytometry. 
Finally, high levels of IL-5 are associated with increased amounts of eosinophils.26 
Eotaxin is the most potent chemoattractant for eosinophils, and using an ELISA, we 
found that eotaxin levels did not differ between control and anti-OX40L-treated mice, 
whereas the reduction in cholesterol upon the switch to chow diet did reduce eotaxin 
levels (data not shown).
Decreased mast cell activity in anti-OX40L-treated mice
Besides promoting the development of naive T cells into Th2 cells, IL-4 also affects 
IgG and IgE isotype switching in B cells. Because interruption of the OX40-OX40L 
pathway reduces IL-4 levels and Th2 development (as indicated by the number of 
GATA3+ T cells), we determined whether IgE secretion was affected by anti-OX40L 
treatment. We found a 68% decrease in IgE levels in anti-OX40L-treated mice (36±7 
ng/mL) compared with control (113±25 ng/mL, P<0.01) and baseline (110±23 
ng/mL, P<0.01, Figure 6A) mice. Paralleling the reduction in IgE serum levels, a 
20% reduction in mast cells (MC) was found in the atherosclerotic lesions of the 
aortic root in anti-OX40L-treated mice (18.5±1.6 MC/mm2) compared with control 
(23.2±1.1 MC/mm2, P<0.05) and baseline (24.4±1.6 MC/mm2, P<0.05, Figure 6B-C) 
mice. Moreover, 40% and 63% decreases in activated mast cells were found in anti-
OX40L-treated mice (2.1±0.32 MC/mm2) compared with control (3.5±0.35 MC/mm2, 
P<0.01) and baseline (5.6±0.66 MC/mm2, P<0.001, Figure 6D) mice, respectively. 
Figure 5. Anti-OX40L treatment 
induces Th5 cells via IL-33. LDLr-/- 
mice received 10 weeks Western-
type diet and were subsequently 
put on chow diet for 10 weeks and 
treated with anti-OX40L (n=14) 
or PBS (n=14). At sacrifice, 
CD4+ T cells secreting IL-5 in the 
peritoneum were determined 
with flow cytometry (A). mRNA 
expression of IL-33 in the spleen 
was determined in response to anti-
OX40L treatment (B). Expression 
of IL-33 is expressed relative to 
36B4 and HPRT, and subsequently 
compared with the expression in 
control mice. Bone-marrow derived 
macrophages (C) and DCs (D) 
were cultured in the presence of 
2.5 μg/mL oxLDL with increasing 
concentrations of anti-OX40L. IL-33 




















































































Notably, cholesterol reduction alone reduces mast cell degranulation but does not 
change the total number of mast cells. 
Discussion 
Experimental therapies aimed at achieving regression of atherosclerotic lesions in 
both human and animal models currently focus on lowering plasma LDL levels using 
statins2 and improving reverse lipid transport and plasma HDL levels using agents such 
as phosphatidylcholine (PC) liposomes27, CETP inhibitors28, LXR agonists6, and more 
recently, modulators of miR-33 expression.29 Atherosclerosis, however, results not only 
from lipid accumulation but is also a chronic autoimmune-like disease and immune 
responses promote disease in every stage of atherosclerosis. Immune cells such as 
APCs, T cells, B cells and mast cells contribute to lesion initiation and progression, 
and modulation of these cells may yield an unexplored therapeutic strategy to induce 
regression of well-established atherosclerotic lesions. Therefore, in the present study, 
we aimed to simulate the effect of plasma lipid lowering (mimicking statin treatment) 
by switching mice from a Western-type diet to a chow diet in combination with 
reducing the immune response by interfering with the OX40-OX40L pathway. 
Here, we show that lipid lowering alone increased lesion stability, as demonstrated by 
increases in collagen content, but only additional anti-inflammatory treatment with 
an anti-OX40L antibody induced lesion stabilization and regression. Furthermore, a 
robust loss in macrophage content was observed in both control and anti-OX40L-
treated mice compared with baseline mice. The biological processes underlying the 
morphological changes of a regressing lesion are subjects of discussion. Whether 
a decrease in lesion macrophage content during regression results from enhanced 
macrophage efflux6, reduced monocyte influx7, increased macrophage apoptosis7, or 
enhanced influx of functional phagocytes that clear debris from the lesions is currently 
being debated.30 Notably, we show herein that after the switch to chow diet, control 
mice show a 5-fold increase in adventitial CD3+ T cells compared with the number of 















































Figure 6. Reduction of IgE and mast cell activation in anti-OX40L treated mice. LDLr-/- mice received 
Western-type diet for 10 weeks and were subsequently put on chow diet for 10 weeks and simultaneously 
treated with anti-OX40L (n=14) or PBS (n=14). A baseline group was sacrificed after 10 weeks of 
Western-type diet (n=13). IgE was measured in the serum of baseline, control and anti-OX40L treated 
mice (A). Sections of the aortic root were stained with CAE to detect mast cells (B). Mast cell numbers (C) 
and the extent of mast cell degranulation (D) were assessed manually. *P<0.05, **P<0.01, ***P<0.001
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attracted to the lesion and parallels the decrease in the number of macrophages, which 
may indicate that macrophage death within the lesion results in the attraction of these 
adventitial T cells. These newly infiltrating T cells may support a new, fibrosis-like 
inflammatory process and thereby prevent lesion regression in control mice, whereas 
anti-OX40L-treated mice, which have a significantly lower influx of adventitial CD3+ T 
cells, show significant lesion regression in the aortic root and arch. The reduction in 
T cell numbers in the regressed lesions correlates with the significant 47% reduction 
in circulating OX40-expressing CD4+ T cells and the reduced mast cell activation, 
although the number of adventitial CD3+ T cells in these mice was still higher than in 
baseline mice. 
Previously, we demonstrated that anti-OX40L treatment reduces initial atherosclerosis 
in part via a reduced Th2 response.15 We now confirm that interruption of the OX40-
OX40L pathway also induces elevated levels of IL-5, a characteristic Th2 cytokine, 
and enhances oxLDL-specific IgM levels in serum when plasma cholesterol levels 
are normal. We also show that the source of the enhanced IL-5 levels is a specific 
subset of T helper cells. Consistent with previous findings, interruption of the OX40-
OX40L pathway reduced the Th2 response, as shown by decreases in GATA-3, IL-4 
and IL-10 expression in anti-OX40L-treated mice. Notably, we demonstrate that 
the two typical Th2 cytokines, IL-5 and IL-4, are differentially expressed after anti-
OX40L treatment, which may result from the fact that IL-4 and IL-5 are differentially 
regulated at the transcriptional level. Whereas differentiation of IL-4-producing T cells 
is dependent on STAT631 and GATA-332, Kurowska et al. showed that IL-5-producing T 
cells differentiate independently of STAT6 and GATA-3.24 These CD4+-IL-5 producing 
T cells can be induced by IL-33, a novel cytokine and a member of the IL-1 family. 
IL-33 binds to a receptor complex composed of ST2L and IL-1RAcP, which is expressed 
on Th2 cells and mast cells.25 Recently, Miller et al. showed that IL-33 reduces the 
development of atherosclerosis in ApoE-/- mice via induction of IL-5 and anti-oxLDL-
specific IgM antibody formation.33 Furthermore, IL-33 inhibits foam cell formation via 
a decrease in oxLDL uptake and an increase in cholesterol efflux34 and can protect 
against the development of adipose tissue inflammation during obesity.35 Indeed, a 
4-fold increase in IL-33 expression in the spleen was observed in anti-OX40L-treated 
mice compared with control mice. In addition, in vitro experiments showed that 
IL-33 production is dose-dependently increased by anti-OX40L treatment of DCs and 
macrophages exposed to oxLDL. We also found an increase in the numbers of B1 
cells, which subsequently produce oxLDL-specific IgM. These findings are consistent 
with a study by Binder et al., who showed that IL-5-mediated stimulation of B1 cells 
is responsible for the increased secretion of natural IgM that is specific to oxLDL.22 
OxLDL-specific IgM plays a protective role in atherosclerosis because it prevents foam 
cell formation by inhibiting oxLDL uptake by macrophages, helps clear apoptotic cells 
and prevents inflammatory reactions towards oxLDL and other modified lipids.36, 
37 Furthermore, IL-5 deficiency leads to decreased oxLDL-specific IgM titers and 
enhanced atherosclerosis.22
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The increases in the atheroprotective factors IL-33, IL-5 and oxLDL-specific IgM in anti-
OX40L-treated mice likely contribute to the observed regression of atherosclerosis. 
The exact mechanism of IL-33 secretion is unknown; however, IL-33 acts as an 
alarmin and is secreted by necrotic cells.38 Blockade of the OX40-OX40L pathway 
induces anergy in cells39, which may induce secretion of the alarmin IL-33, and 
IL-33 may directly contribute to lesion regression by enhancing cholesterol efflux from 
macrophages within the lesion. 
An additional pathway via which OX40-OX40L blockade may facilitate lesion regression 
is a reduction in IgE levels and subsequent mast cell activation. IL-4 induces isotype 
switching of B cells from IgM- to IgE- and IgG-producing cells. Previously, we showed 
that anti-OX40L treatment reduces IgG1 levels15; we now show that interruption 
of OX40-OX40L treatment also induces a strong reduction in serum IgE, which is 
consistent with several studies that show reduced IL-4 production and IgE serum 
levels upon anti-OX40L treatment40, 41 or in OX40L-/- mice following H. polygyrus 
exposure.42 IgE is a common mast cell activator that binds to the high-affinity Fc epsilon 
receptor present on mast cells and subsequently induces the release of inflammatory 
compounds, such as histamine, TNFα and IL-6. This IgE-induced mast cell activation 
is of particular interest with respect to atherosclerosis and lesion regression because 
mast cells are implicated in cardiovascular disease. Activated mast cells are found in 
the adventitia of vulnerable and ruptured lesions of patients suffering from myocardial 
infarction43, 44, and mast cell numbers correlate with the incidence of plaque rupture 
and erosion.43 Our lab has previously shown that mast cells also play a crucial role in 
plaque progression and destabilization in vivo.45 We now demonstrate that a reduction 
in plasma IgE levels reduces mast cell numbers and activation in anti-OX40L-treated 
mice. Mast cells not only contribute to atherosclerosis by releasing proteases and 
histamine but also secrete pro-inflammatory molecules that directly interact with T 
cells and can function as so-called “non-professional” APCs. Nakae et al. showed 
that anti-OX40L treatment reduces IgE/Ag-dependent mast cell-mediated T cell 
proliferation and cytokine production.46 Thus, reductions in mast cell numbers and 
activation may contribute to the reduction in adventitial CD3+ T cells observed in anti-
OX40L-treated mice compared with control mice. Furthermore, switching mice to a 
low-fat diet does not affect mast cell numbers but reduces mast cell activation, thereby 
possibly reducing the recruitment of new immune cells to the site of inflammation. 
In addition, enhanced IgE levels were observed in patients with unstable angina 
pectoris and in dyslipidemia47, 48 and recently, Wang et al. showed that IgE promotes 
atherosclerosis in ApoE-/- mice.49 In line with these findings, we suggest that IgE may 
play an important role in atherosclerosis and show that modulation of the OX40-
OX40L pathway reduces IgE levels and thereby contributes to lesion regression.
Conversely, IL-33 enhances inflammatory responses in other autoimmune diseases, 
such as rheumatoid arthritis. IL-33 is abundantly expressed in synovial fluid50 and 
induces the expression of pro-inflammatory cytokines such as TNFα, IL-1β and IFN-γ.51 
Furthermore, IL-33 exacerbates collagen-induced arthritis via the activation of mast 
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cells.52 Notably, in this study, plasma IgE levels were strongly reduced, and vascular 
mast cell activation was inhibited by anti-OX40L treatment, despite the upregulation 
in IL-33. These results may indicate that the anti-OX40L-dependent reductions in IL-4 
and IgE contribute more strongly to mast cell activation than does IL-33. Notably, 
although Miller et al. observed a reduction in atherosclerosis upon IL-33 treatment, 
they did not determine the numbers of mast cells present in the atherosclerotic lesions.
In conclusion, modulation of the OX40-OX40L pathway, combined with cholesterol 
reduction, induces regression of atherosclerosis via (1) the induction of IL-5-
producing T cells and oxLDL-specific IgM and (2) Th2 reduction and subsequent 
mast cell inhibition. It must be noted that interruption of the OX40-OX40L pathway 
does not induce maximal regression of lesions. Further research into modulating 
immune responses to induce regression must be explored and, in combination with 
lipid lowering, may hold the key to therapies for cardiovascular patients with well-
established lesions. 
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Abstract 
Objective: Costimulatory molecules tightly control immune responses by providing 
positive signals that promote T cell activation or by transducing inhibitory signals 
that limit T cell responses. CD30 and CD30L are members of the TNF(R) superfamily 
and are involved in activation and proliferation of T and B cells, which have been 
implicated in the initiation and progression of atherosclerosis. In the present study, 
we thus aimed to determine the role of the CD30-CD30L pathway in the development 
of atherosclerosis. 
Methods and Results: Western-type diet fed LDL receptor deficient (LDLr-/-) mice 
were treated with an anti-CD30L antibody for 8 weeks, which resulted in a reduction 
of atherosclerotic lesion formation in the aortic root by 35%. Reduced numbers of 
adventitial CD3+ T cells were found in anti-CD30L-treated mice, whereas no differences 
were observed in collagen and macrophage content of the atherosclerotic lesions. 
B cell and mast cell responses were also not affected upon anti-CD30L treatment. 
Interestingly, splenocyte proliferation was reduced with 53%, while T cell numbers 
were concomitantly reduced in anti-CD30L-treated mice compared with control mice. 
These data thus indicate that the CD30-CD30L pathway solely exerts its function via 
inhibition of T cell responses.
Conclusions: In the present study, we are the first to show that interruption of the 
CD30-CD30L pathway reduced initial atherosclerosis development by modulating T 
cell function.
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Introduction
Atherosclerosis is considered a chronic autoimmune-like disease resulting from 
endothelial damage and subsequent cholesterol accumulation in the arterial wall.1, 
2 Within the atherosclerotic lesion a chronic inflammation manifests by a continuous 
infiltration of immune cells. Antigen presenting cells, such as dendritic cells (DCs) and 
macrophages, present antigens such as oxidized LDL-cholesterol to T cells, resulting 
in their activation. As a result both T cells and macrophages secrete cytokines, 
and more immune cells are attracted to the site of inflammation, which aggravates 
atherosclerotic lesion development. 
T cell activation is tightly controlled by a complex network of costimulatory molecules, 
which can either provide positive or negative signals. Two large families of costimulatory 
molecules are known; the B7-CD28 superfamily, that includes CD28/CD80/CD86 and 
PD-1/PD-L1/2, and the TNF-TNFR superfamily, including OX40/OX40L and CD40/
CD40L. Numerous studies have shown the crucial role of costimulatory molecules in 
the pathogenesis of atherosclerosis.3-5 Previously, our lab showed that interruption of 
the OX40-OX40L interaction using an OX40L-blocking antibody leads to a reduction 
in the initiation of atherosclerosis.4 Signaling of CD40-CD40L has been shown to 
affect advanced atherosclerosis, as lesions of CD154-/-ApoE-/- mice contained fewer 
lipids, showed increased collagen levels and reduced numbers of immune cells such 
as T cells and macrophages, compared to ApoE-/- mice.3 In addition, Gotsman et al. 
showed that the negative costimulatory pathway PD-1/PD-L1/2 downregulates pro-
atherogenic T cell responses and atherosclerosis, since PD-L1/2 LDLr double knockout 
mice developed significantly larger atherosclerotic lesions compared with LDLr-/- mice.5 
CD30 (TNFRSF8) and CD30L (TNFSF8, CD153) also belong to the TNF-TNFR superfamily. 
Whereas CD30 and CD30L are both present on activated B and T cells, CD30L is also 
expressed on other cell types, such as mature DCs, macrophages and mast cells. 
Triggering via CD30-CD30L has been shown to induce activation and proliferation of 
T cells.6, 7 Furthermore, the CD30-CD30L pathway has been implicated as a major 
player in secondary humoral immune responses. CD30-/- mice have impaired follicular 
germinal center responses and reduced secondary antibody responses.8, 9 In addition, 
CD30L transgenic mice show increased numbers and activity of splenic germinal 
centers and have elevated serum antibody levels, such as IgG2b and IgE.10 
The in vivo role of the interaction between CD30 and CD30L can be investigated using 
anti-CD30L antibodies, which interrupt the CD30-CD30L pathway. CD30 deficiency 
or treatment with a CD30L blocking antibody (RM153) significantly reduced airway 
inflammation in a murine asthma model11, while Blazar et al. showed that anti-CD30L 
prolongs survival of mice in graft versus host disease.12 Furthermore, administration of 
anti-CD30L completely suppressed the development of spontaneous/type I diabetes 
in NOD mice.13 
Although macrophages bearing CD30 have been identified in ruptured plaques of 
patients with coronary artery disease14, the involvement of the CD30-CD30L pathway 
in the development of atherosclerosis has not been investigated. In the present study, 
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we therefore investigated the role of the CD30-CD30L pathway in the initiation of 
atherosclerosis by treatment of LDLr-/- mice with a CD30L blocking antibody.
Methods 
Animals
Female LDLr deficient (LDLr-/-) mice, 10-12 weeks old, were obtained from Jackson 
Laboratories. The animals were kept under standard laboratory conditions and were 
fed a normal chow diet or a Western-type diet containing 0.25% cholesterol and 
15% cocoa butter (Special Diet Services, Witham, Essex, UK). Diet and water were 
provided ad libitum. All animal work was approved by the regulatory authority of 
Leiden University and carried out in compliance with the Dutch government guidelines.
CD30L expression during atherosclerosis
After 2 weeks of Western-type, atherosclerosis was induced in LDLr-/- mice by 
collar placement (2 mm long, inner diameter 0.3 mm) around both carotid 
arteries and continuous Western-type diet feeding.15 Mice were sacrificed at 0, 2, 
4, 6, 8 and 10 weeks after collar placement and tissues were harvested after in 
situ perfusion using PBS. Carotid arteries and spleens (n=4-6 per timepoint) 
were isolated and mRNA was extracted using the guanidium isothiocyanate 
(GTC) method and reverse transcribed (RevertAid M-MuLV reverse transcriptase). 
Quantitative gene expression analysis was performed on a 7500 Fast Real-
Time PCR system (Applied Biosystems, CA) using SYBR green technology. The 
following primer pairs were used: 5’-CCAAGAAGTCATGGGCCTACCTCCAA-3’ and 
5’-GCAAACGATGAAGTACAAGCCAGGGAA-3’ for CD30L, 5’-GAGCTCTTGTTGGTTG-
GGAA-3’ and 5’-CGAACATCTGTGAAGGCAAA-3’ for CD4 and 5’-GTTGGGGCAGT-
TGTAGGAAG-3’ and 5’-TGTGAAGCCAGAGGACAGTG-3’ for CD8. The following primers 
were used as endogenous references: 5’-GGACCCGAGAAGACCTCCTT-3’ and 5’ 
GCACATCACTCAGAATTTCAATGG-3’ for acidic ribosomal phosphoprotein PO (36B4) 
and 5’-TTGCTCGAGATGTCATGAAGGA-3’ and 5’-AGCAGGTCAGCAAAGAACTTATAG-3’ 
for hypoxanthine phosphoribosyltransferase (HPRT). Protein levels of CD30L were 
determined in blood of LDLr-/- mice fed a Western-type diet (n=5) or a chow diet (n=5) 
for 0, 4 and 8 weeks. Red blood cells were removed from blood using erythrocyte lysis 
buffer (0.15 M NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA, pH 7.3). Cells were stained 
with CD4 and CD30L and positive cells were determined with flow cytometry. All 
antibodies were purchased from eBioscience (Vienna). FACS analysis was performed 
on a FACSCantoII (Beckton Dickinson, Mountain View, CA). Data were analyzed using 
FACSDiva software (Beckton Dickinson). 
Functionality of the anti-CD30L antibody under hypercholesterolemic conditions
To determine the effect of anti-CD30L on splenocyte proliferation, splenocytes from 
Western-type diet fed mice (n=3) were cultured for 24 hours in triplicate in a 96-wells 
round-bottom plate (2×105 cells/well, Greiner Bio-One) in RPMI 1640 supplemented 
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with L-Glutamine, 100 U/mL streptomycin/penicillin and 10% FCS. Splenocytes were 
cultured in the absence or presence of αCD3 and αCD28 (2 μg/mL) with anti-CD30L 
(0.1–10 μg/mL). Proliferation was measured by addition of 3H-thymidine (0.5 μCi/well, 
Amersham Biosciences, The Netherlands) 16 hours prior to cell lysis. The amount of 
3H-thymidine incorporation was measured using a liquid scintillation analyzer (Tri-Carb 
2900R). Responses are expressed as stimulation index (SI): ratio of mean counts per 
minute of triplicate cultures with αCD3/CD28 stimulation to triplicate cultures without 
stimulation. 
Atherosclerosis
Atherosclerosis was induced in LDLr-/- mice by feeding a Western-type diet for 8 weeks. 
Mice were treated i.p. with 250 µg anti-mouse CD30L (RM153) (n=12) or sterile 
PBS (n=12) twice a week. Anti-mouse CD30L was kindly provided by Hideo Yagita 
and prepared as previously described.16 At week 8 mice were sacrificed and tissues 
were harvested after in situ perfusion using PBS. Tissues for histology were fixed in 
Zinc Formal-Fixx (Shandon Inc. Pittsburg, USA). Tissues were frozen in nitrogen and 
stored at -80 °C until further use. 
Serum cholesterol levels
During the experiments, mice were weighed and blood samples were obtained by tail 
vein bleeding. The total cholesterol levels in serum were determined at week 0, 2, 
4, 6 and 8 after start of the Western-type diet feeding. The concentrations of serum 
cholesterol were determined using enzymatic colorimetric procedures (Roche/Hitachi, 
Mannheim, Germany). Precipath (Roche/Hitachi) was used as an internal standard. 
Histological analysis and morphometry
Cryosections of the aortic root (10 µm) were made and stained with Oil-Red-O. To 
determine the number of adventitial T cells, a CD3 staining was performed using anti-
mouse CD3 (1:100, SP7, Immunologic, The Netherlands). Lesion collagen content 
was determined with a Masson’s Trichrome staining. Furthermore, corresponding 
sections on separate slides were stained immunohistochemically with an antibody 
directed against a macrophage specific antigen (Moma-2, monoclonal rat IgG2b, 
diluted 1:1000). Goat anti-rat IgG alkaline phosphatase conjugate (dilution 1:100) 
was used as a secondary antibody and nitro blue tetrazolium and 5-bromo-4-chloro-
3-indolyl phosphate as enzyme substrates. Mast cells were visualized by staining with 
Chloro-Acetate Esterase (CAE, Sigma-Aldrich) according to manufacturer’s protocol. 
Mast cell numbers and the extent of mast cell degranulation were assessed manually. 
The necrotic core was defined as the a-cellular, debris-rich plaque area as percentage 
of total plaque area. In addition, the aortic arch and its main branch points were 
excised (4 µm), fixed, and embedded in paraffin. Longitudinal sections of the aortic 
arch were analyzed for lesion extent with a hematoxylin and eosin staining. Spleen 
sections were stained with hematoxylin and eosin. Morphology was studied using a 
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Leica DM-RE microscope and LeicaQwin software (Leica imaging systems, Cambridge, 
UK). 
Flow cytometry
At sacrifice, blood, spleen and mediastinal lymph nodes (LN) were isolated (n=5 per 
group). Single cell suspensions were obtained by squeezing the organs through a 
70 µm cell strainer. Red blood cells were removed from blood and splenocytes using 
erythrocyte lysis buffer (0.15 M NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA, pH 7.3). Cells 
were stained with CD4, CD8 and CD19 to detect T cells and B cells. For intracellular 
staining, cells were fixed and permeabilized according to manufacturer’s protocol 
(eBioscience, Vienna). Subsequently, the cells were stained for the transcription 
factors T-bet, GATA-3, RORγt or Foxp3 and the cytokines IFN-γ, IL-4, IL-5, IL-10 and 
IL-17. FACS analysis was performed as described above.
Spleen cell proliferation 
At sacrifice, splenocytes (n=5 per group) were cultured for 72 hours in quintuplicate 
in a 96-wells round-bottom plate (2×105 cells/well, Greiner Bio-One) in RPMI 1640 
supplemented with L-Glutamine, 100 U/mL streptomycin/penicillin and 10% FCS. As 
a positive control cells were stimulated with αCD3 and αCD28 (2 μg/mL). Proliferation 
was measured as described above.
Cytokine determination in serum and supernatant of splenocytes 
To detect IL-8 in serum an ELISA was performed according to manufacturer’s protocol 
(Biosource). Serum samples were 1:1 diluted in assay diluent and absorbance was 
detected at 450 nm. To detect IL-4 and IL-5 in the serum an ELISA was performed 
according to manufacturer’s protocol (eBioscience, Vienna). Serum samples were 1:1 
diluted in assay diluent and absorbance was detected at 450 nm. 
Serum antibody detection
IgM, IgG1, IgG2a and IgG2b levels against oxLDL were detected in serum using 
Abs recognizing mouse IgM, IgG1, IgG2a and IgG2b and HRP-labeled goat anti-rat 
Ig (BD Pharmingen). OxLDL (5 µg/mL) was dissolved in NaHCO3/Na2CO3 buffer (pH 
9.6) and was coated o/n onto a flat-bottom 96-well high binding plate (Corning, NY). 
Serum samples were 1:1 diluted in PBS and absorbance was detected at 450 nm. 
Total IgE in serum was determined by a mouse IgE quantitative ELISA according to 
manufacturer’s protocol (Bethyl Laboratories, Montgomery TX, USA). 
Statistical analysis
All data are expressed as mean±SEM. An unpaired two-tailed student’s T-test was 
used to compare normally distributed data between two groups of animals. Probability 
values of P<0.05 were considered significant. 
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Results
CD30L is upregulated in the initial stages of atherosclerosis 
Since we aimed to interrupt the CD30-CD30L pathway via blockade of CD30L, we 
first monitored the expression of CD30L in atherosclerotic lesions and the lymphoid 
tissue. While it is known that costimulatory molecules such as OX404 and PD-117 are 
upregulated in atherosclerotic lesions, it is unclear whether CD30L is regulated as 
well. LDLr-/- mice were fed a Western-type diet and slightly constrictive perivascular 
collars were placed around the carotid arteries, which leads to the development of 
shear stress induced atherosclerotic lesions at the proximal site of the collars.15 At 
0-10 weeks after collar placement, RNA was isolated from the atherosclerotic lesions. 
As shown in Figure 1A, induction of atherosclerotic lesion development is reflected by 
an increase in CD68 expression over time (P<0.01). CD30L was also induced during 
lesion development and showed the highest expression after 2 weeks of Western-type 
diet feeding (P<0.05), coinciding with the influx of CD68 positive macrophages, but 
also with the influx of various immune cells, such as CD4 and CD8 positive T cells 
(Figure 1B). Parallel to the data on the lesion, CD30L mRNA levels in the spleen of 
LDLr-/- mice significantly increased during Western-type diet feeding (P<0.05, Figure 
1C). In addition, we determined protein levels of CD30L and as shown in Figure 1D 
and E, CD4+ T cells expressing CD30L increase in blood of Western-type diet fed mice 
(P<0.05). 
























































































































Figure 1. Relative mRNA levels of CD68 (A), CD30L, CD4 and CD8 in lesions of the carotid arteries were 
determined with RT-PCR (B). Relative mRNA levels of CD30L in spleens were determined with RT-PCR (C). 
At 0, 4 and 8 weeks CD30L expression was determined on CD4+ T cells in blood from LDLr-/- mice fed a 
Western-type diet (n=5) and a chow diet (n=5) by flow cytometry (D-E). Splenocytes were cultured with 
αCD3/CD28 in the presence of anti-CD30L (0.1-10 µg/mL) and proliferation was assessed by the amount 
of 3H-thymidine incorporation (F).* P<0.05, ** P<0.01, *** P<0.001, # P<0.01 for all celltypes
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Blockage of CD30L reduces proliferation of splenocytes from Western-type 
diet fed mice
To determine whether interruption of the CD30-CD30L pathway impairs T cell function 
of LDLr-/- mice fed a Western-type diet for 8 weeks ex vivo, we stimulated splenocytes 
with αCD3/CD28 in the presence or absence of RM153, a blocking CD30L antibody. 
This antibody was generated by Shimozato et al.16 and potently inhibits the binding 
of CD30 to CD30L and the proliferation of αCD3/CD28 activated T cells. As shown in 
Figure 1F, blockage of the CD30-CD30L pathway by using RM153 dose-dependently 
reduced splenocyte proliferation of Western-type diet fed LDLr-/- mice (P<0.01).  
Impaired T cell numbers and function in anti-CD30L treated mice
RM153 has been shown to reduce murine autoimmune diabetes13, prolong survival 
of mice in a graft versus host disease model12, and together with OX40L blockade 
reduced autoimmune disease in Foxp3 deficient mice18 when administered i.p. twice a 
week during the experiments (200-500 μg/dose). To study the effect of CD30-CD30L 
interruption on T cells in vivo, we therefore treated LDLr-/- mice with 250 μg of RM153 
twice a week, while the mice were fed a Western-type diet for 8 weeks. The relative 
number of CD4+ T cells (Figure 2A) in spleen and mediastinal heart lymph nodes of 


































































































Figure 2. Atherosclerosis was induced in LDLr-/- mice by feeding a Western-type diet for 8 weeks. Mice 
were treated with anti-mouse CD30L (RM153) (n=12) or sterile PBS (n=12) twice a week. At sacrifice, 
spleen and LN cells were isolated and stained for CD4 (A) and CD8 (B) and analyzed by flow cytometry 
(n=5 per group). T-bet, GATA-3, RORγt and Foxp3 expression in T cells from the spleen were also 
determined by flow cytometry (C). Splenocytes of control and anti-CD30L-treated mice (n=5 per group) 
were cultured in the presence or absence of CD3/CD28 stimulation. Proliferation was assessed by the 
amount of 3H-thymidine incorporation in dividing cells and is expressed as stimulation index (D). CD4+ T 
cells isolated from splenocytes were cultured for 72 hours in the presence of CD3/CD28 stimulation and 
stained for CD4 and Ki-67, a proliferation marker. Positive cells were assessed with flow cytometry (E). 
IFN-γ, IL-4, IL-5, IL-10 and IL-17 secretion by these CD3/CD28-stimulated CD4+ T cells were determined 
by flow cytometry (F). * P<0.05, ** P<0.01 
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anti-CD30L-treated mice was reduced compared with control mice (P<0.05), whereas 
CD8+ T cell numbers were not affected by the anti-CD30L treatment (Figure 2B). 
Furthermore, the differentiation of naive CD4+ T cells into Th1, Th2, Th17 or Treg cells 
was unaffected by anti-CD30L treatment (Figure 2C). To determine the proliferative 
capacity of T cells from anti-CD30L-treated mice in comparison with control mice, 
splenocytes from both groups were cultured for 72 hours in the presence of αCD3/
αCD28 stimulation. A significant 53% decrease in splenocyte proliferation was 
observed in mice treated with anti-CD30L (stimulation index of 27.0±2.5) compared 
to control mice (stimulation index of 58.1±6.1, P<0.01, Figure 2D). As shown in 
Figure 2E, we demonstrate that CD4+ T cells are the main effector cells, as CD4+ 
T cells isolated from anti-CD30L-treated mice (n=5) showed an 52% reduction in 
αCD3/αCD28-mediated proliferation in comparison with CD4+ T cells isolated from 
control mice (n=5, P<0.05), whereas CD8+ T cell proliferation was unaffected (data 
not shown). In addition, we determined cytokine secretion by these CD4+ T cells with 
flow cytometry; no significant differences in cytokine profiles between control and 






























































Figure 3. Anti-CD30L treatment reduces atherosclerosis development in LDLr-/- mice (n=12) fed a 
Western-type diet for 8 weeks in comparison with control treatment (n=12). Representative cross-sections 
of lesion formation in the three valves area of the aortic root stained with Oil-Red-O and hematoxylin 
are shown and lesion size was determined (A). The aortic arch and its main branch points were excised, 
fixed, and embedded in paraffin. Longitudinal sections of the aortic arch were stained with hematoxylin 
and eosin to analyze lesion extent (B). Corresponding sections of the aortic root on separate slides were 
stained for CD3 (red) to determine the number of infiltrating T cells (B). *P<0.05, *** P<0.001
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Interference in the CD30-CD30L pathway reduces the development of 
atherosclerosis 
To determine whether the anti-CD30L-mediated reduction in T cell responses affects 
atherosclerosis development, we determined atherosclerotic lesion sizes upon 
treatment with anti-CD30L. Figure 3A shows representative cross-sections of lesions 
in the three-valve area of the aortic root. We observed a significant 35% reduction in 
the aortic root lesion size in anti-CD30L-treated mice (4.3×105±0.3×105 µm2) 
compared with control mice (6.5×105±0.5×105 µm2, P<0.001). Treatment with rat 
IgG (isotype control for RM153) did not alter atherosclerotic lesion size in comparison 
with PBS treatment (data not shown). In addition, lesion formation in the aortic arch 
was reduced in anti-CD30L-treated mice compared with control mice (P=0.09, Figure 
3B). During the experiment, anti-CD30L treatment did not affect body weight and 
total plasma cholesterol levels (data not shown). In line with reduced T cell percentages 
and splenocyte proliferation following anti-CD30L treatment, we observed a significant 
31% reduction in the number of CD3+ T cells within the adventitia of anti-CD30L-
treated mice (71.9±5.3 T cells/section) compared with control mice (104.9±14.1 T 
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Figure 4. No differences in lesion composition after anti-CD30L treatment. Sections of the aortic root 
were stained for collagen using Masson’s trichrome staining. The percentage of collagen relative to the 
lesion size was determined. Furthermore, relative macrophage content was determined with a MOMA-
2 staining and quantified. The necrotic core was defined as the a-cellular, debris-rich plaque area as 
percentage of total plaque area.
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treated mice was not a consequence of impaired migration and adhesion of CD4+ and 
CD8+ T cells (data not shown). In addition, we determined T cell subsets and cytokine 
expression locally in the plaque with qPCR. In line with our previous findings, we did 
not find any differences in T cell subsets and their cytokines (data not shown).
Anti-CD30L treatment does not affect lesion composition 
With respect to the composition of the lesion (Figure 4), no differences were found 
in lesion collagen content (18.6±1.3% vs. 19.3±1.3%) and macrophage content 
(46.2±3.6% vs. 49.7±2.7%) between anti-CD30L-treated mice and control mice, 
respectively. In addition, no differences in necrotic cores were observed between 
anti-CD30L-treated mice (49.9±3.7%) and control mice (54.8±3.2%). 
Humoral responses in anti-CD30L treated mice are not affected
The CD30-CD30L pathway is described to be involved in germinal center responses 
and secondary antibody responses.8, 9 However, in our study both the percentage of B 
cells in blood and spleen (Figure 5A) and the levels of oxLDL-specific IgM, IgG1, IgG2a 
and IgG2b in serum did not differ between control mice and anti-CD30L-treated mice 
(Figure 5B). Furthermore, we did not observe any differences in spleen morphology in 
anti-CD30L-treated mice compared with control mice (Figure 5C). 
Anti-CD30L treatment does not inhibit mast cells 
Treatment with anti-CD30L significantly reduced serum IgE levels in a murine asthma 
model11 and several other studies reported decreased IgE levels following CD30-
CD30L pathway interruption.8, 9 In our study, a trend towards lowered serum IgE 
was observed in anti-CD30L-treated mice (363±90 ng/mL) compared with control 
mice (609±132 ng/mL, Figure 6A). Since IgE is a common mast cell activator and 
mast cells can aggravate atherosclerosis19, we analyzed the number of adventitial 
mast cells. However, the numbers of activated mast cells and total number of 
mast cells (MC, Figure 6B) in the aortic root remained unaffected by anti-CD30L 
treatment (activated: 13.8±1.9 MC/mm2 and total: 29.4±2.4 MC/mm2 versus control 
































Figure 5. CD30-CD30L pathway interruption does not affect humoral responses under hypercholesterolemic 
conditions. At sacrifice, blood and spleen cells were isolated and stained for CD19 and analyzed by flow 
cytometry (n=5 per group, A). oxLDL-specific IgM, IgG1, IgG2a and IgG2b production was detected in 
serum of control (n=12) and anti-CD30L treated mice (n=12) (B). Spleen sections were stained with 
hematoxylin and eosin. Representative sections are shown (C).
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treatment; activated: 12.5±1.6 MC/mm2 and total: 28.1±3.0 MC/mm2). In addition, 
the percentage of activated mast cells did not differ (control: 44.2±2.8% versus 
anti-CD30L: 45.1±4.5%, Figure 6C). Interestingly, CD30-CD30L signaling can induce 
degranulation-independent mast cell activation via the secretion of IL-8.20 However, 
anti-CD30L treatment also did not influence serum levels of KC, the mouse analogue 
of IL-8 (Figure 6D). 
Discussion 
Optimal T cell activation is regulated by costimulatory signals and modulation of these 
signals provides a very promising therapeutic strategy to improve the outcome of 
autoimmune diseases. T cells play an important role in atherosclerosis and whereas 
the CD30-CD30L pathway has been implicated in various autoimmune diseases, such 
as asthma11, GVHD12 and type I diabetes13, no studies describe a role for the CD30-
CD30L axis in atherosclerosis.
In the present study, we found that CD30L expression within the atherosclerotic lesion 
highly correlated with CD4+ and CD8+ T cell infiltration and that CD30L expression 
in the spleen was upregulated after 8 and 12 weeks of Western-type diet feeding. 
In addition, CD4+ T cells expressing CD30L are increased in Western-type diet-fed 
mice, suggesting a pro-atherogenic role of the CD30-CD30L pathway. We therefore 
chose to intervene with the CD30-CD30L pathway during the development of 
atherosclerosis as a therapeutic approach. Interruption of CD30-CD30L by using the 
CD30L blocking antibody RM153 reduced atherosclerosis development in LDLr-/- mice 
with 35% and coincided with a 31% reduction in adventitial T cell numbers. CD30L 
signaling is reported to enhance proliferation of T cells16 and blocking CD30L therefore 
Figure 6. Mast cells are 
unaffected in anti-CD30L 
treated mice. IgE was 
measured in the serum 
of control and anti-CD30L 
treated mice (A). Sections 
of the aortic root were 
stained with CAE to detect 
mast cells. Mast cell 
numbers (activated and 
not-activated, B) and the 
percentage of mast cell 
degranulation (C) were 
assessed manually. Serum 
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diminishes proliferation of T cells as shown by several studies.11, 13, 21 We showed 
that anti-CD30L inhibited the proliferation of splenocytes from Western-type diet fed 
mice ex vivo. Interruption of the CD30-CD30L interaction also potently reduced T 
cell numbers in vivo, as we found reduced percentages of CD4+ T cells in the spleen 
and LN of anti-CD30L-treated mice compared with control mice. Furthermore, a 56% 
reduction in splenocyte proliferation was observed following anti-CD30L treatment, 
which was particularly due to reduced CD4+ T cell proliferation. Additionally, we show 
that anti-CD30L does not interfere with the migration and adhesion capacity of T 
cells. The role of T cells in atherosclerosis has been established already in several 
studies.22-24 CD4+ T cells can be subdivided in several subclasses; Th1, Th2, Th17 
and Treg cells. However, no differences were found in T cell subsets following anti-
CD30L treatment, which indicates that interruption of the CD30-CD30L pathway 
under hypercholesterolemic conditions impairs T cell numbers and function but does 
not influence their differentiation. In line with our findings, Chakrabarty et al. showed 
that anti-CD30L (RM153) treatment reduced T cell proliferation in response to islet 
antigens and markedly inhibited the development of spontaneous diabetes in NOD 
mice. Furthermore, they showed that anti-CD30L inhibited the incidence of diabetes 
in NOD-SCID mice after diabetogenic T cell transfer.13 
Signaling via CD30-CD30L may also affect humoral responses. Mice deficient in CD30 
mice show reduced levels of several immunoglobulins, such as IgG1, IgG2c and IgE.8 
CD30L Tg mice show increased numbers and activity of splenic germinal centers 
and elevated basal serum concentrations of IgG2a, IgG2b and IgE.10 In addition, 
Shanebeck et al. showed that mouse splenic B cells stimulated via CD30L induced 
increased amounts of a number of immunoglobulins, such as IgG1 and IgE.9 However, 
under hypercholesterolemic conditions, we did not find any significant difference 
in immunoglobulin production or spleen morphology in anti-CD30L-treated mice 
compared with control mice. 
In a murine asthma model, CD30 deficiency or treatment with anti-CD30L significantly 
reduced airway inflammation, splenocyte proliferation, Th2 responses and serum IgE 
levels.11 Whereas in the present study we also observed a reduction in splenocyte 
proliferation and a trend towards reduced serum IgE, we did not observe reduced Th2 
responses as shown by GATA-3 expressing CD4+ cells and serum IL-4 and IL-5 levels 
(data not shown). IgE may induce activation of mast cells, which are correlated with 
the incidence of plaque rupture and erosion25 and also play a crucial role in plaque 
progression and destabilization in vivo.19 Furthermore, mast cells are the predominant 
CD30L-expressing cells in Hodgkin’s disease, which are involved in tumorigenesis and 
tumor progression.26 However, despite a reduction in serum IgE, anti-CD30L-treated 
mice did not have reduced numbers of mast cells or activated mast cells as shown by 
adventitial mast cells and IL-8 release. 
In conclusion, we are the first to demonstrate that anti-CD30L treatment inhibits 
plaque development in LDL receptor deficient mice independent of plasma cholesterol 
levels and lesional macrophage and collagen content. Given the profound inhibition 
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of anti-CD30L treatment on T cell proliferation and activation, we propose that 
anti-CD30L treatment, at least partly, exerts its protective effects by modulating 
this process. These data thus identify anti-CD30L treatment as a novel therapeutic 
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Abstract 
Objective: Atherosclerosis is a chronic autoimmune-like disease in which lipids and 
fibrous elements accumulate in the arterial blood vessels. T cells are present within 
atherosclerotic plaques, and their activation is partially dependent on costimulatory 
signals, which can either provide positive or negative signals that promote T cell 
activation or limit T cell responses, respectively. T cell immunoglobulin and mucin 
domain 3 (Tim-3) is a coinhibitory type I transmembrane protein, which affects the 
function of several immune cells involved in atherosclerosis, such as monocytes, 
macrophages, effector T cells and regulatory T cells (Tregs). In the present study, we 
determined the role of Tim-3 in the development of atherosclerosis. 
Methods and Results: Western-type diet fed LDLr-/- mice were treated with an anti-
Tim-3 antibody for 8 weeks. Anti-Tim-3 administration increased atherosclerotic plaque 
formation with 35% in the aortic root and with 50% in the aortic arch. Furthermore, 
blockade of Tim-3 signaling increased percentages of circulating monocytes with 33% 
and lesional macrophages with 20%. Additionally, anti-Tim-3 administration increased 
CD4+ T cells with 17% and reduced percentages of Tregs with 18% and regulatory B 
cells (Bregs) with 37%. 
Conclusions: In the present study, we show that Tim-3 acts as a negative regulator 
of atherosclerosis, since anti-Tim-3 treatment augments lesion development by 
enhancing monocyte and macrophage expansion and by decreasing IL-10 producing 
Tregs and Bregs.
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Introduction
Costimulatory and coinhibitory molecules are important regulators of the 
immune system by fine-tuning innate and adaptive immune responses. Studies 
on atherosclerosis, a chronic inflammatory disease1, show that modulation of 
costimulatory and coinhibitory pathways affects its development by regulating T 
cell responses.2 In secondary lymphoid tissues but also in the arterial wall, antigen-
presenting cells (APCs), such as dendritic cells (DCs) and macrophages, present 
antigens, such as oxidized LDL-cholesterol, to T cells. The T cells can become either 
activated in the presence of costimulatory molecules, or inhibited when T cells and 
APCs interact via coinhibitory molecules. Therefore, stimulating coinhibitory molecules 
may provide a novel therapeutic approach to prevent the activation or function of 
autoreactive immune cells in atherosclerosis. Previously, Gotsman et al. showed that 
the coinhibitory pathway PD-1/PD-L1/2 inhibits pro-atherogenic T cell responses and 
atherosclerosis, since PD-L1/2-/-LDLr-/- mice develop significantly larger atherosclerotic 
lesions compared with LDLr-/- mice.3 
T cell immunoglobulin and mucin domain (Tim) proteins, are type 1 transmembrane 
proteins expressed on various immune cells and are similar to PD-1/PD-L1/2 negative 
regulators of immune responses. Four functional TIM genes have been identified in 
the murine genome (TIM-1-4), whereas the human genome only contains three TIM 
genes (TIM-1,3 and 4).4 The genes encoding Tim proteins are located on chromosome 
11 (mouse) and chromosome 5 (human), which are associated with enhanced 
susceptibility to allergy and several autoimmune diseases, such as EAE and diabetes.4
Tim-3 was first discovered as a specific marker for Th1 cells5 but is also expressed on 
a variety of immune cells such as NK cells, monocytes, macrophages and mast cells.6 
During innate immune responses, Tim-3 promotes inflammation via TNFα secretion 
by monocytes and APCs7 and enhances macrophage clearance of intracellular 
pathogens.8 However, in adaptive immune responses, Tim-3 terminates IFN-γ driven 
inflammation by inducing cell death of T cells after binding to its ligand galectin-9, a 
soluble molecule which is upregulated by IFN-γ.9 In addition, Tim-3 can induce Treg 
activity10 and induce expansion of myeloid-derived suppressor cells, which play an 
important role in tumor immunology.11 Recently, Zhang et al. showed that Tim-3 can 
also negatively regulate innate immune responses, since reduced Tim-3 signaling by 
antibody blockade or knock-down with siRNA increases the activation of monocytes.12 
The in vivo role of Tim-3 can be investigated using anti-Tim-3 antibodies, which 
interrupt the Tim-3-galectin-9 interactions. Previously, it was shown that blocking 
Tim-3 with either a Tim-3 blocking antibody or a Tim-3-Ig fusion protein, enhances 
type 1 diabetes in NOD-mice and prevents the generation of immunological tolerance 
in a transplantation model, by dampening the function of Tregs.13 Furthermore, in vivo 
administration of a Tim-3 blocking antibody enhances inflammation and demyelination 
in a mouse model of EAE by increasing the number and activation of macrophages.5 
Blockade of the Tim-3-galectin-9 interaction also accelerates graft versus host disease 
via enhanced activation of Th1 cells and cytotoxic T cells.14 In addition, blocking Tim-3 
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signaling aggravates inflammatory heart disease in BALB/c mice by decreasing CD80 
expression on macrophages and mast cells and by reducing Tregs.15 
Recently, Hou et al. showed that patients with atherosclerosis have augmented Tim-3 
expression on NK cells, which might affect NK cell function during atherosclerosis.16 
However, to date, the exact role of Tim-3 in atherosclerosis has not been investigated. 
In the present study, we therefore examined the role of Tim-3 during atherosclerosis 
development by treatment of LDLr-/- mice with a Tim-3 blocking antibody. This 
research provides novel information on the importance of the Tim-3 pathway in 




Female LDLr deficient (LDLr-/-) mice, 10-12 weeks old, were obtained from Jackson 
Laboratories. The animals were kept under standard laboratory conditions and were 
fed a Western-type diet containing 0.25% cholesterol and 15% cocoa butter (Special 
Diet Services, Witham, Essex, UK). Diet and water were provided ad libitum. All animal 
work was approved by the regulatory authority of Leiden University and carried out in 
compliance with the Dutch government guidelines.
TIM-3 expression during atherosclerosis
After 2 weeks of Western-type diet, atherosclerosis was induced as previously 
described by collar placement (2 mm long, inner diameter 0.3 mm) around both 
carotid arteries and continuous Western-type diet feeding.17 Mice were sacrificed at 
0, 2, 4, 6, 8 and 10 weeks after collar placement and tissues were harvested after in 
situ perfusion using PBS and subsequent perfusion using Zinc Formal-Fixx (Shandon 
Inc. Pittsburg, USA). Carotid arteries (n=4-6 per timepoint) were isolated and 
mRNA was extracted using the guanidium isothiocyanate (GTC) method and reverse 
transcribed (RevertAid M-MuLV reverse transcriptase). Quantitative gene expression 
analysis was performed on a 7500 Fast Real-Time PCR system (Applied Biosystems, 
CA) using SYBR green technology. The following primer pair was used for Tim-3: 
5’-TGGAGTGGGAGTCTCTGCTGGGT-3’ and 5’-GCTCCTGCATTTGCCAACCCTCC-3’. The 
following primers were used as endogenous references: 5’-GGACCCGAGAAGACCTCCTT
-3’ and 5’-GCACATCACTCAGAATTTCAATGG-3’ for acidic ribosomal phosphoprotein PO 
(36B4), 5’-TTGCTCGAGATGTCATGAAGGA-3’ and 5’-AGCAGGTCAGCAAAGAACTTATAG-3’ 
for hypoxanthine phosphoribosyltransferase (HPRT), 5’-AGCAGGTCAGCAAAGAACTTAT-
AG-3’ and 5’-AGCAGGTCAGCAAAGAACTTATAG-3’ for Rps13 and 5’-AACCGTGAAAAG-
ATGACCCAGAT-3’ and 5’-CACAGCCTGGATGGCTACGTA-3’ for α-actin.
Atherosclerosis
Atherosclerosis was induced in LDLr-/- mice by feeding a Western-type diet for 8 
weeks. Mice were treated twice a week i.p. with 250 µg anti-Tim-3 antibody (RMT3-
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23, n=12) or sterile PBS (n=11). At week 8, mice were sacrificed and tissues were 
harvested after in situ perfusion using PBS. Tissues for histology were fixated in Zinc 
Formal-Fixx (Shandon Inc. Pittsburg, USA). Tissues for RNA analysis were frozen in 
nitrogen and stored at -20 °C until further use. 
Serum cholesterol levels
During the experiments, mice were weighed and blood samples were obtained by tail 
vein bleeding. The total cholesterol levels in serum were determined at week 0, 2, 
4, 6 and 8 after start of the Western-type diet feeding. The concentrations of serum 
cholesterol were determined using enzymatic colorimetric procedures (Roche/Hitachi, 
Mannheim, Germany). Precipath (Roche/Hitachi) was used as an internal standard. 
Histological analysis and morphometry
Cryosections of the aortic root (10 µm) were made and stained with Oil-Red-O to 
determine lesion size. Lesion collagen content was determined with a Masson’s 
Trichrome staining. Furthermore, corresponding sections on separate slides were 
stained immunohistochemically with an antibody directed against a macrophage 
specific antigen (Moma-2, monoclonal rat IgG2b, diluted 1:1000). Goat anti-rat IgG 
alkaline phosphatase conjugate (dilution 1:100) was used as a secondary antibody 
and nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate as enzyme 
substrates. The necrotic core was defined as the a-cellular, debris-rich plaque area as 
percentage of total plaque area. To determine apoptosis, TUNEL positive nuclei were 
counted manually and the percentage of apoptotic cells was determined as percentage 
of total cells. In addition, the aortic arch and its main branch points were excised, 
fixed, and embedded in paraffin. Longitudinal sections of the aortic arch (4 µm) were 
analyzed for lesion extent with a hematoxylin and eosin staining. Morphology was 
studied using a Leica DM-RE microscope and LeicaQwin software (Leica imaging 
systems, Cambridge, UK). 
Flow cytometry
At sacrifice, blood, spleen and peritoneal cells were isolated (n=5 per group). Single 
cell suspensions were obtained by squeezing the organs through a 70 µm cell strainer. 
Red blood cells were removed from blood and splenocytes using erythrocyte lysis 
buffer (0.15 M NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA, pH 7.3). Different immune 
cells were analyzed with flow cytometry: T cells (CD4, CD8), B cells (CD19), DCs 
(CD11c), neutrophils (CD11b+Ly6G+), monocytes (CD11b+Ly6G-), NK cells (CD3-
NK1.1+), Bregs (splenic subset: CD5+CD1dhiCD21+, peritoneal subset: CD5+CD1dhi), 
Tregs (CD4+CD25+Foxp3+) and IL-10+ cells. To detect Tregs and IL-10 producing cells, 
cells were fixed and permeabilized according to manufacturer’s protocol (eBioscience, 
Vienna). Subsequently, the cells were stained for Foxp3 or IL-10. All antibodies were 
purchased from eBioscience (Vienna) and Beckton Dickinson (Mountain View, CA). 
To detect apoptotic cells, an Annexin-V/PI staining was performed on splenocytes 
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according to manufacturer’s protocol (eBioscience, Vienna). FACS analysis was 
performed on a FACSCantoII (Beckton Dickinson). Data were analyzed using FACSDiva 
software (Beckton Dickinson).
MCP-1 determination in serum and supernatant of oxLDL-loaded macrophages 
To detect MCP-1 in serum an ELISA was performed according to manufacturer’s 
protocol (eBioscience, Vienna) and absorbance was detected at 450 nm. To determine 
MCP-1 secretion by oxLDL-loaded macrophages, bone marrow cells were harvested 
from the femora and tibia of C57BL/6J mice and were cultured for 7 days in complete 
RPMI supplemented with M-CSF (L929 supernatant) to obtain macrophages. Immature 
macrophages were stimulated with copper-oxidized LDL (2.5 µg/mL) in the absence 
or presence of 0, 2, 10, 25 or 50 µg/mL anti-Tim-3 (RMT3-23) for 24 hours. MCP-1 
production was measured in the supernatant with ELISA as described above.
Statistical analysis
All data are expressed as mean±SEM. An unpaired two-tailed student’s T-test was 
used to compare normally distributed data between two groups of animals. Probability 
values of P<0.05 were considered significant. 
Results
TIM-3 is upregulated during atherosclerosis development 
To determine TIM-3 expression in atherosclerotic lesions, LDLr-/- mice were fed a 
Western-type diet and slightly constrictive perivascular collars were placed around the 
carotid arteries, which leads to the development of shear stress induced atherosclerotic 
lesions at the proximal site of the collars. As shown in Figure 1A, TIM-3 expression 
was elevated following placement of collars around carotid arteries of LDLr-/- mice fed 
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Figure 1. Tim-3 expression in lesions of the carotid arteries was determined with RT-PCR. Fold induction 
of Tim-3 mRNA relative to Tim-3 mRNA expression before collar placement is shown (A). Protein levels 
of Tim-3 were determined on immune cells in the circulation of mice fed a chow diet (n=5) or a Western-
type diet (n=5) for 8 weeks (B). * P<0.05, ** P<0.01
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placement (52-fold increase, P<0.05). To investigate which circulating cell types 
express Tim-3 and upregulate Tim-3 during Western-type diet feeding, we determined 
Tim-3 expression on the surface of several immune cells of mice fed a chow or 
Western-type diet for 8 weeks with flow cytometry (n=5 per group, Figure 1B). Only 
minor populations of T cells, B cells and neutrophils express Tim-3 on their surface, 
while larger populations of DCs, monocytes and NK cells express Tim-3. Western-type 
diet feeding significantly enhanced the percentage of Tim-3+ cells from 35.5±2.2% 
(chow) to 45.2±2.5% in DCs (P<0.05), from 28.8±2.3% to 46.3±3.3% in monocytes 
(P<0.01) and from 31.4±4.7% to 50.7±3.4% in NK cells (P<0.01). 
Blocking Tim-3 signaling aggravates atherosclerosis 
Because interference of the Tim-3 signaling pathway aggravates autoimmune 
diseases such as EAE5, type 1 diabetes13 and GVHD14 by dampening regulatory 
cells and enhancing monocyte and macrophage activation, we determined the role 
of Tim-3 in the initiation of atherosclerosis. We treated LDLr-/- mice with a Tim-3 
blocking antibody (RMT3-23) and determined atherosclerotic lesion development. 
Figure 2A shows representative cross-sections of lesions in the aortic valve area. We 
observed a significant 35% increase in the aortic root lesion size in anti-Tim-3-treated 
mice (5.2±0.5×105 µm2) compared with control mice (3.8±0.2×105 µm2, P<0.05). 
Previously, we showed that treatment with rat IgG, the isotype control for RMT3-23, 
did not alter atherosclerotic lesion size in comparison with PBS treatment.18 During 
the experiment, anti-Tim-3 treatment did not affect body weight and total plasma 
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Figure 2. Anti-Tim-3 treatment exacerbates atherosclerosis development compared with PBS (n=11) 
treatment in LDLr-/- mice (n=12) fed a Western-type diet for 8 weeks. Representative cross-sections of 
lesion formation in the aortic valve area stained with Oil-Red-O and hematoxylin are shown and lesion 
size was determined (A). Sections of the aortic root were stained for collagen using Masson’s Trichrome 
staining. The percentage of collagen relative to the lesion size was determined (B). *P<0.05 
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Furthermore, no differences were found in lesion collagen content (anti-Tim-3 mice: 
11.1±1.5% and control mice: 12.1±1.8%, Figure 2B). To check whether anti-Tim-3 
treatment also affects atherosclerosis development at another site of the vasculature, 
we determined lesion size in the aortic arch. As shown in Figure 3, anti-Tim-3 
treatment (1.1±0.2×104 µm2) aggravated atherosclerosis with 50% compared with 




















Figure 3. Anti-Tim-3 treatment aggravates atherosclerosis development in the aortic arch compared with 
PBS treatment in LDLr-/- mice (n=11/12 per group) fed a Western-type diet for 8 weeks. Representative 
cross-sections of lesion formation in the aortic arch stained with hematoxylin are shown and lesion size 









































































Figure 4. Increased circulating monocytes and lesional macrophages in anti-Tim-3-treated mice. 
At sacrifice, blood cells were isolated (n=5 per group) and stained for CD11b+Ly6G- monocytes (A). 
Relative macrophage content was determined with a MOMA-2 staining (B) and quantified (C). MCP-1 
concentrations were measured in the serum of control (n=11) and anti-Tim-3-treated mice (n=12) with 
ELISA (D). BM-derived macrophages were stimulated for 24 hours with 2.5 μg/mL oxLDL in the presence 
of various concentrations of anti-Tim-3. MCP-1 levels in the supernatant were determined with ELISA (E). 
*P<0.05, **P<0.01, ***P<0.001
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TIM-3 blockade enhances the number of circulating monocytes and lesional 
macrophages
Monocytes play an important role in atherosclerosis development, since monocytes 
migrate into the sub-endothelial space where they can differentiate into macrophages 
and eventually become foam cells. Previously, Tim-3 blockade has been associated 
with increased monocyte and macrophage activation and induces the expansion of 
macrophages.12 In our study, mice that received the Tim-3 antibody showed a 33% 
increase in circulating monocytes (anti-Tim3: 6.2±0.3% versus control: 4.6±0.6%, 
P<0.01, Figure 4A). In addition, lesional macrophage content was increased with 20% 
in anti-Tim-3-treated mice (49.0±2.3%) compared with control mice (40.7±2.9%, 
P<0.05, Figure 4B-C). An important key regulator of monocytes is the chemokine 
MCP-1, which enhances monocyte recruitment into the arterial wall.19 As shown in 
Figure 4D, we did not observe differences in MCP-1 levels in serum of anti-Tim-3 and 
control-treated mice. However, oxLDL-stimulated macrophages exposed to anti-Tim-3 
in vitro enhanced their secretion of MCP-1 in a dose-dependent manner (Figure 4E).  
Anti-Tim-3 treatment reduces apoptosis of lymphocytes
Tim-3 expressed on macrophages and dendritic cells is also involved in phagocytosis of 
apoptotic cells by recognizing apoptotic cells through the FG loop in the IgV domain.20 
In addition, Tim-3 can induce cell death of T cells. As shown in Figure 5A, we did not 
observe differences in lesion necrotic core content of anti-Tim-3 mice (24.5±2.7%) 
and control mice (28.7±2.5%). In addition, the percentage of apoptotic cells within 
the lesions did not significantly differ between anti-Tim-3 mice (0.70±0.21%) and 





















































Figure 5. Necrotic areas within atherosclerotic lesions of anti-Tim-3 and control mice were determined 
(A). The necrotic core was defined as the a-cellular, debris-rich plaque area as percentage of total plaque 
area. Apoptosis was defined by TUNEL positive nuclei as percentage of total number of cells present in the 
atherosclerotic lesions (B). The percentage of apoptotic lymphocytes in the spleen was determined with 
an Annexin-V/PI staining and analyzed with flow cytometry (C). **P<0.01
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lymphocytes isolated from anti-Tim-3 mice (26.2±0.9%) underwent apoptosis than 
control splenocytes (32.7±1.3%, P<0.01, Figure 5C). 
Reduced IL-10 producing regulatory T and B cells in anti-Tim-3-treated mice
Several studies showed that interactions of Tim-3 with galectin-9 are essential 
for the generation of Tregs.13, 21 Tregs play an important role in the regulation of 
T cell-mediated immune responses through suppression of T cell proliferation and 
cytokine production. Therefore, increased Treg numbers may be beneficial for patients 
suffering from atherosclerosis. In accordance with previous findings, we observed an 
18% reduction of circulating Tregs within the CD4+ T cell population in anti-Tim-3-
treated mice (8.8±0.2%) compared with control mice (10.8±0.6%, P<0.05, Figure 
6A). Additionally, a 17% reduction of Tregs in the spleen was observed in anti-
Tim-3-treated mice (5.8±0.3%) compared with control mice (7.0±0.4%, P<0.05, 
Figure 6A). Since Tregs control effector T cells and Tim-3 blockade reduces Tregs, 
we determined the percentage of effector T cells. As expected, we found significantly 
increased CD4+ T cell numbers in anti-Tim-3 treated mice (25.1±1.4%) compared 
with control mice (21.4±0.6%, P<0.05, Figure 6B). Another regulatory cell type is 
the regulatory B cell (Breg), which is an IL-10 producing B cell that induces Treg 
differentiation and inhibits pro-inflammatory cytokine production.22 We observed a 
37% decrease of splenic Bregs (CD5+CD1dhiCD21+ cells) in anti-Tim-3-treated mice 
(3.7±0.6%) compared with control mice (5.8±0.4%, P<0.05) and a 44% decrease in 
peritoneal Bregs (CD5+CD1dhi) in anti-Tim-3 treated mice (6.5±1.6%) compared with 
control mice (11.7±0.7%, P<0.05, Figure 6C). Additionally, a 55% decrease in IL-
10 producing cells was measured in spleens of anti-Tim-3-treated mice (3.5±1.0%) 
compared with the control group (7.9±1.5%, P<0.05, Figure 6D). 
Figure 6. At sacrifice, 
blood and spleen cells were 
isolated and stained for 
CD4+CD25+Foxp3+ regulatory 
T cells (A) and analyzed by 
flow cytometry (n=5 per 
group). CD4+ T cells were 
determined in the blood (B). 
Spleen and peritoneal cells 
were stained for regulatory B 
cells, which were quantified as 
CD5+CD1dhiCD21+ cells and 
CD5+CD1dhi cells, respectively 
(C). The amount of IL-10 
producing cells in the spleen 
was determined by flow 
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Discussion
Acute cardiovascular syndromes are a major cause of death in Western society and 
are generally triggered by rupture of an atherosclerotic plaque. In atherosclerosis an 
imbalance between pro- and anti-inflammatory T cells exists, with increased numbers 
of the first. Restoration of this balance by modulation of costimulatory and coinhibitory 
molecules may provide a very promising strategy to prevent cardiovascular disease. 
The role of coinhibitory Tim-3 has been established in several autoimmune diseases, 
such as EAE5, GVHD14 and type 1 diabetes13, however, the contribution of Tim-3 to 
atherosclerosis development remained to be elucidated. 
In the present study, we show that TIM-3 is expressed within the atherosclerotic 
lesion and increases during Western-type diet feeding. Furthermore, we found that 
Tim-3 was expressed on large populations of monocytes, dendritic cells and NK cells, 
whereas only a few T cells, B cells and neutrophils expressed Tim-3 on their surface. 
Previously, Hou et al. showed that patients with atherosclerosis have increased 
Tim-3+ NK cells compared with healthy controls.16 In line with these findings, we 
observed that Western-type diet feeding increased the percentage of Tim-3+ NK cells, 
but also the percentage of Tim-3+ monocytes and Tim-3+ DCs, cell types that largely 
contribute to the inflammatory process of atherosclerosis.
To investigate the contribution of Tim-3 to atherosclerosis development, we treated 
Western-type diet fed LDLr-/- mice with an anti-Tim-3 antibody for 8 weeks. Blockade 
of Tim-3 increased atherosclerosis development with 35% in the aortic root and with 
50% in the aortic arch compared with control treatment, independent of plasma 
cholesterol levels. Whereas there was no difference in lesion stability, lesions of anti-
Tim-3 treated mice contained significantly more macrophages than lesions of control 
mice. In agreement, circulating monocytes were enhanced in anti-Tim-3 mice, and 
since monocytes migrate into the arterial wall and differentiate into macrophages that 
can take up oxLDL, we believe that blockade of Tim-3 increases monocyte recruitment 
into the arterial wall and thus enhances the lesional macrophage content. To mimic 
foam cell responses in the lesion, we exposed oxLDL-loaded macrophages to anti-
Tim-3 in vitro and showed that blockade of Tim-3 enhanced MCP-1 secretion, which 
may be responsible for increased monocyte infiltration and subsequent elevated 
lesional macrophages in anti-Tim-3-treated mice. This is in line with studies that 
show an essential role for Tim-3 in monocyte and macrophage function. Monney et 
al. appointed increased macrophage numbers and activation as the major cause of 
exacerbated EAE in mice treated with a blocking anti-Tim-3 antibody.5 Frisancho-Kiss 
et al. showed that anti-Tim-3 treatment during the innate response to viral infection 
in BALB/c mice increases macrophages and their activation in the heart, resulting in 
increased inflammatory heart disease15 and Zhang et al. found that Tim-3 regulated 
pro- and anti-inflammatory cytokine expression in human CD14+ monocytes.12 
Since Tim-3 signaling has previously been associated with apoptosis, we determined 
the percentage of apoptotic cells and necrotic core in lesions of anti-Tim-3-treated 
mice. In early lesions apoptosis of macrophages limits lesion cellularity and suppresses 
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lesion progression. However, in advanced stages it induces necrotic core formation, 
which makes lesions susceptible for rupture. Therefore it has to be taken into account 
that Tim-3 signaling could be beneficial in initial stages of atherosclerosis, but in 
later stages of atherosclerosis could promote plaque rupture. In our study, we do not 
observe differences in apoptosis or necrotic core content in the lesions of anti-Tim-
3-treated mice and Tim-3 signaling also enhances Tregs, which have been shown to 
promote lesion stability in advanced stages of atherosclerosis.23 More specifically, it 
has been reported that the Tim-3-galectin 9 interaction promotes apoptosis of T cells.9 
We did observe reduced apoptosis of lymphocytes in anti-Tim-3-treated mice, which 
in turn could be responsible for the increase in CD4+ T cells. 
Moreover, Tim-3 has also been implicated in regulating pro-inflammatory T cell 
responses by promoting regulatory T cell function. Tregs dampen the immune 
response in atherosclerosis by secreting anti-inflammatory cytokines, such as IL-10, 
and by directly inhibiting effector T cell proliferation. Seki et al. reported that Tim-3 
activation by galectin-9 resulted in an induction of Tregs21 and Frisancho-Kiss et al. 
showed that anti-Tim-3 administration reduces Treg populations in the heart during 
acute myocarditis.15 In addition, blockade of the Tim-3 pathway accelerated type I 
diabetes in nonobese diabetic mice in part by dampening Treg function.13 In accordance 
with these findings, we also observed reduced Treg levels in spleen and blood after 
anti-Tim-3 administration, which contributed to the exacerbation of atherosclerosis. 
Additionally, Bregs were significantly decreased with 37% in the spleen and with 44% 
in the peritoneum of anti-Tim-3-treated mice. The exact role of Bregs in atherosclerosis 
has not been clarified yet, however, Bregs secrete IL-10 and thereby inhibit secretion 
of pro-inflammatory cytokines and support Treg differentiation, which indicates a 
protective role for Bregs in atherosclerosis. The atheroprotective role of IL-10 has 
already been shown by von der Thüsen et al. who showed that IL-10 overexpression 
reduced atherosclerosis in LDLr-/- mice.24 Furthermore, adoptive transfer of Bregs 
inhibited the initiation of EAE in Bl6 mice immunized with MOG peptides25 and Mauri 
et al. demonstrated that a transfer of IL-10 producing B cells into DBA mice prevented 
rheumatoid arthritis development and ameliorated established arthritis.26 Finally, the 
percentage of IL-10-producing splenocytes was decreased with 55% after anti-Tim-3 
treatment, which is in line with decreased Tregs and Bregs in anti-Tim-3 mice, which 
exert their function in part via IL-10 secretion. 
In the present study, we are the first to provide direct evidence that the Tim-3 pathway is 
involved in the development of atherosclerosis. We show that Tim-3 acts as a negative 
regulator of atherosclerosis, since blockade of Tim-3 augmented atherosclerotic lesion 
development and enhances immune responses by increasing circulating monocytes 
and lesional macrophages, and by decreasing IL-10 producing Tregs and Bregs. In the 
future, approaches to promote the Tim-3 pathway, such as treatment with agonistic 
Tim-3 antibodies or galectin-9, may represent novel therapeutic strategies to inhibit 
atherosclerotic lesion development and prevent cardiovascular diseases. 
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Abstract 
Objective: Costimulatory and coinhibitory molecules are mainly expressed on T 
cells and antigen presenting cells (APCs) and strongly orchestrate adaptive immune 
responses. Whereas costimulatory molecules enhance immune responses, signaling 
via coinhibitory molecules dampens the immune system thereby showing great 
therapeutic potential to prevent cardiovascular diseases. Signaling via coinhibitory 
T cell immunoglobulin and ITIM domain (TIGIT) directly inhibits T cell activation and 
proliferation, and therefore represents a novel therapeutic candidate to specifically 
dampen pro-atherogenic T cell reactivity. In the present study, we used an agonistic 
anti-TIGIT antibody to determine the effect of excessive TIGIT-signaling on 
atherosclerosis. 
Methods and Results: TIGIT was upregulated on CD4+ T cells isolated from mice 
fed a Western-type diet in comparison with mice fed a chow diet. Agonistic anti-
TIGIT suppressed T cell activation and proliferation both in vitro and in vivo. However, 
agonistic anti-TIGIT treatment of LDLr-/- mice fed a Western-type diet for 4 or 8 weeks 
did not affect atherosclerotic lesion development in comparison with PBS and control 
IgG treatment. Furthermore, elevated percentages of dendritic cells were observed 
in the blood and spleen of agonistic anti-TIGIT-treated mice. Additionally, these cells 
showed an increased activation status. 
Conclusions: Despite the inhibition of T cell responses, agonistic anti-TIGIT treatment 
does not affect initial atherosclerosis development, possibly due to increased activity 
of dendritic cells.
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Introduction
Atherosclerosis, a chronic autoimmune-like disease, results from imbalanced pro- and 
anti-inflammatory responses, which promotes infiltration of inflammatory cells in the 
vessel wall. This results in the formation of an atherosclerotic plaque and eventually 
causes plaque rupture. Immune responses are regulated by a network of costimulatory 
and coinhibitory molecules present on T cells and antigen presenting cells (APCs), 
such as macrophages and dendritic cells (DCs). The immune system provides a large 
diversity of costimulatory and coinhibitory pathways and each pathway has its own 
unique effect on the fate of individual immune cells. Costimulatory signals can promote 
T cell survival, cell cycle progression and differentiation to effector and memory T cells, 
whereas coinhibitory molecules can terminate these processes directly or indirectly 
via for example the induction of regulatory T cells (Tregs).
A new-emerging complex network of costimulatory and coinhibitory molecules is 
formed by T cell immunoreceptor with Ig and ITIM domains (TIGIT, Vstm3, WUCAM), 
CD226 (DNAM-1), CD112 (PVRL2, nectin-2), and the poliovirus receptor (PVR, 
CD155). TIGIT is expressed on different subsets of T cells, including Tregs, activated 
CD4+ T cells, CD8+ T cells, and on NK cells and NKT cells. PVR is highly expressed 
on DCs, fibroblasts, endothelial cells and some tumor cells.1, 2 Signaling through the 
TIGIT-PVR pathway can inhibit T cell responses in a cell-intrinsic manner by directly 
targeting the TCR signaling cascade as well as via the induction of tolerogenic DCs that 
produce increased levels of IL-10.3-5 In addition, TIGIT engagement may modulate DC 
responses by influencing ERK activity.5 TIGIT also interacts with CD112 present on 
APCs while PVR can bind to CD226 present on T cells. TIGIT and CD226 share common 
binding sites on PVR and CD112 and are therefore cross-competing for binding to PVR 
and CD112.3 Several studies showed that CD226 is associated with costimulatory T 
cell signals, as it was capable to induce Th1 responses.6-8 Since TIGIT and CD226 
compete for PVR binding, it is also believed that TIGIT attenuates T cell responses by 
interference of the CD226-mediated costimulation.3 
Interference in this pathway by using TIGIT deficient mice has been shown to 
aggravate EAE through elevated secretion of pro-inflammatory cytokines, such as 
IL-6, IL-17 and IFN-γ, and by increased T cell proliferation.4 In line with this finding, 
Levin et al. showed that TIGIT overexpression reduces the development of EAE.3 
Furthermore, soluble TIGIT inhibits collagen-induced arthritis by dampening CD4+ T 
cell responses and by interfering with CD226-mediated costimulation. Additionally, 
blocking TIGIT accelerated mortality in a mouse model of graft versus host disease.3
To date, the role of the coinhibitory TIGIT-PVR axis in atherosclerosis has not been 
explored. In the present study, we therefore treated LDLr-/- mice with an agonistic 




Female LDLr deficient (LDLr-/-) mice, 10-12 weeks old, were obtained from Jackson 
Laboratories. The animals were kept under standard laboratory conditions and were 
fed a normal chow diet or a Western-type diet containing 0.25% cholesterol and 
15% cocoa butter (Special Diet Services, Witham, Essex, UK). Diet and water were 
provided ad libitum. All animal work was approved by the regulatory authority of 
Leiden University and carried out in compliance with the Dutch government guidelines.
TIGIT expression on CD4+ T cells under hypercholesterolemic conditions
Splenocytes were isolated from LDLr-/- mice fed a Western-type or chow diet. Single 
cell suspensions were obtained by squeezing the organs through a 70 µm cell strainer. 
Red blood cells were removed using erythrocyte lysis buffer (0.15 M NH4Cl, 10 mM 
NaHCO3, 0.1 mM EDTA, pH 7.3). Subsequently, CD4+ T cells (>95% purity) were 
isolated by using the BD IMagTM mouse CD4 T lymphocyte enrichment set according to 
the manufacturer’s protocol (Beckton Dickinson, Mountain View, CA). After isolation, 
CD4+ T cells were stained with a fluorescent antibody for CD4 and TIGIT (clone 1G9). 
FACS analysis was performed on a FACSCantoII (Beckton Dickinson, Mountain View, 
CA). Data were analyzed using FACSDiva software (Beckton Dickinson). 
Functionality of the TIGIT agonist under hypercholesterolemic conditions
The agonistic anti-TIGIT antibody was kindly provided by Nicole Joller (Center for 
Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School).4 To 
investigate the effect of agonistic anti-TIGIT on splenocyte activation and proliferation 
under hypercholesterolemic conditions, splenocytes from Western-type diet fed mice 
(n=3) were cultured for 48 hours at 37°C in triplicate in a 96-wells round-bottom plate 
(2×105 cells/well, Greiner Bio-One) in RPMI 1640 supplemented with L-Glutamine, 
100 U/mL streptomycin/penicillin and 10% FCS. Splenocytes were stimulated with 
αCD3 and αCD28 (2 μg/mL) in the presence of different concentrations of agonistic 
anti-TIGIT (0–30 μg/mL). Activated T cells (CD4+CD25+) were determined with FACS 
as described above. Proliferation was measured by addition of 3H-thymidine (0.5 μCi/
well, Amersham Biosciences, The Netherlands) 16 hours prior to cell lysis. The amount 
of 3H-thymidine incorporation was measured using a liquid scintillation analyzer (Tri-
Carb 2900R). Responses are expressed as stimulation index (SI): ratio of mean counts 
per minute of quintuplicate cultures with αCD3/αCD28 stimulation to quintuplicate 
cultures without stimulation. To detect IL-2 in the supernatant of splenocytes, an 
ELISA was performed according to manufacturer’s protocol (eBioscience, Vienna). 
Absorbance was measured at 450 nm.
Atherosclerosis
Atherosclerosis was induced in LDLr-/- mice by feeding a Western-type diet for 4 and 
8 weeks. Mice were treated i.p. with 100 µg agonistic anti-TIGIT antibody (n=9 and 
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n=12, respectively), 100 µg hamster IgG (Innovative Research, n=8 and n=12, 
respectively) or sterile PBS (n=9 and n=11, respectively) at day 0, 2, 4, 10, 17 and 
24 after start of Western-type diet. At week 4 and week 8 mice were sacrificed and 
tissues were harvested after in situ perfusion using PBS. Tissues for histology were 
fixated in Zinc Formal-Fixx (Shandon Inc. Pittsburg, USA). 
Serum cholesterol levels
During the experiments, mice were weighed and blood samples were obtained by tail 
vein bleeding. The total cholesterol levels in serum were determined at week 0 and 
4 after start of the 4 week experiment and at week 0, 2, 4, 6 and 8 after start of the 
8 week experiment. The concentration of serum cholesterol was determined using 
enzymatic colorimetric procedures (Roche/Hitachi, Mannheim, Germany). Precipath 
(Roche/Hitachi) was used as an internal standard. 
Histological analysis and morphometry
Cryosections of the aortic root (10 µm) were made and stained with Oil-Red-O. Lesion 
collagen content was determined with a Masson’s Trichrome staining. Furthermore, 
corresponding sections on separate slides were stained immunohistochemically with 
an antibody directed against a macrophage specific antigen (Moma-2, monoclonal rat 
IgG2b, diluted 1:1000). Goat anti-rat IgG alkaline phosphatase conjugate (dilution 
1:100) was used as a secondary antibody and nitro blue tetrazolium and 5-bromo-
4-chloro-3-indolyl phosphate as enzyme substrates. Morphology was studied using a 
Leica DM-RE microscope and LeicaQwin software (Leica imaging systems, Cambridge, 
UK). 
Flow cytometry
At sacrifice, blood and splenocytes were isolated (n=5 per group). Single cell 
suspensions were obtained as described above. Cells were stained with fluorescent 
antibodies for CD11c, MHC II and CD40 to detect dendritic cells and to determine their 
activation status. 
Spleen cell proliferation 
At sacrifice, splenocytes (n=5 per group) were cultured for 72 hours in quintuplicate 
in a 96-wells round-bottom plate (2×105 cells/well, Greiner Bio-One) in RPMI 1640 
supplemented with L-Glutamine, 100 U/mL streptomycin/penicillin and 10% FCS. As 
a positive control cells were stimulated with αCD3 and αCD28 (2 μg/mL). Proliferation 
was measured as described above.
Statistical analysis
All data are expressed as mean±SEM. A one-way ANOVA with post test was performed 
to compare normally distributed data between three groups of animals. Probability 
values of P<0.05 were considered significant. 
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Results
TIGIT is upregulated on CD4+ T cells from Western-type diet fed LDLr-/- mice
The coinhibitory molecule TIGIT is mainly expressed on T cells and previous studies 
have shown that upon TCR stimulation the number of TIGIT expressing CD4+ T cells 
increases.3-5 To investigate the effect of a high-fat diet on the surface expression of 
TIGIT on CD4+ T cells, splenocytes were isolated from chow diet fed mice (n=3) and 
Western-type (cholesterol-rich) diet fed mice (n=3) and cultured for 48 hours in the 
presence or absence of αCD3/αCD28 stimulation. As shown in Figure 1, Western-
type diet feeding significantly enhanced the percentage of TIGIT+ cells within the 
unstimulated CD4+ T cell population (8.5±0.7%) in comparison with chow diet 
feeding (3.7±0.9%, P<0.05). In addition, we show that αCD3/αCD28 stimulation 
indeed increased the percentage of TIGIT+ cells within the CD4+ T cells in both chow 
(10.1±1.3%, P<0.05) and Western-type diet mice (16.4±2.3%, P<0.05). 
Agonistic anti-TIGIT inhibits the activation and proliferation of splenocytes
Since TIGIT can directly inhibit T cell proliferation, we determined ex vivo the capacity 
of the agonistic anti-TIGIT antibody to impair T cell reactivity in our atherosclerosis 
mouse model; LDLr-/- mice fed a Western-type diet. We stimulated splenocytes from 
Western-type diet fed mice for 72 hours with αCD3/αCD28 in the presence or absence 
of different concentrations of agonistic anti-TIGIT. As shown in Figure 2A, agonistic 
anti-TIGIT decreased the percentage of activated T cells (P<0.01). Most importantly, 
splenocyte proliferation as measured by the amount of 3H-thymidine incorporation 
(Figure 2B) and IL-2 secretion (Figure 2C), was strongly inhibited in a dose-dependent 
manner upon excessive TIGIT triggering. 
Impaired T cell function in agonistic anti-TIGIT-treated mice






































Figure 1. Representative FACS dot plots of TIGIT surface expression on CD4+ T cells isolated from LDLr-/- 
mice fed a chow diet or a Western-type (WT) diet (A). Splenocytes from LDLr-/- mice fed a chow diet (n=3) 
and Western-type diet (n=3) were cultured for 48 hours in the presence or absence of αCD3/αCD28. The 
percentage TIGIT expressing CD4+ T cells was determined with flow cytometry (B). * P<0.05
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treated with an agonistic anti-TIGIT antibody at day 0, 2, 4, 10, 17 and 24, while being 
fed a Western-type diet for 4 weeks. As a control, mice were treated with Armenian 
hamster IgG (n=8) and PBS (n=9). To determine the proliferative capacity of T cells 
from agonistic anti-TIGIT-treated mice in comparison with PBS and hamster IgG-
treated mice, splenocytes from all groups were cultured for 72 hours in the presence 
of αCD3/αCD28. A significant 45% decrease in splenocyte proliferation was observed 
in mice treated in vivo with agonistic anti-TIGIT (stimulation index of 20.8±1.8) 
compared with PBS mice (stimulation index of 37.4±0.8, P<0.01) and hamster IgG 
mice (stimulation index of 38.2±3.2, P<0.001, Figure 2D).
Agonistic anti-TIGIT treatment does not affect initial atherosclerosis 
development 
To determine whether the TIGIT-mediated impairment of T cell function affects the 
development of early atherosclerosis (4 weeks of Western type diet), we measured 
atherosclerotic lesion sizes upon agonistic anti-TIGIT treatment. As shown in Figure 
3A, no difference in atherosclerotic lesion size was observed after agonistic anti-
TIGIT treatment (1.41±0.07x105 μm2) in comparison with hamster IgG treatment 
(1.46±0.15x105 μm2) or PBS (1.59±0.13x105 μm2). During the experiment, agonistic 
anti-TIGIT treatment did not affect body weight and total plasma cholesterol levels 
(data not shown). Furthermore, collagen content did not significantly differ between 
the three groups (PBS: 7.7±0.9%, hamster IgG: 7.0±1.2% and TIGIT: 5.5±1.0%, 
Figure 3B). In addition, the percentage of macrophages in the lesions is comparable in 
all the groups (PBS: 50.3±4.2%, hamster IgG: 47.7±4.9% and agonistic anti-TIGIT: 
53.2±3.5%, Figure 3C). 
Increased percentages and activation of dendritic cells in agonistic anti-
TIGIT-treated mice
Whereas agonistic anti-TIGIT treatment reduced T cell proliferation, dendritic cells 











































































Figure 2. Splenocytes from Western-type diet fed mice (n=3) were cultured for 72 hours with αCD3/
αCD28 in the presence or absence of agonistic anti-TIGIT (0-30 µg/mL). Activated T cells (CD4+CD25+) 
were determined with flow cytometry (A). Proliferation was assessed by the amount of 3H-thymidine 
incorporation in dividing cells and is expressed as stimulation index (B) and by the amount of IL-2 
produced by the splenocytes as determined with ELISA (C). Splenocytes of PBS, Armenian Hamster IgG 
and agonistic anti-TIGIT-treated mice (n=5 per group) were cultured in the presence of αCD3/αCD28 
stimulation and proliferation was assessed by the amount of 3H-thymidine incorporation expressed as 



















































Figure 3. No difference in atherosclerotic lesion size between agonistic anti-TIGIT, Armenian Hamster 
IgG and PBS treated LDLr-/- mice fed a Western-type diet for 4 weeks. Representative cross-sections of 
lesion formation in the three valves area of the aortic root stained with Oil-Red-O and hematoxylin are 
shown and lesion size was determined (A). Sections of the aortic root were stained for collagen using 
Masson’s trichrome staining. The percentage of collagen relative to the lesion size was determined (B). 
Furthermore, relative macrophage content was determined with a MOMA-2 staining (C).
which are also involved in the pathogenesis of atherosclerosis were elevated in these 
mice. As shown in Figure 4A, agonistic anti-TIGIT treatment significantly enhanced the 
percentage of dendritic cells (14.7±1.3%, P<0.05) in the circulation in comparison with 
hamster IgG and PBS treatment (10.7±0.4% and 10.8±0.4%, respectively). Similar 
results were observed in the spleen (Figure 4B), where agonistic anti-TIGIT treatment 
enhanced the percentage of dendritic cells (15.6±1.2%, P<0.05) in comparison with 
hamster IgG and PBS treatment (12.0±1.2 and 11.6±0.3%, respectively). Moreover, 
their activation status as measured with MHC II and CD40 is also elevated in agonistic 
anti-TIGIT-treated mice compared with both control groups.  
Figure 4. At sacrifice, blood 
(A) and spleen (B) cells 
were isolated and stained 
for dendritic cells and 
their activation status and 
analyzed by flow cytometry 
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Agonistic anti-TIGIT treatment does not affect atherosclerosis after 8 weeks 
of Western-type diet
We also determined atherosclerosis development after 8 weeks of Western-type diet 
feeding in combination with agonistic anti-TIGIT treatment. Lesion size in the agonistic 
anti-TIGIT-treated mice (n=12, 5.15±0.32x105 μm2) was not affected compared with 
lesion size in the hamster IgG-treated mice (n=12, 5.12±0.26x105 μm2). In fact, both 
groups of antibody-treated mice have 18% smaller atherosclerotic lesions compared 
with the PBS group (n=11, 6.28±0.44x105 μm2), although this did not reach statistic 
significance (Figure 5A). Furthermore, no differences were observed in collagen 
content (PBS: 13.1±1.0%, hamster IgG: 13.3±2.0% and TIGIT agonist: 11.1±1.5%, 
Figure 5B) and macrophage content (PBS: 47.2±2.3%, IgG: 47.4±1.9% and TIGIT 
agonist: 47.9±2.6%, Figure 5C) of the atherosclerotic lesions. 
Discussion 
The TIGIT/CD226 pathway has been associated with several human autoimmune 
diseases8 and studies in mice demonstrate that interference in this pathway may be 
an attractive approach to modulate autoimmune diseases.3-5 In the present study we 
determined the role of TIGIT in atherosclerosis.

















































Figure 5. Agonistic anti-TIGIT treatment (n=12) and Armenian Hamster IgG treatment (n=12) reduces 
atherosclerosis development in LDLr-/- mice fed a Western-type diet for 8 weeks in comparison with PBS 
treatment (n=11). Representative cross-sections of lesion formation in the three valves area of the aortic 
root stained with Oil-Red-O and hematoxylin are shown and lesion size was determined (A). Sections of 
the aortic root were stained for collagen using Masson’s trichrome staining. The percentage of collagen 
relative to the lesion size was determined (B). Furthermore, relative macrophage content was determined 
with a MOMA-2 staining and quantified (C).
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cells in both men and mice.4, 9 We have previously shown that during the induction 
of atherosclerosis by feeding a Western-type diet, T cells are activated.10 We now 
observe that TIGIT expression was upregulated on CD4+ T cells in Western-type diet 
fed LDLr-/- mice in comparison with chow diet fed LDLr-/- mice. The expression of TIGIT 
was further enhanced after αCD3/αCD28 stimulation of isolated splenic T cells. This 
increase in TIGIT surface expression has been associated with a decrease in T cell 
proliferation in a number of studies4, 9, while TIGIT deficiency remarkably increased 
T cell proliferation in lymph nodes and spleen upon immunization.4 Since T cell 
activation is strongly correlated with the development of atherosclerosis11-13, we aimed 
to diminish T cell responses by using an agonistic anti-TIGIT antibody which triggers 
TIGIT signaling. First we showed that exposure of splenocytes isolated from Western-
type diet fed mice to agonistic anti-TIGIT ex vivo greatly inhibited T cell activation 
and proliferation, as measured by 3H-thymidine incorporation and IL-2 secretion. In 
agreement with our in vitro data, LDLr-/- mice that received Western-type diet for 4 
weeks and were treated with the agonistic anti-TIGIT antibody, show a 45% decrease 
in splenocyte proliferation in comparison with PBS and Hamster IgG-treated mice. 
Subsequently, we investigated whether agonistic anti-TIGIT treatment can be 
beneficial for the development of atherosclerosis since TIGIT-mediated dampening 
of T cell responses has been associated with decreased susceptibility to several 
autoimmune diseases. Levin et al. showed that administration of soluble TIGIT 
inhibited the severity of collagen-induced arthritis by decreasing T cell infiltration in 
the paws and by reducing T cell proliferation.5 Interestingly, both pro-inflammatory 
cytokines, such as IL-6, IL-17A and TNFα, and anti-inflammatory cytokines, such as 
IL-10, were reduced in soluble TIGIT-treated mice. Furthermore, TIGIT transgenic 
mice are protected against the development of EAE5, whereas TIGIT-/- mice develop 
exacerbated EAE through elevated T cell proliferation and increased IL-6, IFN-γ, and 
IL-17 secretion.4 In addition, adoptive transfer of TIGIT-deficient T cells accelerated 
GVHD in comparison with transfer of wild-type T cells.5 Surprisingly, the significant 
effect of the TIGIT agonist on T cell responses did not affect the development of 
atherosclerosis after 4 and 8 weeks of Western-type diet feeding, as we observed no 
significant differences in atherosclerotic lesion sizes between PBS, hamster IgG and 
agonistic anti-TIGIT-treated mice. Furthermore, in both atherosclerosis studies we did 
not observe any differences in the collagen and macrophage content of these lesions.
Interestingly, the beneficial effect of the TIGIT agonist on T cell activity was 
accompanied by an activating effect on DCs. Dendritic cells are potent antigen 
presenting cells and numerous studies have shown the importance of DCs in the 
development of atherosclerosis. The number of DCs increases with the progression 
of atherosclerosis in ApoE-/- mice14, 15 and Wu et al. showed that CD11c-/-ApoE-/- mice 
fed a Western-type diet have reduced atherosclerosis with a concomitant attenuation 
of lesional macrophages.16 Additionally, Paulson et al. showed that CD11c-diphtheria 
toxin receptor (DTR) LDLr-/- mice fed a cholesterol-rich diet for 5-10 days have a 
55% reduced intimal lipid area in comparison with non-depleted mice.17 Therefore, 
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increased percentages and activation of dendritic cells in agonistic anti-TIGIT-treated 
mice can possibly counteract the diminished T cell activity in these mice and thereby 
neutralize the effect on atherosclerosis. This more pro-inflammatory phenotype of 
DCs in agonistic anti-TIGIT-treated mice may be caused by the agonistic antibody, 
which blocks the interaction between TIGIT and PVR expressed on DCs, normally 
resulting in a tolerogenic phenotype of DCs.  
In conclusion, we showed that, although triggering of the TIGIT pathway decreases 
proliferation and activation of T cells both in vitro and in vivo, agonistic anti-TIGIT 
treatment does not affect atherosclerosis development. Future research should 
concentrate more on the role of TIGIT-PVR signaling, since the generation of tolerogenic 
DCs in combination with intrinsic T cell inhibition possibly does affect atherosclerosis. 
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Objective: Regulatory T cells are crucial for immune homeostasis and an impaired 
regulatory T cell function results in many pathological conditions. Regulatory T cells 
have already been described to be protective in atherosclerosis. However the exact 
contribution of Foxp3 expressing natural regulatory T cells in atherosclerosis has not 
been elucidated yet. 
Methods and Results: In this study we vaccinated LDL receptor deficient mice with 
dendritic cells, which are transfected with Foxp3 encoding mRNA, and studied the 
effect on initial atherosclerosis. Vaccination against Foxp3 resulted in a reduction of 
Foxp3+ regulatory T cells in several organs and in an increase in initial atherosclerotic 
lesion formation. Furthermore we observed an increase in plaque cellularity and 
increased T cell proliferation in the Foxp3 vaccinated mice.
Conclusions: We further establish the protective role of Tregs in atherosclerosis. 
The results illustrate the important role for Foxp3 expressing regulatory T cells in 
atherosclerosis, thereby providing a potential opportunity for therapeutic intervention 
against this disease.
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Introduction
Atherosclerosis is an autoimmune like disease, in which both innate and adaptive 
immune responses are involved.1 T helper (Th) cells are crucial for an adequate 
immune response and can be divided in Th1 and Th2 cells. Several studies show that 
inflammatory processes in atherosclerosis are associated with a Th1-driven immune 
response (IFN-γ, IL-12), while the Th2 cells (IL-5 and IL-13) exert an anti-atherogenic 
role.2, 3 It was postulated that an imbalance between Th1 and Th2 cells was, at 
least partially, responsible for the development of atherosclerotic lesions. However, 
more recently, IL-4, a Th2-cytokine, was found to be pro-atherogenic in early lesion 
formation.4, 5 This finding, together with studies establishing an anti-atherogenic role 
for regulatory T cells (Tregs), suggested another mechanism of immune regulation 
in atherosclerosis, where T cells (both Th1 and Th2) are suppressed by regulatory T 
cells (Tregs).
Tregs are characterized by the expression of both CD4 and CD25 and are subdivided 
in adaptive Tregs and natural Tregs. Adaptive Tregs develop from naive T cells in 
the periphery and can produce IL-10 (Tr1 cells) and TGF-β (Th3 cells). Natural Tregs 
originate from the thymus as CD4+CD25+ cells and exert their suppressive function 
especially via cell-cell contact and membrane bound TGF-β and CTLA-4. Forkhead box 
protein P3 (Foxp3) is characteristically expressed in this subclass of Tregs and this 
transcription factor is necessary for the development of Tregs. Deficiency in Foxp3 
leads to a lack of Tregs and severe auto-immune disorders.6-9 
Recently, we showed that oral administration of atherosclerosis-related antigens 
(HSP60 and oxLDL) increases the number of Foxp3-expressing Tregs in several organs, 
which leads to a decrease in development of atherosclerotic lesions in LDLr-/- mice.10, 
11 These results are in line with studies on the role of Tregs in atherosclerosis after 
oral and nasal tolerance induction12-14 but our studies specifically demonstrate the 
contribution of Foxp3+ Tregs. Furthermore, a study by Mallat and colleagues showed 
that a transfer of Tregs reduced lesion formation in ApoE-/- mice15, while others showed 
that treatment of ApoE-/- mice with a depleting CD25-specific antibody (PC61), results 
in an increase in lesion size.16 Additionally, bone marrow transplantation of CD80-/-
CD86-/- bone marrow into LDLr-/- mice results in a decrease in the number of Tregs 
and an increase in lesion size, again indicating an inverse relationship between the 
presence of Tregs and atherosclerotic lesion development.16
However, these studies do not directly demonstrate the role of Foxp3 expressing cells 
in atherosclerosis. To specifically establish the role of Foxp3-expressing Tregs, we 
targeted Foxp3 expressing cells using DCs electroporated with mRNA encoding for 
Foxp3 as described by Nair et al., which induces a cytotoxic T lymphocyte response 
against Foxp3.17 In the present study, we show that vaccination against Foxp3 results 
in a reduction of Foxp3+ Tregs and a subsequent increase in initial atherosclerotic lesion 




All animal work was approved by the regulatory authority of Leiden University and 
carried out in compliance with the Dutch government guidelines. Female LDLr-/- mice 
were obtained from Jackson Laboratories. Male C57BL/6J mice were from Charles 
River Laboratories. All mice were kept under standard laboratory conditions and were 
fed a normal chow diet or a Western-type diet containing 0.25% cholesterol and 15% 
cocoa butter (Special Diet Services, Witham, Essex, UK). All mice used were 10-12 
weeks of age. Diet and water were administered ad libitum.
Synthesis of Foxp3 and GFP mRNA
The pSP73-Spf/Foxp3/A64 construct was kindly provided by E. Gilboa (Duke University 
Medical Center, Durham, NC, USA).17 As a control we created a pSP73-Spf/eGFP/A64 
construct. The pSP73-Spf/Foxp3/A64 and pSP73-Spf/eGFP/A64 constructs were used 
as a DNA template in a T7 mMessage mMachine® (Ambion, Austin, TX) reaction 
to produce large amounts of capped Foxp3 and GFP in vitro transcribed mRNA. 
To eliminate excessive DNA, a TurboDNase® (Ambion, Austin, TX) treatment was 
performed. The Megaclear Kit® (Ambion, Austin, TX) was used for purifying mRNA 
from the in vitro transcription reactions. All reactions were performed according to the 
manufacturer’s protocol. 
Generation and assessment of the DC based vaccine
Bone marrow cells were isolated from the tibia and femora of C57BL/6J mice. Cells were 
pooled and cultured in the presence of granulocyte-macrophage colony-stimulating 
factor (GM-CSF) for 10 days in IMDM supplemented with 8% fetal calf serum (FCS, 
PAA), 100 U/mL streptomycin/penicillin (PAA), 2 mM glutamax (Invitrogen, The 
Netherlands) and 20 μM β-mercaptoethanol. Hereafter, the DCs were harvested, 
washed, and resuspended in Opti-MEM (GIBCO, Grand Island, NY). The used DC 
culture medium was saved as conditioned media for later use. 5 x 106 DCs in 200 μl 
Opti-MEM were electroporated with either GFP or Foxp3 mRNA as described by Nair et 
al.18 After electroporation the DCs were transferred to culture petridishes containing 
GM-CSF and a 1:1 combination of conditioned DC growth medium and fresh medium. 
Transfected DCs were incubated at 37°C, 5% CO2 overnight, and subsequently were 
washed 2 times in PBS before vaccination. As a control for maturation of DCs, LPS (1 
μg/mL) was added to one group of DCs for 24 hours. To assess the maturation profile, 
the electroporated DCs were stained against surface markers (CD80-FITC, CD86-PE 
and CD40-PE) and analyzed using FACS. To detect intracellular Foxp3 expression in the 
electroporated DCs, the cells were stained with Foxp3-APC. For intracellular staining 
of Foxp3, DCs were fixated and permeabilized overnight and subsequent stained 
against Foxp3. All antibodies were purchased from eBioscience (Belgium) and used for 
FACS analysis according the manufacturer’s protocol. Total RNA was isolated from the 
electroporated DCs using the GTC method.19 cDNA synthesis was performed using Revert 
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AidTM M-MuZV Reverse Transcriptase (Fermentas Life Science). Quantitative Foxp3 
gene expression (5’-GGAGCCGCAAGCTAAAAGC-3’ and 5’-TGCCTTCGTGCCCACTGT-3’) 
analysis was performed on a 7500 fast Real-Time PCR System (Applied Biosystem) 
using SYBR Green technology. Acidic ribosomal phosphoprotein PO (36B4; 
5’-GGACCCGAGAAGACCTCCTT-3’ and 5’-GCACATCACTCAGAATTTCAATGG-3’) and 
hypoxanthine phosphoribosyl transferase (HPRT; 5’-TTGCTCGAGATGTCATGAAGGA-3’ 
and 5’-AGCAGGTCAGCAAAGAACTTATAG-3’) were used as reference genes. 
Vaccination and the induction of atherosclerosis
Mice were injected with 5x105 DCs in 100 μl per mouse (GFP n=14, Foxp3 n=13) 
subcutaneously at the base of the ear pinna at day 0. Mice of the control group (n=15) 
were injected with 100 μl PBS. After treatment, the mice were fed a Western-type diet 
(0.25% cholesterol and 15% cocoa butter) for 8 weeks to induce hypercholesterolemia 
and atherosclerosis. At sacrifice, tissues were harvested after in situ perfusion using 
PBS and subsequent perfusion with Zinc Formal-Fixx (Shandon Inc. Pittsburg, USA). 
Tissues were snap-frozen in nitrogen and stored at –80 °C until further use. During 
the experiment blood samples were obtained by tail vein bleeding at various time 
points. The concentration of serum cholesterol was determined using an enzymatic 
colorimetric procedure (Roche/Hitachi). Precipath (Roche/Hitachi, Mannheim, 
Germany) was used as an internal standard. Blood samples of week 5 were also used 
to determine the percentage of Tregs in blood using flow cytometry as described 
below.
Flow cytometry
At sacrifice, Peripheral Blood Mononuclear Cells (PBMCs) were isolated via orbital 
bleeding and erythrocytes were removed by incubating the cells with erythrocyte lysis 
buffer (0.15 M NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA, pH 7.3). Spleens, heart lymph 
nodes (HLN) and mesenteric lymph nodes (MLN) were dissected from the mice (n=5/
group) and a single cell suspension was obtained by passing the organs through a 
70 µm cell strainer (Falcon, The Netherlands; n=5/group). Cells were stained with 
surface markers (0.25 μg antibody/300.000 cells) and subsequently analyzed by flow 
cytometric analysis. For the detection of CD4+CD25+Foxp3+ T cells, the spleen, blood, 
MLN and HLN were stained with CD4-FITC and CD25-PE and subsequently intracellularly 
with Foxp3-APC. All antibodies were purchased from eBioscience (Immunosource, 
Belgium). All data were acquired on a FACSCalibur (Becton Dickinson, Mountain View, 
CA) and analyzed with CELLQuest software (BD Biosciences, The Netherlands). 
Spleen cell proliferation
Splenocytes (n=5/group) were cultured for 72 hours in triplicate in a 96-wells round-
bottom plate (2 x 105 cells/well, Greiner Bio-One) in RPMI 1640 supplemented with 
L-Glutamine, 10% FCS and 100 U/mL streptomycin/penicillin. As a positive control 
cells were stimulated with Concanavalin A (2 μg/mL, Con A, Sigma Diagnostics, MO). 
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Proliferation was measured by addition of 3H-thymidine (0.5 μCi/well, Amersham 
Biosciences, The Netherlands) for the last 16 hours. The amount of 3H-thymidine 
incorporation was measured using a liquid scintillation analyzer (Tri-Carb 2900R). The 
proliferation is expressed in disintegrations per minute (dpm). 
Histological analysis
The heart was embedded in OCT compound (TissueTek; Sakura Finetek, The 
Netherlands) and cryosections (10 µm) of the aortic root containing the three aortic 
valves were made. Cryosections were routinely stained with Oil-Red-O and hematoxylin 
(Sigma Diagnostics, MO). Corresponding sections on separate slides were also stained 
for collagen, macrophages and fibroblasts using Masson’s Trichrome staining (Sigma 
Diagnostics), MoMa-2 antibody (Research Diagnostics Inc.), and ER-TR7 antibody 
(AbD Serotec), respectively, according to manufacturer’s protocols. For the cellularity 
assessment a hematoxylin staining was performed. The different histological stainings 
were quantified using a Leica DM-RE microscope and Leica Qwin Imaging software 
(Leica Ltd., Germany). 
Statistical Analysis
All data are expressed as mean±SEM. The two-tailed student’s T-test was used to 
compare individual groups of mice or cells. When indicated, a Mann-Whitney test 
was used to analyze not normally distributed data. The frequency of thickened cap 
structure was analyzed by a Fisher’s exact test. P values of <0.05 were considered 
significant.
Results
A DC based vaccination strategy against Foxp3








































































Figure 1. Expression of costimulatory molecules on electroporated DCs. After electroporation with either 
PBS (control, n=3), GFP mRNA (n=3) or Foxp3 mRNA (n=3) the DCs were cultured o/n. One group of DCs 
were stimulated with LPS as a positive control for maturation (mDCs). Unstimulated DCs (imDCs) were 
used as a negative control for maturation. DCs were subsequently stained for CD80, CD86 and CD40 and 
analyzed by FACS. ***P<0.001
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based vaccination strategy was used in which DCs were transfected with mRNA 
encoding for Foxp3. A significant increase in the surface expression of the co-
stimulatory molecules, CD80, CD86 and CD40 was observed in DCs that were 
electroporated with mRNA encoding Foxp3 or GFP, when compared with electroporation 
without mRNA (Control) and immature DCs (imDCs). The increase is comparable to 
the LPS induced maturation of DCs (mDCs) (Figure 1). After electroporation with 
mRNA encoding for Foxp3 a strong increase in Foxp3 expression in DCs was observed 
on mRNA level, which indicated a successful transfection of the DCs (Figure 2A). To 
determine the intracellular protein expression of Foxp3, an intracellular Foxp3 FACS 
staining was performed (Figure 2B and C). Foxp3 transfected DCs expressed 6.3-fold 
more intracellular Foxp3 compared to GFP transfected DC, which expressed no Foxp3. 
Vaccination against Foxp3 reduces the number of Tregs
To asses the efficacy of the Foxp3 vaccine, LDLr-/- mice were vaccinated with Foxp3 
electroporated DCs to induce a cytotoxic immune response against Foxp3 as described 
by Nair et al.17 As a control, mice were vaccinated with DCs electroporated with mRNA 
encoding for GFP. Before vaccination, the number of Tregs in blood in all groups of 
mice was equal, but five weeks after vaccination a 34% reduction in the number of 
Foxp3+ Tregs in Foxp3 vaccinated mice was observed, compared to GFP vaccinated 
mice (Figure 3A; 0.773±0.032% versus 1.175±0.065%; P<0.001). Upon sacrifice, 
vaccination with Foxp3 transfected DCs (black bars; Figure 3B) resulted in a 27-30% 
decrease in Foxp3+ Tregs in blood (0.67±0.045% versus 0.92±0.096%, P<0.05), 
spleen (2.88±0.24% versus 3.94±0.34%, P<0.05), MLN (3.59±0.10% versus 
5.01±0.45%, P<0.05) and HLN (3.68±0.08% versus 5.50±0.46%, P<0.01), when 
compared to mice vaccinated with DCs electroporated with mRNA encoding for GFP 
(grey bars; Figure 3B). As a control for the DC vaccination, one group of mice was 
treated with PBS. We observed no differences in the numbers of Foxp3+ Tregs in 



































































Figure 2. Assessment of Foxp3 specific mRNA and the subsequent expression in DCs. After electroporation 
of DCs with mRNA encoding for Foxp3 or GFP, total RNA was isolated and cDNA was synthesized. 
Subsequently the amount of mRNA was detected with Foxp3 specific qPCR primers (A). The expression is 
relative to HPRT and 36B4. Next we determined, with FACS analysis, the intracellular expression of Foxp3 
in PBS (green), GFP (blue) and Foxp3 (pink) electroporated DCs. Additionally, electroporated DCs were 
cultured o/n and stained intracellularily for Foxp3 and analyzed by FACS. A representative histogram (B) 
and percentage of intracellular Foxp3 expression is depicted (C).
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Figure 3. Effect of vaccination against Foxp3 on the percentage of Tregs in lymphoid organs and on 
spleen cell proliferation. LDLr-/- mice were vaccinated against GFP or Foxp3 using electroporated DCs. As a 
second control, one group of mice was vaccinated with PBS. Five weeks after vaccination blood was taken 
from the mice vaccinated with either PBS (A, n=5, white bar), GFP (n=5, grey bar) or Foxp3 (n=5, black 
bar) and was analyzed for CD4+CD25+Foxp3+ cells using FACS analysis. Eight weeks after vaccination 
the mice vaccinated with either PBS (B, n=5, white bars), GFP (n=5, grey bars) or Foxp3 (n=5, black 
bars) were sacrificed. Blood, spleen, MLN and HLN, were isolated and the number of CD4+CD25+Foxp3+ 
cells in these organs was determined. The effect of vaccination against Foxp3 on spleen cell proliferation 
was determined by culturing splenocytes isolated after 8 weeks ex vivo (C). Proliferation was assessed 
by the amount of 3H-thymidine incorporation in dividing cells. The amount of 3H-thymidine incorporation 
was measured using a liquid scintillation analyzer (Tri-Carb 2900R). The proliferation is expressed in 
disintegrations per minute (dpm). *P<0.05, **P<0.01, ***P<0.001
DCs electroporated with mRNA encoding for GFP (white bars; Figure 3A and B). 
Regulatory T cells have an inhibitory effect on T cell proliferation. Therefore we 
investigated whether a vaccination against Foxp3 and a subsequent reduction in the 
number of Tregs influences the proliferation of splenic T cells. We observed a significant 
1.9-fold increase in spleen cell proliferation compared to the GFP vaccinated mice 
(Figure 3C: 4148.5±941.4 dpm versus 8230.5±1542.5 dpm P<0.05).
Vaccination against Foxp3 increased lesion formation in LDLr-/- mice
Eight weeks after vaccination and Western-type diet feeding the plaque size at the 
aortic root was analyzed. Representative slides of the aortic root of GFP and Foxp3 
vaccinated mice are shown in Figure 4A and B, respectively. Mice vaccinated against 
Foxp3 showed a significant 34% increase in plaque size compared to the GFP 
























Figure 4. Effect of vaccination against Foxp3 on initial atherosclerotic lesion development. Eight weeks 
after vaccination and Western-type diet feeding the LDLr-/- mice were sacrificed and the hearts of GFP 
treated (A) and Foxp3 treated (B) mice were sectioned and stained with Oil-Red-O and hematoxylin. The 
lesions were quantified and the plaque size was determined (C). **P<0.01
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P<0.01). During the experiment, all mice developed hypercholesterolemia, however 
no significant differences in serum cholesterol levels and body weight (data not 
shown) were observed between the different groups of mice. No differences in plaque 
size were observed between PBS treated mice and mice vaccinated against GFP (data 
not shown). 
Vaccination against Foxp3 results in increased plaque cellularity
To investigate whether there is a change in plaque composition in the enlarged initial 
plaques of the Foxp3 vaccinated mice the number of cells within the lesions were 
quantified. The plaques of Foxp3 vaccinated mice showed a 27% increase in cellularity 
compared to GFP vaccinated mice (Figure 5A-C; 3.84x10-3±0.19x10-3 cells/μm2 versus 
2.81x10-3±0.79x10-3 cells/μm2, respectively; P<0.01). Subsequently we determined 
the plaque stability by measuring both the amount of collagen within the plaque and 
the fibrous cap thickness. The collagen content of the plaque was not significantly 
changed between the Foxp3 and GFP vaccinated mice (Figure 5D-F, 9.0±1.1% versus 
6.5±1.9%, respectively). 
Additionally, we noticed that the lesions in 9 of the 13 Foxp3-vaccinated mice displayed 
significant characteristic changes in morphology. These lesions are characterized by 
a thickened fibrous cap-like structure (Figure 6, arrows). This cap however does not 








































Figure 5. Effect of vaccination against Foxp3 on plaque composition. Eight weeks after vaccination and 
Western-type diet feeding the LDLr-/- mice were sacrificed and the hearts of GFP treated (A) and Foxp3 
treated (B) mice were sectioned and stained with hematoxylin to stain the nucleus of the cells within 
the lesion. The number of nuclei was quantified (C). Sections of the hearts of GFP treated (D) and Foxp3 
treated (E) mice were also analyzed for collagen content using the Masson’s Trichrome staining which 
stains collagen blue. The percentage of collagen relative to the lesion size was determined (F). **P<0.01 
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structure does not seem to provide a stable phenotype. When compared with GFP 
vaccinated mice in which 2 out of 14 mice showed these thickened structures, a 
significant difference is observed when a Fisher’s exact test is performed (Figure 6, 
P<0.01). These thickened structures do not contain any macrophages or fibroblasts 
and overall there was no significant difference in cap thickness in the different groups. 
Discussion
In this study we demonstrate that vaccination against Foxp3+ Tregs aggravates 
atherosclerotic lesion formation, thereby directly establishing the protective role 
of Foxp3+ Tregs in atherosclerosis. The beneficial role of Tregs in atherosclerosis is 
already indicated in a number of publications.16, 20 We showed before that induction 
of Foxp3 positive Tregs via oral tolerance induction against HSP60 and oxLDL 
reduces atherosclerotic lesion formation.10, 11 Furthermore, Ait-Oufella and colleagues 
demonstrated that a deficiency in costimulatory molecules promotes atherosclerosis 
because of a decrease in the number of Tregs and showed that a depletion of CD25+ 
cells using anti-CD25 antibodies increased lesion formation.16 However, the final 
proof for the involvement of Foxp3 expressing T cells in atherosclerosis has not been 
provided since CD25 is not exclusively expressed on Tregs, as it is also present on 
activated T cells21, NK cells22 and myeloid DCs.23 
To specifically study the role of Foxp3 positive Tregs in atherosclerosis, we vaccinated 





No thickened cap Thickened cap
12 2
4 9
Figure 6. Thickened cap structure in Foxp3 vaccinated mice. Within the Foxp3 vaccinated group more 
thickened structures in the fibrous cap (arrows) were observed when compared to the GFP vaccinated 
mice. Frequency of thickened structure between GFP and Foxp3 vaccinated mice is depicted in the table. 
A Fisher’s exact test was used (P<0.01).
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electroporated with mRNA encoding for Foxp3 and this approach, described by Nair et 
al, results in a cytotoxic T lymphocyte (CTL) response against Foxp3 and a subsequent 
depletion of Foxp3+ Tregs.17 As a control, mRNA encoding for GFP was used to exclude 
that mRNA electroporation into DCs activates the DCs leading to immune modulatory 
effects. In all the experiments, the treatment with GFP electroporated DCs was 
compared with PBS treatment and no differences were observed between both control 
treatments. After electroporation of DCs with mRNA, either with GFP or with Foxp3, 
an activated phenotype of DCs was observed. This was not observed when DCs were 
electroporated without mRNA. It is known that single stranded RNA (ssRNA), such as 
mRNA, is a natural ligand for Toll like receptors 7 and 8,24, 25 which may explain the 
activated phenotype of the DCs after electroporation with mRNA. 
We successfully demonstrated that the DCs were transfected with the mRNA coding for 
Foxp3 via qPCR and FACS analysis. Foxp3 is a nuclear product and is not expressed on 
the cell surface. However, we use a truncated Foxp3 in which the nuclear localization 
sequence is removed. This results in relatively high concentration of cytosolic Foxp3 
protein and therefore may result in the cross-presentation of Foxp3-peptides on MHC 
class I. Furthermore, mRNA may act as a natural agonist of TLR7/8 and thereby even 
further enhance cross-presentation, which is already described by other groups.24-27 
This may lead to the presentation of Foxp3 peptides to CD8+ T cells, which subsequently 
target Foxp3 expressing cells.
Our present data show a significant reduction in Foxp3+ Tregs in blood 5 weeks after 
vaccination. A similar reduction in Foxp3+ Tregs was observed within the blood, HLN, 
MLN and spleen, 8 weeks after vaccination, indicating a systemic reduction in Foxp3+ 
Tregs and a persistent effect of the vaccination. As shown before by Nair et al.17 this 
reduction in Tregs is caused by the induction of a robust Foxp3-specific cytotoxic T 
lymphocyte response. Additionally, we observed an increased spleen cell proliferation 
in the Foxp3 vaccinated mice compared with GFP vaccinated mice which is indicative 
for a reduced number of Tregs since these cells suppress effector T cells. The reduction 
in Foxp3+ Tregs resulted in a 34% increase in initial lesion size. The increase in 
atherosclerosis is not related to a change in total cholesterol serum levels since there 
is no significant difference in cholesterol levels between the different groups.
Besides an increase in lesion size, vaccination against Foxp3 also induced a 30% 
increase in cellularity of the initial lesions. The increased cellularity may indicate an 
increase in inflammation within the lesion. This may be caused by an increase in 
proliferation of inflammatory cells or by an increase in influx of inflammatory cells, 
which in normal conditions would be under the control of Tregs. The increase in 
cellularity is not caused by an accumulation of macrophages or fibroblasts. 
In addition to plaque cellularity, we analyzed the plaque stability but no differences 
in both the collagen content and the fibrous cap thickness were observed between 
GFP and Foxp3 vaccinated mice. In spite of the fact that the fibrous cap thickness was 
not changed, we observed significant more thickened fibrous cap-like structures in 
the Foxp3 vaccinated mice. These thickened structures, which also seem to grow into 
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the lesion, do not contain macrophages and fibroblasts and do not cover the entire 
plaque. The exact composition and function of these structures remains therefore 
unclear and needs further investigation, especially because these cap-like structures 
do not look like a stable fibrous cap. 
The results in this study are in line with the observations that the induction of Tregs 
exerts an atheroprotective effect. The increase in lesion size is comparable with the 
decrease of initial lesion size upon the induction of Tregs via oral administration of 
oxLDL (30.0%) or HSP60 (27.5%).10, 11 In conclusion, we confirmed the protective 
role of Foxp3+ Tregs in atherosclerosis by vaccinating LDLr-/- mice using a DC based 
Foxp3 vaccination strategy. The results illustrate an important role for Foxp3+ Tregs in 
atherosclerosis, thereby providing a potential opportunity for therapeutic intervention 
against atherosclerosis.
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Abstract
Objective: Regulatory T cells (Tregs) play an important role in the regulation of T 
cell-mediated immune responses through suppression of T cell proliferation and 
cytokine production. In atherosclerosis, a chronic autoimmune-like disease, an 
imbalance between pro-inflammatory cells (Th1/Th2) and anti-inflammatory cells 
(Tregs) exists. Therefore, increased Treg numbers may be beneficial for patients 
suffering from atherosclerosis. In the present study, we determined the effect of a 
vast expansion of Tregs on the initiation and regression of well-established lesions. 
Methods and Results: For in vivo Treg expansion, LDL receptor deficient (LDLr-/-) 
mice received repeated intraperitoneal injections of a complex of IL-2 and anti-IL-2 
mAb. This resulted in a 10-fold increase in CD4+CD25hiFoxp3+ T cells, which potently 
suppressed effector T cells ex vivo. During initial atherosclerosis, IL-2 complex 
treatment of LDLr-/- mice fed a Western-type diet reduced atherosclerotic lesion 
formation by 39%. The effect on pre-existing lesions was assessed by combining IL-2 
complex treatment with a vigorous lowering of blood lipid levels in LDLr-/- mice. This 
did not induce regression of atherosclerosis, but significantly enhanced lesion stability.
Conclusions: Our data show differential roles for Tregs during atherosclerosis: Tregs 
suppress inflammatory responses and attenuate initial atherosclerosis development, 
while during regression Tregs can improve stabilization of the atherosclerotic lesions.
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Introduction
Atherosclerosis is considered a chronic autoimmune-like disease with an underlying 
imbalance between pro-inflammatory and anti-inflammatory processes.1, 2 Restoration 
of this delicate balance by induction of Tregs has proven to be of therapeutic potential 
in the treatment of several autoimmune diseases such as diabetes and rheumatoid 
arthritis.3, 4 As key regulators of T cell-mediated immune responses, Tregs exert 
suppressive effects on effector T cells. Suppression mainly occurs through secretion 
of IL-10 and TGF-β, and cell-cell contact, mediated by membrane-bound TGF-β, 
CTLA-4 or GITR.5, 6 In mice, Tregs are characterized by the expression of the surface 
molecules CD4 and CD25, and expression of the transcription factor Forkhead box 
protein P3 (Foxp3).7 
The role of Tregs in atherosclerosis has been the subject of intense investigation. 
Adoptive transfer of CD4+CD25+ T cells causes a reduction in atherosclerotic lesion 
development8 while a depletion of CD4+CD25+ T cells or more specifically Foxp3 
expressing Tregs aggravates lesion development.8, 9 Our group has shown that 
induction of antigen-specific Tregs via oral tolerance induction against oxLDL shows 
the beneficial effect of Tregs on the initiation and progression of atherosclerosis.10
Tregs have been shown to depend on IL-2 for optimal growth and survival.11-14  Recently, 
it is shown that repeated injections of an IL-2 complex consisting of recombinant 
IL-2 and a specific anti-IL-2 monoclonal antibody (JES6-1A12) results in a specific 
expansion of Tregs15, which very potently induce resistance to EAE and suppressed 
graft rejections16, type I diabetes17, murine-asthma18 and myasthenia gravis.19
In order to obtain a clinically relevant therapy for atherosclerosis, an experimental 
therapy inducing regression of atherosclerosis is a prerequisite, as most of the 
cardiovascular patients will already have well-established lesions. The effect of Tregs 
on the stabilization and regression of established atherosclerosis, however, remains to 
be elucidated. In the present study, we therefore not only determined the beneficial 
effect of IL-2 complex induced Tregs on the initiation of atherosclerosis, but more 
importantly, determined their therapeutic potential in a model for regression of 
atherosclerotic lesions.
Material and methods 
Animals
Male LDLr deficient (LDLr-/-) mice, 10-12 weeks old, were obtained from Jackson 
Laboratories. The animals were kept under standard laboratory conditions and were 
fed a normal chow diet or a Western-type diet containing 0.25% cholesterol and 
15% cocoa butter (Special Diet Services, Witham, Essex, UK). Diet and water were 
provided ad libitum. All animal work was approved by the regulatory authority of 
Leiden University and carried out in compliance with the Dutch government guidelines.
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Preparation of IL-2 complexes
IL-2 complexes were prepared by mixing 1 μg recombinant IL-2 (Peprotech) with 5 μg 
anti-IL-2 mAb (clone JES6-1A12, R&D, Abington, UK) in sterile PBS and incubated at 
37°C for 30 minutes before injecting intraperitoneally (i.p.).  
Initiation and regression of atherosclerosis
Atherosclerosis was induced in LDLr-/- mice by feeding a Western-type diet for 8 
weeks. Two weeks after start of Western-type diet mice were treated i.p. with the IL-2 
complex (n=11) or with sterile PBS as a control (n=11). Initially, mice were treated 
i.p. with IL-2 complexes for three consecutive days to boost the expansion of Tregs, 
thereafter mice were injected every 10 days to maintain high levels of Tregs. To study 
regression of atherosclerosis, mice were put on a Western-type diet for 10 weeks. 
At week 10, a baseline group (n=11) was sacrificed to determine disease extent at 
the beginning of the treatment. Subsequently, mice were put on a chow diet and 
simultaneously treated i.p. with the IL-2 complex as mentioned above (n=13). As a 
control, mice were treated with sterile PBS (n=14). At week 20, mice were sacrificed 
and tissues were harvested after in situ perfusion using PBS and subsequent perfusion 
using Zinc Formal-Fixx (Shandon Inc. Pittsburg, USA). Tissues were frozen in nitrogen 
and stored at -80 °C until further use. 
Serum cholesterol levels
During the experiments, mice were weighed and blood samples were obtained by tail 
vein bleeding. The total cholesterol levels in serum were determined at week 0, 2 and 
8 after start of the initial atherosclerosis experiment and at week 0, 5, 10, 14, 18 and 
20 after start of the regression experiment. The concentrations of serum cholesterol 
were determined using enzymatic colorimetric procedures (Roche/Hitachi, Mannheim, 
Germany). Precipath (Roche/Hitachi) was used as an internal standard. 
Histological analysis and morphometry
Cryosections of the aortic root (10 µm) were made and stained with Oil-Red-O.  Lesion 
collagen content was determined with a Masson’s Trichrome staining. Furthermore, 
corresponding sections on separate slides were stained immunohistochemically with 
an antibody directed against a macrophage specific antigen (Moma-2, monoclonal rat 
IgG2b, diluted 1:1000). Goat anti-rat IgG alkaline phosphatase conjugate (dilution 
1:100) was used as a secondary antibody and nitro blue tetrazolium and 5-bromo-
4-chloro-3-indolyl phosphate as enzyme substrates. To determine the number of T 
cells in the lesions, a CD3 staining was performed using anti-mouse CD3 (1:50, BD 
Biosciences Pharmingen, San Diego. CA). In addition, the aortic arch and its main 
branch points were excised (4 µm), fixed, and embedded in paraffin. Longitudinal 
sections of the aortic arch were analyzed for lesion extent with a hematoxylin and 
eosin staining. Morphology was studied using a Leica DM-RE microscope and LeicaQwin 
software (Leica imaging systems, Cambridge, UK). 
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Flow cytometry
During the experiments, levels of Tregs were monitored in the blood at several time 
points. Red blood cells were lysed using erythrocyte lysis buffer (0.15 M NH4Cl, 10 mM 
NaHCO3, 0.1 mM EDTA, pH 7.3). For the detection of CD4+CD25hiFoxp3+ T cells, the 
blood cells were stained with the surface markers CD4 and CD25 (0.25 µg Ab/200.000 
cells). For intracellular staining of Foxp3, cells were fixated and permeabilized overnight 
and subsequently stained against Foxp3 according to manufacturer’s protocol 
(eBioscience, San Diego, CA). At sacrifice, blood, spleen, mediastinal lymph nodes 
near the heart (HLN) and liver were isolated (n=5 per group). Single cell suspensions 
were obtained by squeezing the organs through a 70 µm cell strainer. Red blood cells 
were removed as described above. For the detection of CD4+CD25hiFoxp3+ T cells, 
the spleen, blood, HLN and liver cells were stained with CD4, CD25 and Foxp3. In 
addition, cells were stained for the transcription factors T-bet, RORγt and GATA-3 and 
the cytokines IFN-γ, IL-17A and IL-4. All antibodies were purchased from eBioscience. 
FACS analysis was performed on a FACSCantoII (Beckton Dickinson, Mountain View, 
CA). Data were analyzed using FACSDiva software (Beckton Dickinson). 
Spleen cell proliferation
The splenocytes (n=5 per group) were cultured for 48 hours in triplicate in a 96-wells 
round-bottom plate (3×105 cells/well, Greiner Bio-One) in RPMI 1640 supplemented 
with L-Glutamine, 100 U/mL streptomycin/penicillin and 10% FCS. As a positive control 
cells were stimulated with αCD3 and αCD28 (2 μg/mL). Proliferation was measured by 
addition of 3H-thymidine (0.5 μCi/well, Amersham Biosciences, The Netherlands) for 
the last 16 hours. The amount of 3H-thymidine incorporation was measured using a 
liquid scintillation analyzer (Tri-Carb 2900R). Responses are expressed as stimulation 
index (SI): ratio of mean counts per minute of triplicate cultures with αCD3/CD28 
stimulation to triplicate cultures without stimulation. 
Suppression assay
Tregs were isolated with greater than 95% purity from splenocytes using the 
CD4+CD25+ Regulatory T Cell Isolation Kit from Miltenyi Biotec (Utrecht, The 
Netherlands). 7.5×104 splenocytes were plated out per well of a 96-well plate with or 
without titrated amounts of isolated Tregs from IL-2 complex and control treated mice. 
Cells were activated with αCD3 and αCD28 (2 μg/mL) and pulsed with 3H-thymidine 
(0.5 μCi/well) on day 3. Proliferation was assessed 16 hours later using a liquid 
scintillation counter. All results are expressed as the mean disintegration per minute 
(dpm) of triplicate cultures. 
Cytokine determination in supernatant of the suppression assay
IL-10 and TGF-β concentrations in the supernatant of effector T cells cultured in a 1:1 
ratio with Tregs for 72 hours were determined by ELISA according to manufacturer’s 
protocol (eBioscience, Belgium). 
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Real-time PCR assays
Spleens from baseline mice (n=11), control mice (n=14) and IL-2 complex mice (n=13) 
were isolated and mRNA was extracted using the guanidium isothiocyanate (GTC) 
method and reverse transcribed (RevertAid M-MuLV reverse transcriptase). Quantitative 
gene expression analysis was performed on a 7500 Fast Real-Time PCR system (Applied 
Biosystems, CA) using SYBR green technology. The following primer pairs were used: 
5’-TCTTACTGACTGGCATGAGGATCA-3’ and 5’-GTCCGCAGCTCTAGGAGCAT-3’ for IL-
10 and 5’-AGGGCTACCATGCCAACTTCT-3’ and 5’-GCAAGGACCTTGCTGTACTGTGT-3’ 
for TGF-β. The following primers were used as endogenous references: 5’- 
GGACCCGAGAAGACCTCCTT-3’ and 5’-GCACATCACTCAGAATTTCAATGG-3’ for acidic 
ribosomal phosphoprotein PO (36B4) and 5’-TTGCTCGAGATGTCATGAAGGA-3’ and 
5’-AGCAGGTCAGCAAAGAACTTATAG-3’ for hypoxanthine phosphoribosyltransferase 
(HPRT). 
Statistical analysis
All data are expressed as mean±SEM. An unpaired two-tailed student’s T-test was 
used to compare normally distributed data between two groups of animals. Probability 
values of P<0.05 were considered significant. 
Results
Persisting high levels of Tregs in LDLr-/- mice due to continuous treatment 
with the IL-2 complex 
To determine whether IL-2 complexes induced Treg expansion in LDLr-/- mice, we 
injected the IL-2 complex or PBS (control) intraperitoneally on 3 consecutive days. 
Mice were sacrificed 5 days after initiation of the experiment. The administration of 
IL-2 complexes resulted in a significant 3-fold increase of Tregs in lymphoid organs 
and an 11-fold increase in the liver, compared to control mice (Figure 1A,B). The 
Tregs expanded in the IL-2 complex treated group were functional as they potently 
suppressed effector T cell proliferation ex vivo (Figure 1C). In addition, Tregs 
expanded by the IL-2 complex were more suppressive than Tregs from control treated 
mice (P<0.001, Figure 1D), whereas no significant differences between solely effector 
T cell proliferation and Treg proliferation of both groups were observed. Cytokine 
determination in the supernatant of this suppression assay showed that IL-2 complex 
expanded Tregs mainly function via IL-10 secretion, whereas no difference in TGF-β 
secretion was observed (P<0.05, Figure 1E).
To control whether the Treg expansion induced by the IL-2 complex is still functional 
under hyperlipidemic, pro-inflammatory circumstances, LDLr-/- mice were fed a 
Western-type diet for 8 weeks. Two weeks after initiation of the experiment, mice 
were i.p. injected with IL-2 complexes for 3 consecutive days to boost the expansion 
of Tregs.  Thereafter, mice were injected every 10 days to maintain persistently high 
Treg levels essential for investigating the effect of high Treg levels on atherosclerosis 
development and regression. As shown in Figure 1F, the IL-2 complex is still able to 
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enhance Tregs in blood under hyperlipidemic conditions. In addition, the level of Tregs 
in the blood persistently remained at a significantly 10-fold higher level than in control 
treated mice (P<0.001).
IL-2 complex administration reduces the development of atherosclerosis 
Since a limited increase in Tregs already affects the initiation of atherosclerosis, we 
postulated that a 10-fold expansion of Tregs in blood observed after IL-2 complex 
administration may significantly potentiate this effect. During the experiment 
enhanced levels of Tregs did not affect body weight and total plasma cholesterol levels 
(data not shown). Eight weeks after the start of the high fat diet mice were sacrificed 
and atherosclerotic lesion size was determined. We observed a significant 39% 
reduction in aortic root lesion size of IL-2 complex treated mice (1.73±0.13×105 
µm2) in comparison with control mice (2.84±0.30×105 µm2, P<0.01, Figure 2A,B). 
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Figure 1. IL-2 complex induces persistent high levels of Tregs in LDLr-/- mice. LDLr-/- mice were injected 
3 times with an IL-2 complex (n=3, black bars) or PBS as a control (n=3, open bars). Mice were sacri-
ficed 5 days after initiation of the experiment. Blood, spleen, mediastinal lymph nodes near the heart 
(HLN), mesenteric lymph nodes (MLN) and liver cells were isolated and the percentage of CD25+Foxp3+ 
cells within CD4+ cells was determined by flow cytometry (A,B). A suppression assay was performed to 
determine the suppressive capacity of the expanded Tregs by measuring the proliferation of splenocytes 
(C, n=3). Data are shown as the mean disintegration per minute (dpm) of triplicate cultures. In a 1:1 
ratio, effector T cells were more potently suppressed by Tregs from IL-2 complex treated mice compared 
to Tregs from control mice (D). Secretion of IL-10 and TGF-β in the supernatant of Tregs cultured with 
effector T cells in a 1:1 ratio was determined with ELISA (E, control: open bars, IL-2 complex: black 
bars). To induce atherosclerosis, LDLr-/- mice were fed a Western-type diet for 8 weeks. Two weeks after 
initiation of the experiment, mice received i.p. injections with the IL-2 complex (black arrows). Levels of 
CD4+CD25hiFoxp3+ T cells were monitored in the blood at week 2, 3, 5 and 7 using flow cytometry (F, n=5 




















































Figure 2. Expansion of Tregs reduces lesion formation. LDLr-/- mice were fed a Western-type diet for 8 
weeks and were treated i.p. with the IL-2 complex (n=11) or PBS as a control (n=11). Representative 
cross-sections of lesion formation in the three valves area of the aortic root stained with Oil-Red-O and 
hematoxylin are shown (A) and lesion size was determined (B). Corresponding sections on separate slides 
were stained for collagen using Masson’s trichrome staining (C). The percentage of collagen relative to 
the lesion size was determined (D). Furthermore, relative macrophage content was determined with a 
MOMA-2 staining and quantified (E,F). ** P<0.01
was observed between IL-2 complex treated mice (16.0±1.5%) and control treated
mice (18.8±0.9%) (Figure 2C,D). Furthermore, no difference in macrophage content 
was observed (control: 61.4±3.3% and IL-2 complex: 53.0±4.4%, Figure 2E,F). 
At sacrifice, we determined whether the high amounts of CD4+CD25hiFoxp3+ T cells 
measured in blood corresponded to increased Treg levels in spleen, mediastinal 
lymph nodes located near the heart (HLN), and liver. In agreement with increased 
Treg levels in the blood of IL-2 complex treated mice, we observed a significant 3-fold 
(P<0.001), 1.5-fold (P<0.05), and 9.2-fold (P<0.05) increase in Tregs in the spleen, 
HLN, and liver, respectively, as compared with control treated mice (Figure 3A). To 
determine the suppressive capacity of the IL-2 complex expanded Tregs, splenocytes 
isolated from both groups were cultured for 48 hours in the presence of αCD3/αCD28 
stimulation. A significant 43% decrease in T cell proliferation was observed in mice 
treated with the IL-2 complex (stimulation index of 9.7±1.5) compared to control 
mice (stimulation index of 17.1±3.3), showing that the induced Tregs are functional 
(Figure 3B, P<0.05). Since Tregs function in part via IL-10 and TGF-β secretion, 
we determined the gene expression of these cytokines in the spleen. IL-2 complex 
treated mice showed a 4.7-fold increase in IL-10 expression compared with control 
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mice (P<0.05), whereas TGF-β expression remained unchanged (Figure 3C). This 
suggests that Tregs induced by the IL-2 complex may exert their suppressive function 
predominantly via the secretion of IL-10.
Effect of Treg expansion on other T cell subsets 
It has been suggested that Tregs have the capacity to specifically target and suppress 
effector T cells, such as Th1, Th2 and Th17 cells.19, 20 To evaluate whether the IL-2 
complex expanded Tregs inhibit a specific T cell subset in vivo during initiation of 
atherosclerosis, splenocytes were stained for the transcription factors T-bet, GATA-3, 
and RORγt, which control the differentiation of Th0 cells into Th1, Th2 and Th17 cells, 
respectively. Flow cytometry analysis showed that IL-2 complex treated mice have 
significant reduced T-bet expression (Figure 3D, 1.7±0.2% vs. 3.6±0.4%, P<0.01) 
and reduced GATA-3 expression (16.1±0.6% vs. 19.8±1.3%, P<0.05) in the CD4+ T 
cell population of the spleen, compared to the control group. Accordingly, reduced 
CD4+IFN-γ+ T cells were observed (Figure 3E, 6.1±0.5% vs. 9.4±1.0%, P<0.05). 
Interestingly, the percentage of IL-4+ cells did not change in the spleen, but was 
decreased in the blood (13.5±2.1% vs. 23.8±1.8%, P<0.01, Figure 3F). Th17 
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Figure 3. Effect of the IL-2 complex on the percentage and functionality of the Tregs. Eight weeks after 
induction of atherosclerosis mice were sacrificed. Spleen, HLN and liver cells were isolated and stained 
for CD4, CD25, and Foxp3 and analyzed by flow cytometry (n=5 per group, A). The effect of boosting 
Tregs with the IL-2 complex on spleen cell proliferation was determined by culturing splenocytes (n=5 
per group) in the presence or absence of CD3/CD28 stimulation (B). Proliferation was assessed by the 
amount of 3H-thymidine incorporation in dividing cells. The proliferation is expressed as stimulation in-
dex. mRNA levels of IL-10 and TGF-β in the spleen were determined with RT-PCR (C). Spleen cells were 
stained for CD4 and the transcription factors T-bet (Th1), RORγt (Th17) and GATA-3 (Th2, D). In addition, 
cytokine production in the spleen (E) and blood (F) was evaluated by flow cytometry. Cells were stained 
for CD4, IFN-γ, IL-17A and IL-4. * P<0.05, ** P<0.01, *** P<0.001
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IL-2 complex-expanded Tregs stabilize lesions in a regression model
Since it is clinically more relevant to determine the effect of Tregs on pre-existing 
lesions, we combined lipid lowering with a treatment with the IL-2 complex. To this 
end, we put LDLr-/- mice, which were fed a Western-type diet for 10 weeks, on a 
chow diet for another 10 weeks, combined with simultaneous administration of IL-2 
complexes. In addition, a baseline group was sacrificed after 10 weeks of Western-
type diet to determine the effect of treatment on atherosclerotic lesion size. No 
differences in weight and cholesterol levels were found between baseline, control 
and IL-2 complex treated mice during Western-type diet feeding (Figure 4A, B). In 
addition, no differences in weight were found between control and IL-2 complex 
treated mice after switching to chow diet and Treg induction (Figure 4A). Only a 
10-20% reduction (P<0.05) in plasma cholesterol levels could be observed in IL-2 
complex-treated mice compared to control mice at 4, 8 and 10 weeks after switching 
to a low cholesterol diet (Figure 4B). Throughout the experiment, Treg levels in 
blood remained significantly higher in the IL-2 complex group as compared to control 
treated mice and at sacrifice ex vivo effector T cell proliferation was suppressed (data 
not shown). In addition, highly elevated Treg levels were observed in blood, spleen 
and HLN at sacrifice (Figure 4C).
Both the control and the IL-2 complex treated mice displayed no reduction in lesion 
size (control: 3.06±0.25×105 µm2 and IL-2 complex: 3.10±0.25×105 µm2) when 
compared with the baseline group (2.74±0.10×105 µm2, Figure 5A,C). The same 
effect was observed in the aortic arch, where both IL-2 complex treated and control 
mice showed no reduction in lesion size (data not shown). Furthermore, the collagen 
and macrophage content of the lesions was determined (Figure 5B and 5D-E). 
Lesions from IL-2 complex treated mice (38.3±2.3% collagen) showed a substantially 
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Figure 4. Effect of IL-2 complex on weight, cholesterol levels and Tregs during regression of atheroscle-
rosis. LDLr-/- mice received 10 weeks Western-type diet and were subsequently put on chow diet for 10 
weeks and treated with the IL-2 complex (n=13, black circles) or PBS (n=14, open circles). A baseline 
group was sacrificed after 10 weeks of Western-type diet (n=11, grey circles). During the experiment, 
mice were weighed (A) and blood was taken by tail vein bleeding. Total cholesterol concentration was 
determined within the serum (B). To check whether the IL-2 complex expanded the Tregs, at sacrifice, 
blood, spleen and HLN cells were isolated and stained for CD4, CD25, and Foxp3, and analyzed with flow 
cytometry (n=5 per group, C). * P<0.05, *** P<0.001
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Additionally, both groups showed very significantly increased collagen content 
(P<0.001) compared to baseline mice (12.2±1.2%). No difference in relative 
macrophage content was observed between the IL-2 complex treated group 
(12.4±1.9%) and the control group (14.3±1.6%). Both groups, however, showed a 
significantly 60% reduction in the relative macrophage content compared to the 
baseline group (36.7±2.6%, P<0.001, Figure 5E), indicative for regressed lesions in 
both groups. Together these results suggest that increasing the number of Tregs 
during well-established atherosclerosis results in more stable lesions, with increased 
collagen content, but does not affect lesion size. In addition, we analyzed the aortic 
root for CD3+ T cells within lesions and found almost no T cells in lesions of both IL-2 
complex treated mice and control mice. However, we found a 60% increase of CD3+ T 
cells within the adventitia of IL-2 complex treated mice (86.4±10.6 cells/section) 
compared to control treated mice (40.3±6.3 cells/section, P<0.01, Figure 6).
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Figure 5. IL-2 complex treatment stabilizes atherosclerotic lesions during regression. LDLr-/- mice re-
ceived Western-type diet for 10 weeks and were subsequently put on chow diet for 10 weeks and simul-
taneously treated with the IL-2 complex (n=13) or PBS (n=14). A baseline group was sacrificed after 10 
weeks of Western-type diet (n=11). Sections of the aortic root were stained with Oil-Red-O and hema-
toxylin (A) and subsequently lesion size was determined (C). Corresponding sections on separate slides 
were also stained for collagen using Masson’s trichrome staining (B). The percentage of collagen relative 
to the lesion size was determined (D). Furthermore, relative macrophage content was determined with a 
MOMA-2 staining and quantified (E).  * P<0.05, *** P<0.001 
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Discussion 
Regulatory CD4+CD25hiFoxp3+ T cells are important regulators of immune responses 
and have been shown to play a major role in autoimmune diseases. Since autoimmune 
diseases result from an imbalance between effector and regulatory cells, with reduced 
numbers of the latter, Tregs show great potential to be used as a therapeutic regime. 
Their beneficial role in atherosclerosis has been particularly elucidated in the initiation 
of atherosclerosis using adoptive transfer, induction and depletion of Tregs.8, 9, 11, 21-23 
However, in these studies, only a modest increase in Treg numbers was achieved in 
the order of 1.5- to 2-fold, mostly for 2-3 weeks. We therefore determined whether 
significantly higher Treg levels for longer periods of time could even more drastically 
attenuate atherosclerosis development. We used the recently published technique 
using the IL-2 complex consisting of IL-2 and a neutralizing anti-IL-2 mAb, a treatment 
that beneficially affected the outcome of a number of autoimmune-like diseases.16-19 
In the present study, LDLr-/- mice were fed a Western-type diet for 8 weeks. The 
treatment with the IL-2 complex was started after 2 weeks of feeding the Western-
type diet in order to counteract the pro-inflammatory effects of the diet. We now show 
that stimulation of Tregs with the IL-2 complex resulted in a highly significant 10-fold 
increase of CD4+CD25hiFoxp3+ T cells in blood of LDLr-/- mice, which was maintained 
for 6 weeks. The expansion of Tregs during diet was comparable to the level we 
obtained in chow fed animals indicating that the pro-inflammatory effect of the high-
cholesterol diet did not affect this expansion. The extent of expansion is in line with a 
previous study by Webster et al., in which IL-2 complexes with a similar molar ratio of 
IL-2 and anti-IL-2 mAb induced a 10-fold increase of Tregs.16 
The significantly high expansion of CD4+CD25hiFoxp3+ T cells resulted in a 39% 
decrease in initial atherosclerosis in the aortic root. It was previously shown that oral 
tolerance induction to oxLDL, an atherosclerosis-specific antigen, induced a maximal 
2-fold increase in Tregs, with a 30% reduction in lesion size in the aortic root.10 
These Tregs however, were antigen-specific Tregs, whereas the IL-2 complex has been 



























Figure 6. Increased adventitial CD3+ T cell infiltration in IL-2 complex treated mice. LDLr-/- mice received 
10 weeks Western-type diet and were subsequently put on chow diet for 10 weeks and simultaneously 
treated with the IL-2 complex (n=13) or PBS (n=14). Sections of the aortic root were stained for CD3 
(red) to determine the number of infiltrating T cells (A-B). **P<0.01
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specific Tregs dropped 2 weeks after treatment, while the present technique enabled 
us to maintain the enhanced numbers of Tregs for more than 6 weeks. Interestingly, 
only an additional reduction of approximately 10% in lesion size was observed. These 
results may indicate that Tregs only reduce lesion development to a maximal extent 
and it may be suggested that only a vast, prolonged expansion of antigen-specific 
Tregs by combining oral tolerance with IL-2 complex treatment may lead to a greater 
reduction in lesion size. 
The IL-2 complex expanded Tregs in the LDLr-/- mice reduced Th1 and Th2 responses 
and potently suppressed proliferation of splenocytes by 43%. We observed an 
increase in gene expression of IL-10 in the spleen and increased IL-10 secretion by 
Tregs, which suggests that the IL-2 complex expanded Tregs exert their suppressive 
capacity via IL-10. In agreement with this finding, Webster et al. show enhanced 
expression of IL-10 mRNA but little change in TGF-β by the IL-2 complex expanded 
Tregs.16 In addition, the suppression of airway inflammation via the IL-2 complex is 
dependent on IL-10.18 The increase of IL-10 in the IL-2 complex treated mice may 
at least partially be responsible for the decrease in lesion size since several studies 
showed the protective role of IL-10 in atherosclerotic lesion development.24-26
The development of experimental therapies for the treatment of atherosclerosis 
mainly focuses on preventing the initiation and to a minor extent on the progression 
of atherosclerosis. A clinically more relevant therapy for atherosclerosis would be a 
therapy which induces regression of atherosclerosis as most of the cardiovascular 
patients already have well-established lesions. In the present study, we therefore 
aimed to simulate the treatment of cardiovascular patients by changing the diet 
(as a mimic of statin induced lipid lowering) in combination with a reduction in the 
inflammatory status by inducing Tregs. This approach is comparable to Verschuren 
et al. who induced regression of atherosclerosis in apoE*3Leiden mice by switching 
high-fat diet to chow diet and treatment with the atheroprotective Liver-X-receptor 
(LXR)-agonist.27 In our current study, we were able to induce high levels of Tregs 
in mice that previously were fed a cholesterol rich diet for 10 weeks comparable to 
the levels obtained in chow fed and Western-type diet fed mice. We observed no 
lesion regression in the control group (only lipid lowering) and despite extensive Treg 
induction also no lesion regression was found in the IL-2 complex treated group. 
However, we observed that Treg induction increased lesion stability as indicated 
by increased collagen content in the lesions. This effect cannot be ascribed to the 
significant 10-20% reduction in cholesterol observed in IL-2 complex treated mice, 
since we did not found a correlation between collagen content and cholesterol levels. 
Possibly, the reduction in cholesterol can be ascribed to an increase of IL-10 produced 
by IL-2 complex expanded Tregs. Previously it was shown that IL-10 influences 
parenchymal liver cells, thereby lowering cholesterol levels in LDLr-/-mice.25
Interestingly, a 60% increase of adventitial CD3+ T cells within lesions of IL-2 
complex treated mice was observed. This strong increase correlates with a highly 
significant 85% increase of circulating Tregs, which likely migrate towards the site 
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of inflammation via the adventitia. Moreover, we see a significant suppression of 
effector T cell proliferation in the IL-2 complex treated group by expanded Tregs. This 
proves that these Tregs are functional in suppressing effector T cell expansion and 
function and limits the possibility of effector T cell expansion and migration towards 
inflammatory sites. In addition to the apparent phenotype of T cells in the IL-2 
complex treated group, the observed increase in IL-10 additionally suggests an anti-
inflammatory environment in these mice. This again suggests an inhibition of effector 
T cell proliferation but also implies that T cells found in this environment will be of an 
anti-inflammatory phenotype. 
In conclusion, our data clearly illustrate the potential of IL-2 complexes to selectively 
expand Tregs capable of attenuating initial atherosclerotic lesion development, and 
further prove their capability to stabilize well-established lesions in a regression 
model. In the future, it may be of great interest to induce antigen specific Tregs with 
the IL-2 complex. 
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Abstract
Objective: Restoration of immune homeostasis in atherosclerosis represents the 
ultimate goal of an immune-based therapy. Myeloid-derived suppressor cells (MDSCs) 
are a population of immature myeloid cells that potently suppress immune responses 
in various pathological settings, via multiple mechanisms, including inhibition of T cell 
responses. They express the myeloid markers CD11b and Gr-1 and can be subdivided 
in monocytic-MDSCs, expressing high levels of Ly6C, or granulocytic-MDSCs, 
which are Ly6G positive. In the present study, we determined the role of MDSCs in 
atherosclerosis by an adoptive transfer of CD11b+Gr-1+ cells into LDLr-/- mice fed a 
Western-type diet.
Methods and Results: We isolated CD11b+Gr-1+ cells from LDLr-/- mice fed a Western-
type diet for 2 weeks with magnetic beads and found that they strongly suppressed 
αCD3/CD28-induced splenocyte proliferation in an IFN-γ and iNOS-dependent 
manner. Subsequently, we adoptively transferred 6x106 MDSCs every 10 days into 
LDLr-/- mice fed a Western-type diet for 6 weeks, which resulted in a 35% reduction 
in atherosclerotic lesion formation in the aortic root. MDSC treatment reduced splenic 
Th1 and Th17 cells with 50% and diminished B cells, in particular circulating B2 cells, 
and concomitantly impaired their proliferative capacity.
Conclusions: Our data prove that MDSCs could represent a novel cell-based 
immune-therapy to dampen pro-atherogenic immune responses and thereby reduce 
atherosclerosis.
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Introduction
Myeloid-derived suppressor cells (MDSCs) form a heterogeneous population of cells 
that consists of early myeloid progenitor cells and immature myeloid cells, which 
strongly suppress immune responses during cancer and other diseases. MDSCs 
express the myeloid cell markers CD11b and Gr-1 and are found in spleen and bone 
marrow.1 In healthy individuals, MDSCs differentiate into neutrophils, macrophages or 
dendritic cells. However, under pathological conditions, this differentiation is partially 
blocked, which results in the expansion of MDSCs that accumulate in various lymphoid 
and non-lymphoid tissues. Two subtypes of MDSCs have been identified based on the 
expression of surface markers; granulocytic-MDSCs, which are CD11b+Ly6G+Ly6Clow, 
and monocytic-MDSCs, which are CD11b+Ly6G-Ly6Chi.2 
MDSCs particularly suppress T cell function via an increased expression of immune 
suppressive factors, such as inducible nitric oxide synthase (iNOS) and arginase 
1 (arg-1)3, and via increased production of nitric oxide (NO) and reactive oxygen 
species (ROS).4 iNOS expression in MDSCs is driven by Th1 signals5, such as IFN-γ 
and LPS, whereas arg-1 expression is driven by Th2 cytokines, such as IL-4, IL-10 and 
IL-13.6 Both iNOS and arg-1 compete for their common substrate L-arginine. iNOS 
consumes L-arginine to NO, which renders T cells non-responsive to IL-2.7 In contrast, 
arg-1 converts L-arginine to urea and polyamines, which reduces the availability of 
L-arginine and subsequently impairs T cell function by loss of CD3ζ expression.8 Both 
arg-1 and iNOS can generate ROS, which inhibits T cell function via nitration of the T 
cell receptor, thereby impairing the T cell-antigen-MHC interaction.3 Moreover, MDSCs 
can also promote de novo development of Foxp3, which results in elevated levels of 
regulatory T cells (Tregs) that efficiently suppress effector T cells.9 Besides regulating 
adaptive immune responses, MDSCs can also stimulate macrophages to a more anti-
inflammatory phenotype, producing more IL-10 and less IL-12.10
MDSCs have been extensively investigated in cancer but their effect on the course of 
other diseases has only recently been appreciated. MDSCs suppresses inflammation in 
obese mice11 and in an EAE mouse model12 and prevented type 1 diabetes13 and graft 
versus host disease.14 However, so far studies that describe the role of MDSCs in the 
development of atherosclerosis are lacking. Atherosclerosis is considered a chronic 
autoimmune-like disease with an underlying imbalance between pro-inflammatory 
and anti-inflammatory processes.15, 16 Restoration of this balance by induction of 
Tregs that suppress effector T cells has proven to be of therapeutic potential in the 
treatment of atherosclerosis.17-19 Since MDSCs can suppress effector T cells, MDSCs 
may represent a novel therapeutic tool to regulate pro-inflammatory immune 
responses in atherosclerosis.
To investigate whether and how MDSCs contribute to the development of 
atherosclerosis, we isolated bone marrow-derived CD11b+Gr-1+ cells from LDLr-/- mice 
fed a Western-type diet for 2 weeks and adoptively transferred them into LDLr-/- mice 
fed a Western-type diet for 6 weeks.
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Material and methods 
Animals
Female LDLr deficient (LDLr-/-) mice, 10-12 weeks old, were obtained from Jackson 
Laboratories. The animals were kept under standard laboratory conditions and were 
fed a Western-type diet containing 0.25% cholesterol and 15% cocoa butter (Special 
Diet Services, Witham, Essex, UK). Diet and water were provided ad libitum. All animal 
work was approved by the regulatory authority of Leiden University and carried out in 
compliance with the Dutch government guidelines.
Isolation of CD11b+Gr-1+ cells 
Bone marrow cells were isolated from front and hind limbs of LDLr-/- mice fed 
a Western-type diet for 2 weeks. CD11b+Gr-1+ cells (MDSCs) were isolated by a 
negative depletion as described by Hasenberg et al.20 An antibody cocktail containing 
biotin-labeled antibodies against CD5, CD45R, CD49b, CD117, F4/80 and TER119 
(eBioscience, Vienna) was added to the cells for 10 minutes at 4°C. After centrifugation, 
the cells were resuspended in 100 µl MACS buffer and 15 µl of Anti-Biotin-Microbeads 
(Miltenyi Biotec, Bergisch Gladbach, Germany) per 107 cells. Cells were incubated 
for 15 minutes at 4°C. Subsequently, the cells were washed with MACS buffer and 
CD11b+Gr-1+ cells were collected using an LS MACS Column (Miltenyi Biotec). Purity 
of the isolated CD11b+Gr-1+ cells (>95 %) was determined with FACS. FACS analysis 
was performed on a FACSCantoII (Beckton Dickinson, Mountain View, CA). Data were 
analyzed using FACSDiva software (Beckton Dickinson).
Suppressive capacity of CD11b+Gr-1+ cells 
The suppressive capacity of CD11b+Gr-1+ cells was determined by co-culture with 
splenocytes. 2×105 splenocytes were plated per well of a 96-well plate with or without 
titrated amounts of isolated CD11b+Gr-1+ cells from LDLr-/- mice fed a Western-
type diet for 2 weeks (n=3). Cells were activated with αCD3 (1 μg/mL) and αCD28 
(0.5 μg/mL) for 72 hours and pulsed with 3H-thymidine (0.5 μCi/well, Perkin Elmer, 
The Netherlands) for the last 16 hours. The amount of 3H-thymidine incorporation 
was measured using a liquid scintillation analyzer (Tri-Carb 2900R). Responses are 
expressed as the mean counts per minute (cpm) of triplicate cultures. To determine 
which suppressive factors are responsible for the MDSC-mediated splenocyte 
suppression, we co-cultured CD11b+Gr-1+ cells from LDLr-/- mice in a 1:1 ratio with 
splenocytes. Cells were activated with αCD3 (1 μg/mL) and αCD28 (0.5 μg/mL) in the 
presence or absence of several compounds: L-NMMA (0.5 mM, Cayman Chemicals), 
superoxide dismutase (SOD) (200 U/mL, Sigma-Aldrich), COX-2 inhibitor II (100 nM, 
Calbiochem), NorNOHA (0.5 mM, Calbiochem) and anti-IFN-γ (10 μg/mL, provided by 
Louis Boon). Proliferation was measured as described above.
Initiation of atherosclerosis
Atherosclerosis was induced in LDLr-/- mice by feeding a Western-type diet for 6 
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weeks. During these 6 weeks, mice received every 10 days an i.v. injection of 6×106 
MDSCs (n=12) or PBS (n=12). After 6 weeks, mice were sacrificed and tissues were 
harvested after in situ perfusion using PBS. Tissues were stored in Zinc Formal-Fixx 
(Shandon Inc. Pittsburg, USA) or snap frozen in nitrogen and stored at -80 °C until 
further use. 
Serum cholesterol levels
During the experiments, mice were weighed and blood samples were obtained by 
tail vein bleeding. The total cholesterol levels in serum were determined at week 0, 
3 and 6 after start of the atherosclerosis experiment. The concentrations of serum 
cholesterol were determined using enzymatic colorimetric procedures (Roche/Hitachi, 
Mannheim, Germany). Precipath (Roche/Hitachi) was used as an internal standard. 
Histological analysis and morphometry
Cryosections of the aortic root (10 µm) were made and stained with Oil-Red-O. Lesion 
collagen content was determined with a Masson’s Trichrome staining. Furthermore, 
corresponding sections on separate slides were stained immunohistochemically with 
an antibody directed against a macrophage specific antigen (Moma-2, monoclonal rat 
IgG2b, diluted 1:1000). Goat anti-rat IgG alkaline phosphatase conjugate (dilution 
1:100) was used as a secondary antibody and nitro blue tetrazolium and 5-bromo-
4-chloro-3-indolyl phosphate as enzyme substrates. Morphology was studied using a 
Leica DM-RE microscope and LeicaQwin software (Leica imaging systems, Cambridge, 
UK). 
Flow cytometry
At sacrifice, blood and spleen cells were isolated (n=5 per group) and a single cell 
suspensions were obtained by squeezing the organs through a 70 µm cell strainer. 
Red blood cells were removed from blood and splenocytes using erythrocyte lysis 
buffer (0.15 M NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA, pH 7.3). Different immune 
cells were analyzed with flow cytometry: T cells (CD4+ and CD8+), naive T cells 
(CD4+CD44lowCD62L+), effector T cells (CD4+CD62Llow), B cells (CD19+), B2 cells 
(CD19+IgMlowIgD+), Th1 cells (CD4+T-bet+), Th2 cells (CD4+GATA-3+), Th17 cells 
(CD4+RORγt+) and Tregs (CD4+CD25+Foxp3+). To detect Th1/Th2/Th17/Treg cells, 
cells were fixed and permeabilized according to manufacturer’s protocol (eBioscience, 
Vienna). Subsequently, the cells were stained for T-bet, GATA-3, RORγt or Foxp3. 
All antibodies were purchased from eBioscience (Vienna) and Beckton Dickinson 
(Mountain View, CA). FACS analysis was performed as described above.
Spleen cell proliferation
At sacrifice, splenocytes (n=5 per group) were cultured in the presence or absence of 
αCD3 (1 μg/mL) and αCD28 (0.5 μg/mL) for 72 hours in quintuplicate in a 96-wells 
round-bottom plate (2×105 cells/well) in RPMI 1640 supplemented with L-Glutamine, 
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100 U/mL streptomycin/penicillin and 10% FCS. Proliferation was measured by 
addition of 3H-thymidine (0.5 μCi/well, Amersham Biosciences, The Netherlands) for 
the last 16 hours. The amount of 3H-thymidine incorporation was measured using a 
liquid scintillation analyzer (Tri-Carb 2900R). Responses are expressed as stimulation 
index (SI): ratio of mean counts per minute of triplicate cultures with αCD3/CD28 
stimulation to triplicate cultures without stimulation. 
Serum antibody detection
IgM, IgG1, IgG2a and IgG2b levels against oxLDL were detected in serum using Abs 
recognizing mouse IgM, IgG1, IgG2a and IgG2b and HRP-labeled goat anti-rat Ig (BD 
Pharmingen). OxLDL (5 µg/mL) was dissolved in NaHCO3/Na2CO3 buffer (pH 9.6) and 
was coated o/n onto a flat-bottom 96-well high binding plate (Corning, NY). Serum 
samples were 1:1 diluted in PBS and absorbance was detected at 450 nm. 
Statistical analysis
All data are expressed as mean±SEM. An unpaired two-tailed student’s T-test was 
used to compare normally distributed data between two groups of animals. Probability 
values of P<0.05 were considered significant.
Results 
MDSCs suppress splenocyte proliferation in an iNOS and IFN-γ dependent 
manner
First, we isolated MDSCs from the bone marrow of LDLr-/- mice fed a Western-type 
diet for 2 weeks by an immunomagnetic negative enrichment of CD11b+Gr-1+ cells 
(purity>95%, Figure 1A). To determine whether these high-fat diet-associated MDSCs 
exert a suppressive function, we performed a suppression assay with titrated amounts 
of MDSCs in co-culture with splenocytes isolated from Western-type diet fed LDLr-/- 
mice in the presence of αCD3/CD28. As shown in Figure 1B, MDSCs very effectively 
suppressed splenocyte proliferation up to 93% when cultured 1:1 with splenocytes 
(1339±108 cpm versus splenocytes only: 18314±1686 cpm, P<0.001). To check 
whether this MDSC-mediated inhibition of splenocyte proliferation is due to enhanced 
apoptosis of splenocytes, we determined the percentage of AnnexinV+PI+ cells with 
flow cytometry. As shown in Figure 1C, MDSCs did not induce apoptosis of splenocytes, 
as no differences were observed in the percentage of apoptotic cells. 
To determine the mechanism by which the high-fat diet-associated MDSCs 
suppress T cells, we added Nor-NOHA, L-NMMA, SOD and a COX-2 inhibitor to the 
co-cultures of MDSCs and splenocytes, to suppress the action of arg-1, iNOS, ROS 
and prostaglandins, respectively. Whereas addition of Nor-NOHA, SOD and a COX-
2 inhibitor did not affect the suppressive function of MDSCs (97%, 99% and 93% 
suppression, respectively, P<0.001), the iNOS inhibitor L-NMMA completely 
abrogated the suppressive capacity of the MDSCs (Figure 1D). Since iNOS expression 
is promoted by IFN-γ, we also added anti-IFN-γ to the co-cultures. Similar to L-NMMA, 
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anti-IFN-γ inhibited MDSC-mediated suppression and resulted in a 30% (P=0.14) 
reduction of splenocyte proliferation. 
Fate of adoptively transferred MSDC
To obtain information on the half-life of MDSCs and their distribution profile, we 
injected MDSCs i.v. in Western-type diet fed LDLr-/- mice and sacrificed them 3 and 
9 days after injection. As shown in Figure 2A, increased numbers of MDSCs are still 
identified in the flow cytometer scatter plots up to 9 days after the injection. Three 
days after the injection we analyzed the percentage of MDSCs (CD11b+Gr-1+ cells) 
with flow cytometry (Figure 2B) and observed a 3-fold increase in MDSCs in the 
circulation (MDSCs: 30.6±4.8% vs. control: 10.5±1.6%, P<0.05) and spleen (MDSCs: 
4.1±0.1% vs. control: 1.4±0.2%, P<0.001) of MDSC-treated mice. Moreover, after 
9 days MDSC levels were still elevated in the circulation (MDSCs: 25.6±2.6% vs. 
control: 13.1±0.2%, P<0.05) and spleen (MDSCs: 6.4±0.1% vs. control: 2.5±0.6%, 
P<0.05) of MDSC-treated mice (Figure 2B). Increased numbers of MDSCs were not 
found in mediastinal lymph nodes near the heart 3 and 9 days after injection.

































































Figure 1. MDSCs (CD11b+Gr-1+ cells) were isolated from LDLr-/- mice fed a Western-type diet for 2 weeks 
and purity was determined with flow cytometry (A). A suppression assay was performed to determine the 
suppressive capacity of MDSCs by measuring the αCD3/CD28 induced proliferation of splenocytes (B). 
Data are shown as the mean counts per minute (cpm) of triplicate cultures. The percentage of apoptotic 
splenocytes was determined with an Annexin-V/PI staining and analyzed with flow cytometry (C). To 
test the mechanism of MDSC-mediated splenocyte proliferation, a suppression assay was performed in 
the presence of several inhibitors: Nor-NOHA (0.5 mM, arg-1 inhibitor), SOD (200 U/mL, ROS inhibitor), 
COX-2 inhibitor (100 nM), L-NMMA (0.5 mM, iNOS inhibitor) and anti-IFN-γ (10 μg/mL) (D). Data are 
shown as the mean counts per minute (cpm) of triplicate cultures. **P<0.01, *** P<0.001
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Adoptive transfer of MDSCs reduces the development of atherosclerosis 
Based on the ability of the MDSCs to inhibit T cell responses, we investigated the 
effect of adoptively transferred MDSCs on atherosclerosis development. LDLr-/- mice 
were fed a Western-type diet for 6 weeks and received four i.v. injections with 6x106 
MDSCs. The first injection was given at the start of the experiment and thereafter 
mice received every ten days an i.v. injection with 6x106 MDSCs. The MDSCs were 












































Figure 3. Adoptive transfer of MDSCs reduces atherosclerosis development compared with PBS treatment 
in LDLr-/- mice (n=12 per group) fed a Western-type diet for 6 weeks. Representative cross-sections of 
lesion formation in the aortic valve area stained with Oil-Red-O and hematoxylin are shown and lesion 
size was determined (A). Sections of the aortic root were stained for collagen using Masson’s Trichrome 
staining. The percentage of collagen relative to the lesion size was determined (B). Relative macrophage 
content was determined with a MOMA-2 staining (C). **P<0.01
PBS
MDSC
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Blood
3 days 9 days
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A B
Figure 2. LDLr-/- mice fed a Western-type diet were injected i.v. with 6x106 MDSCs. The presence of MDSCs 
in blood, spleen and HLN 3 and 9 days after injection was determined with flow cytometry. Representative 
dotplots of the Forward and Side Scatter of blood and spleen at 3 and 9 days are shown (A). Percentages 
of CD11b+Gr-1+ cells in the blood, spleen and HLN are determined (B). *P<0.05, ***P<0.001 
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2 weeks. During the experiment no differences in body weight and total plasma 
cholesterol levels were observed (data not shown). We observed a significant 35% 
reduction in aortic root lesion size of MDSC-treated mice (1.79±0.18×105 µm2) in 
comparison with control mice (2.74±0.25×105 µm2, P<0.01, Figure 3A). No difference 
in lesion stability as determined by Masson’s Trichrome staining was observed 
between MDSC-treated mice (10.4±0.8%) and control mice (12.8±1.6%, Figure 3B). 
Furthermore, no difference in macrophage content was observed (control: 73.0±2.2% 
and MDSC: 75.4±1.6%, Figure 3C). 
Increased naive T cells and reduced Th1 and Th17 cells upon MDSC treatment
Since MDSCs suppress T cells, we determined the effect of MDSC treatment on T cell 
subsets. At sacrifice, there were no differences in the percentages of total CD4+ T cells 
and total CD8+ T cells in the blood and spleen of MDSC-treated mice and control mice 
(Figure 4A). However, we did observe a different balance between naive and effector 
CD4+ T cells in the spleen of MDSC-treated mice compared with control mice (Figure 
4B). Whereas naive CD4+ T cells were increased in MDSC-treated mice (9.6±0.4%) 
in comparison with control mice (7.7±0.2%, P<0.01), effector CD4+ T cells were 
decreased (MDSC: 8.1±0.4% vs. control: 9.6±0.5%, P<0.05). To evaluate whether 
adoptive transfer of MDSCs can affect specific T helper cell subsets, splenocytes were 
stained for the transcription factors T-bet, GATA-3, RORγt and Foxp3, which control 
the differentiation of Th0 cells into Th1, Th2, Th17 cells and Tregs, respectively. Flow 
cytometry analysis showed that MDSC-treated mice had significantly reduced T-bet 
expression (6.4±0.4% vs. 12.9±0.3% in control mice, P<0.001) and reduced RORγt 
expression (2.5±0.1% vs. 5.1±0.2% in control mice, P<0.001) in the CD4+ T cell 
Figure 4. At sacrifice, blood and 
spleen cells were isolated (n=5 per 
group) and percentages of CD4+ 
and CD8+ T cells were determined 
with flow cytometry (A). In addition, 
CD4+CD62Llow effector T cells and 
CD4+CD44low62Lhigh naive T cells 
were determined in the spleen 
(B). Splenic T cell subsets were 
determined by staining for CD4 
and the transcription factors T-bet 
(Th1), GATA-3 (Th2), RORγt (Th17) 
and Foxp3 (CD25+ Tregs) (C). The 
effect of MDSC administration 
on spleen cell proliferation was 
determined by culturing splenocytes 
(n=5 per group) in the presence or 
absence of CD3/CD28 stimulation 
(D). Proliferation was assessed 
by the amount of 3H-thymidine 
incorporation in dividing cells. 
The proliferation is expressed as 











































































population of the spleen compared with control mice (Figure 4C). In contrast, Th2 
and Treg responses remained unchanged following adoptive transfer of MDSCs. 
Although adoptive transfer of MDSCs decreased the pool of splenic effector CD4+ T 
cells and more specifically, decreased Th1 and Th17 cell subsets, we did not observe 
any difference in splenocyte proliferation of MDSC-treated mice (stimulation index 
of 49.7±3.6) in comparison with control mice (stimulation index of 51.8±2.0) after 
stimulation with αCD3/CD28 (Figure 4D). 
Reduced B2 cells in MDSC-treated mice
Adoptive transfer of MDSCs also affected B cell responses since MDSC-treated mice 
had reduced circulating CD19+ B cells (23.7±1.4% vs. 30.3±2.3% in control mice, 
P<0.05, Figure 5A). More particular, we observed a 30% decrease in circulating 
B2 cells in MDSC-treated mice (15.2±1.0%) in comparison with control mice 
(21.6±2.1%, P<0.05, Figure 5B). Furthermore, we found that splenic B cells of 
MDSC-treated mice proliferated less vigorously (29.5±1.4% CD19+Ki-67+ cells) 
than B cells of control mice (35.9±1.2% CD19+Ki-67+ cells, P<0.05, Figure 5C). We 
also determined oxLDL-specific antibodies in serum (Figure 5D) but did not find any 
difference in MDSC-treated mice in comparison with control mice. 
Discussion 
In this study, we propose a novel cellular therapy using MDSCs to inhibit atherosclerosis 
development. MDSCs expand in the bone marrow upon disease as a protective 
negative feedback mechanism and migrate into the periphery to eventually home in 
inflammatory tissues where they are powerful suppressors of immune responses. In 
contrast to cancer where expanded MDSCs aggravate the disease by the suppression 
of cytotoxic T cells, MDSC activity is highly appreciated in autoimmune diseases 
Figure 5. At sacrifice, blood cells 
were isolated (n=5 per group) and 
the percentage of CD19+ B cells was 
determined with flow cytometry 
(A). B2 cells were analyzed as the 
percentage of CD19+IgMlowIgDhigh 
cells (B). Splenocytes were cultured 
for 72 hours and the proliferation 
of B cells was determined by the 
percentage of Ki-67+ cells within 
CD19+ cells (C). oxLDL-specific IgM, 
IgG1, IgG2a and IgG2b production 
was detected in serum of control 
and MDSC-treated mice (n=6 per 
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where the unwanted activation of the immune system needs to be suppressed. 
Although accumulating evidence implicates MDSCs as potent suppressors of several 
autoimmune diseases11, 12, 14, 21, 22, the role of MDSCs in atherosclerosis remains to be 
elucidated.    
We isolated bone marrow-derived MDSCs (CD11b+Gr-1+) from LDLr-/- mice in which 
the immune system was boosted by feeding a high-fat diet for 2 weeks.15 These ‘high-
fat diet-associated MDSCs’ potently suppressed T cell proliferation in vitro without 
inducing T cell apoptosis. MDSCs have been described to suppress T cell responses 
via several factors such as arg-1, iNOS, ROS and NO. Our data show an important role 
for iNOS produced NO and IFN-γ in high-fat diet MDSC-mediated T cell suppression as 
the blockade of these factors with L-NMMA and anti-IFN-γ abrogated the suppressive 
capacity of the MDSCs. iNOS and IFN-γ are strongly associated with each other, since 
activated Th1 cells produce IFN-γ, which induces iNOS expression in MDSCs.9, 23 Our 
findings on atherosclerosis associated MDSCs are in line with studies that have shown 
that blocking IFN-γ abolishes MDSC-mediated T cell suppression.2, 24 In LDLr-/- mice 
fed a high-fat diet, a Th1-biased environment may contribute to this IFN-γ/iNOS-
dependent mechanism of MDSC-mediated T cell suppression. Inhibition of arg-1, ROS 
or prostaglandin synthesis did not affect the suppressive function of MDSCs derived 
from LDLr-/- mice fed a high-fat diet for 2 weeks. Moreover, preliminary data showed 
a differential expression of arg-1 and STAT1 in MDSCs isolated from chow fed mice 
in comparison with high-fat diet fed mice. Arg-1 was significantly lower expressed in 
high-fat diet MDSCs, whereas STAT1, the main regulator activated by IFN-γ signaling, 
was significantly higher (unpublished data). More research will be performed to 
characterize the MDSC phenotype under hypercholesterolemic conditions. 
Adoptive transfer of 6x106 MDSCs into LDLr-/- mice fed a high-fat diet for 6 weeks 
ameliorated atherosclerosis with 35%. No differences were observed in collagen and 
macrophage content of the lesions. This reduction in atherosclerosis formation was 
associated with increased percentages of naive T cells and decreased percentages of 
effector T cell in the spleens of mice that received MDSCs. More specifically, MDSC-
treated mice showed a 50% reduction in splenic Th1 and Th17 cells. Th1 cells produce 
pro-inflammatory cytokines such as IFN-γ and TNFα and LDLr-/- mice deficient in 
T-bet25 or ApoE-/- mice deficient in IFN-γ26, show attenuated atherosclerosis. In line 
with our findings, Highfill et al. showed that bone marrow MDSCs cultured in vitro with 
IL-13 to enhance their suppressive capacity, reduced T cell alloresponses and GVHD 
lethality via dimished effector T cells and strongly reduced IFN-y producing CD4+ and 
CD8+ T cells.14 Zhu et al. showed that MDSCs isolated from the spleen of mice with 
EAE suppressed the production of several cytokines by CD4+ T cells, including IFN-γ 
and IL-17.27 Additionally, iNOS and arg-1 deplete the microenvironment of T cells from 
L-arginine, which results in an inhibition of proliferation and a decreased production 
of IFN-γ.14 
The role of Th17 cells in atherosclerosis is controversial but mainly considered pro-
atherogenic since the expression of IL-17 and RORγt is correlated to plaque size and 
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exogenous IL-17 promotes the formation of atherosclerotic lesions in ApoE-/- mice.28 
Moreover, a deficiency in IL-17R or blockade of IL-17 by using neutralizing antibodies28, 
29 or by use of adenovirus-produced soluble IL17-RA30 reduces atherosclerosis. In 
contrast to our findings, Yi et al. discovered that MDSCs can drive the differentiation 
of Th17 cells under Th17-polarizing conditions (IL-6/TGF-β) and thereby contribute to 
the pathogenesis of EAE.31 However, they show this is an arg-1 dependent mechanism, 
while our high-fat diet-MDSCs do not seem to suppress via this pathway. Moreover, 
in contrast to Yi et al. several other studies indicate a protective role for MDSCs in 
EAE.12, 27 
Despite the reduction in effector T cells in MDSC-treated mice, splenocyte proliferation 
was unaffected in MDSC-treated mice in comparison with control mice. Possibly, 
MDSCs suppress antigen-specific T cells as showed previously by Nagaraj et al.1 and 
the CD3/CD28 activation we used is possibly too aspecific to identify the effect of 
MDSCs on specific T cells involved in the pathogenesis of atherosclerosis. Additionally, 
we did not observe increased percentages of Tregs upon MDSC treatment, which is 
also described as one of the mechanisms through which MDSCs suppress T cells.9, 13
Besides hindering T cell reactivity, we showed that MDSC-treated mice also have 
reduced B cell percentages, in particular B2 cells, possibly as a consequence of 
impaired proliferative capacity. B2 cells comprise the majority of circulating B cells and 
reside in lymphoid tissues. In atherosclerosis, B2 cells are considered pro-atherogenic 
since anti-CD20-mediated depletion of B2 cells ameliorates atherosclerosis and a B2 
cell transfer into ApoE-/- mice aggravates atherosclerosis.32, 33 In line with our findings, 
Green et al. showed that MDSCs, especially monocytic-MDSCs, can inhibit B cell 
proliferation.21
Although we isolated CD11b+Gr-1+ MDSCs from high-fat diet fed LDLr-/- mice and 
adoptively transferred both monocytic and granulocytic MDSC subsets, it seems 
that monocytic-MDSCs are most likely responsible for the observed inhibition of 
atherosclerosis. Previous studies have shown that monocytic-MDSCs are driven by 
Th1 signals5, such as IFN-γ and LPS, and therefore suppress immune cells in an 
iNOS-dependent manner, which is in line with our findings. Furthermore, it has been 
well documented that monocytic-MDSCs exhibit more potent suppressive activity 
than granulocytic-MDSCs2, 34, 35 but the relative potency of monocytic and granulocytic 
MDSCs to provoke immune suppression in atherosclerosis will be an area of future 
investigation. Culturing MDSCs with Nor-NOHA did not interfere with their inhibitory 
capacity, but it remains possible that our high-fat diet-induced MDSCs also act via 
arg-1, since the in vitro microenvironment of splenocytes isolated from high-fat diet 
LDLr-/- mice differs from the in vivo microenvironment in the atherosclerotic lesion. 
Arg-1 can be induced by IL-4, IL-10 and IL-13, cytokines that are differentially 
regulated during atherosclerosis development. Therefore, it is possible that MDSCs 
exhibit distinct biological activities depending on the microenvironment in the different 
pathological stages of atherosclerosis. Future atherosclerosis experiments including 
adoptive transfer of MDSCs isolated from bone marrow of Arg-1-/- and iNOS-/- mice 
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and characterization of the MDSC phenotype under hypercholesterolemic conditions 
will provide more insight. 
Interestingly, a number of atherosclerosis studies refer to CD11b+Ly6G-Ly6Chi cells 
as ‘inflammatory monocytes’ and to CD11b+Ly6G+Ly6Clow as neutrophils, but these 
cell populations may also contain MDSCs as they are also positive for CD11b and 
Ly6G or Ly6C. In other experimental models for diseases such as cancer and EAE, 
MDSCs expand in the bone marrow and are found to accumulate in blood and spleen. 
During atherosclerotic lesion development, monocyte and neutrophil accumulation 
also occurs and correlates strongly to the lesion size.36, 37 However, it remains to 
be determined whether these monocytic and neutrophilic populations also contain 
MDSCs. To clarify this issue, a suppression assay and phenotypic characterization of 
CD11b+Gr-1+ cells isolated from high-fat diet fed LDLr-/- mice in different stages of 
atherosclerosis should be performed.
Although further studies are required to fully comprehend the role of MDSCs in 
cardiovascular diseases, our study defines a specific population of immature immune 
cells that regulates T- and B cells in atherosclerosis. 
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Acute cardiovascular syndromes are a major cause of death in Western society and 
are generally triggered by rupture of an atherosclerotic plaque.1, 2 Current treatment 
of atherosclerosis involves lipid lowering using statins, beta blockers, anti-thrombotic 
drugs, and life style advice. Even though improvements in treatment have led to a 
reduction in atherosclerosis-associated deaths and have led to an improved quality of 
life of patients, present treatment is inadequate to halt progression of cardiovascular 
disease with respect to plaque size (degree of occlusion) or to reverse existing 
plaques, and the number of people diagnosed with atherosclerosis still remains high. 
This indicates an urgent need for new therapeutic strategies to inhibit atherosclerosis 
and to prevent cardiovascular complications and acute syndromes. 
Besides lipid accumulation, inflammation is considered a key process in atherosclerotic 
plaque development and in the pathogenesis of plaque rupture.3, 4 Antigen 
presenting cells, such as dendritic cells and macrophages, play an important role 
in the inflammatory process within atherosclerotic plaques and are responsible for 
presentation of atherosclerosis-related antigens, such as oxLDL and HSP60, resulting 
in the attraction and activation of T cells.5, 6 Upon activation T cells produce large 
amounts of pro-atherogenic cytokines that contribute to both the growth and 
destabilization of lesions, which can result in rupture of the lesion leading to thrombus 
formation and cardiovascular complications. T cells can be divided into several T cell 
subsets that can either be pro-inflammatory/pro-atherogenic, such as Th1 and Th2 
cells, or anti-inflammatory/anti-atherogenic, such as regulatory T cells. 










































































Figure 1. Pro-atherogenic T cells can be inhibited by blocking antibodies for costimulatory molecules or 
by agonistic antibodies for coinhibitory molecules and through the induction of suppressor cells, such as 
Tregs and MDSCs. Examples of possible treatments are provided in the blue boxes. 
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An imbalance between pro- and anti-inflammatory cells exists in atherosclerosis, 
with increased numbers of the first. Therefore, restoration of this balance by (1) 
inhibition of pro-inflammatory responses or by (2) inducing suppressor cells has great 
therapeutic potential to prevent cardiovascular disease (Figure 1). In this thesis, 
several therapeutic strategies to restore the balance of pro- and anti-inflammatory 
immune responses in atherosclerosis were investigated. In Chapter 3-6, modulation 
of costimulatory and coinhibitory pathways, a network of ligands present on antigen 
presenting cells that bind to their corresponding receptors on T cells and can either 
promote or inhibit immune cell function, was evaluated. In Chapter 7-9, the protective 
role of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) was 
studied. 
Modulation of costimulatory and coinhibitory pathways as a treatment of 
atherosclerosis
The immune system provides a large diversity of costimulatory and coinhibitory 
pathways and each pathway has its own unique effect on the fate of individual immune 
cells. Costimulatory signals can promote T cell survival, cell cycle progression and 
differentiation of naive T cells to effector and memory T cells, whereas coinhibitory 
molecules can terminate these processes directly or indirectly via the induction of 
Tregs. In this thesis we performed several studies that addressed the role of several 
costimulatory and coinhibitory pathways in atherosclerosis. 
The costimulatory pathway formed by OX40 and OX40L is involved in the proliferation 
and survival of T cells, particularly Th2 cells, drives isotype switching of B cells, and is 
associated with cardiovascular disease incidence. In Chapter 3, we investigated the 
effect of OX40-OX40L interference on the regression of atherosclerosis in LDLr-/- mice 
by a combined anti-inflammatory (10 week treatment with anti-OX40L) and lipid-
lowering strategy (switching to chow diet after 10 weeks of Western-type diet). Lipid 
lowering alone increased lesion stability without reducing lesion size, while additional 
anti-OX40L treatment also induced lesion regression. Treatment with anti-OX40L 
reduced circulating OX40-expressing CD4+ T cells and adventitial T cells. 
In line with previous findings, interruption of the OX40-OX40L pathway reduced the Th2 
response, as shown by decreases in GATA-3, IL-4 and IL-10 expression.7 Notably, we 
demonstrate that the production of another typical Th2 cytokine, IL-5, was increased 
in B1 cells and T cells. B1 cells are dependent on IL-5 and enhance the secretion 
of atheroprotective natural oxLDL-specific IgM antibodies.8 Anti-OX40L-treated mice 
had increased numbers of B1 cells and increased oxLDL-specific IgM titers. T cells 
that produce IL-5, independently of IL-4, can be induced by IL-33, which previously 
has been shown to be protective in atherosclerosis by inducing IL-5 and anti-oxLDL-
specific IgM antibody formation9, and by inhibiting foam cell formation.10 We observed 
increased IL-33 expression in the spleen of anti-OX40L-treated mice and showed 
that IL-33 production is dose-dependently increased by anti-OX40L treatment of DCs 
and macrophages exposed to oxLDL. The increase in the atheroprotective factors IL-
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33, IL-5 and oxLDL-specific IgM in anti-OX40L-treated mice likely contributed to the 
observed regression of atherosclerosis. 
Another pathway through which OX40-OX40L blockade may facilitate lesion regression 
is via reduced IgE levels and subsequent reduced mast cell numbers and activation. 
IL-4 induces isotype switching of B cells from IgM- to IgE- and IgG-producing cells. 
Previously, we showed that anti-OX40L treatment reduced IgG1 levels7 and we now 
show that interruption of OX40-OX40L treatment also induced a strong reduction in 
serum IgE. Activated mast cells are found in the adventitia of vulnerable and ruptured 
lesions of patients suffering from myocardial infarction 11, 12, and mast cell numbers 
correlate with the incidence of plaque rupture and erosion.11 Our lab has previously 
shown that mast cells also play a crucial role in plaque progression and destabilization 
in vivo.13 In addition, enhanced IgE levels were observed in patients with unstable 
angina pectoris and in dyslipidemia14, 15 and recently, Wang et al. showed that IgE 
promotes atherosclerosis in ApoE-/- mice.16 In line with these findings, we suggest that 
the reduced IgE levels due to the anti-OX40L treatment contribute to the observed 
lesion regression. 
An overview of the mechanism of anti-OX40L-mediated regression of atherosclerosis 
is shown in Figure 2. Finally, it must be noted that interruption of the OX40-OX40L 
pathway did not induce full regression of lesions. Further research into modulating 
immune responses to induce regression must be explored and, in combination with 
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Figure 2. Schematic overview of the mechanism through which OX40-OX40L interruption can reduce 
atherosclerosis. Anti-OX40L treatment induces IL-33, IL-5 and oxLDL-specific IgM and reduces IL-4 and 
IgE levels, resulting in reduced mast cells numbers and activation. 
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Similar to OX40 and OX40L, CD30 and CD30L are members of the TNF(R) superfamily 
and are involved in the activation and proliferation of T and B cells. Whereas the 
CD30-CD30L pathway has been implicated in various autoimmune diseases, such 
as asthma17, GVHD18 and type I diabetes19, no studies describe a role for the CD30-
CD30L axis in atherosclerosis. In Chapter 4 we therefore treated Western-type 
diet fed LDLr-/- mice with an anti-CD30L antibody for 8 weeks, which resulted in a 
reduction in atherosclerotic lesion formation in the aortic root by 35%. This reduction 
in atherosclerosis coincided with reduced adventitial T cell numbers, reduced 
percentages of CD4+ T cells in the spleen and lymph nodes and with strongly reduced 
splenocyte proliferation. In particular, CD4+ T cells isolated from anti-CD30L-treated 
mice proliferated less vigorously after αCD3/CD28 stimulation than CD4+ T cells from 
control mice, whereas their adhesion and migration capacity remained unaffected. 
Although signaling via CD30-CD30L may also affect humoral responses and mast 
cell activity, we did not detect a significant difference in immunoglobulin production 
and mast cell activity in anti-CD30L-treated mice compared with control mice. We 
conclude that the CD30-CD30L pathway solely exerts its function via inhibition of T 
cell responses in atherosclerosis, which identifies anti-CD30L treatment as a novel 
therapeutic modality in the inhibition of atherosclerotic lesion development and the 
prevention of acute cardiovascular syndromes.
In Chapter 5, we studied the role of T cell immunoglobulin and mucin domain 3 in 
atherosclerosis. Tim-3 is a coinhibitory type I transmembrane protein, which affects 
the function of several immune cells involved in atherosclerosis, such as monocytes, 
macrophages, effector T cells and Tregs. It has been reported that patients with 
atherosclerosis have increased Tim-3+ NK cells compared with healthy controls.20 In 
line with these findings, we observed that Western-type diet feeding increased the 
percentage of Tim-3+ NK cells in blood of LDLr-/- mice, but also increased the percentage 
of Tim-3+ monocytes and DCs, cell types that largely contribute to the inflammatory 
process of atherosclerosis. When we treated Western-type diet fed LDLr-/- mice with 
an anti-Tim-3 antibody for 8 weeks, atherosclerotic plaque formation was increased 
with 35% in the aortic root and with 50% in the aortic arch. Although lesion stability 
did not differ between anti-Tim-3-treated mice and control mice, lesions of anti-Tim-
3-treated mice contained significantly more macrophages than lesions of control 
mice. This might be the consequence of an increased influx of monocytes into the 
arterial wall, since we observed increased circulating monocytes in anti-Tim-3-treated 
mice. In addition, oxLDL-loaded macrophages treated with anti-Tim-3 secreted higher 
levels of MCP-1 in vitro, which might suggest that MCP-1 secreted by foam cells in the 
atherosclerotic lesions of anti-Tim-3-treated mice attracts monocytes to the inflamed 
arterial wall. These data are in line with studies by Monney and Frisancho-Kiss et al. 
who show that anti-Tim-3 treatment increases macrophage numbers and activation 
in mouse models of EAE21 and inflammatory heart disease.22 Additionally, we showed 
that anti-Tim-3 administration increased CD4+ T cells and reduced percentages of 
IL-10 producing Tregs and Bregs. Tim-3 has previously been associated with Tregs, as 
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blocking Tim-3 enhances type 1 diabetes in NOD-mice and prevents the generation 
of immunological tolerance in a transplantation model by dampening the function 
of Tregs.23 To conclude, inducing Tim-3 signaling could provide a novel approach to 
inhibit pro-atherogenic immune responses.
To evaluate the contribution of another coinhibitory molecule, T cell immunoreceptor 
with Ig and ITIM domains (TIGIT), to atherosclerosis, we used an agonistic anti-
TIGIT antibody as described in Chapter 6. Signaling via TIGIT directly inhibits T cell 
activation and proliferation through downregulation of the T cell receptor24, 25 but can 
also induce IL-10 producing tolerogenic DCs upon binding to the poliovirus receptor 
(PVR).25, 26 Several studies have shown that TIGIT is essential for T cell function in 
mice and humans and is mainly expressed on activated CD4+ T cells.25, 27 In line 
with these findings, we observed that TIGIT was upregulated on CD4+ T cells from 
Western-type diet fed LDLr-/- mice in comparison with chow diet fed LDLr-/- mice and 
was further enhanced after αCD3/CD28 stimulation. Furthermore, we showed that 
agonistic anti-TIGIT greatly inhibited T cell activation and proliferation. This TIGIT-
mediated downregulation of T cell responses inhibited several diseases such as EAE, 
collagen-induced arthritis and GVHD.24, 25 Surprisingly, we observed that treatment of 
LDLr-/- mice fed a Western-type diet for 4 or 8 weeks with agonistic anti-TIGIT did not 
reduce atherosclerosis development and did not affect lesion composition. Possibly, 
the reduced T cell function was counteracted by enhanced activity of dendritic cells, 
which were elevated and expressed higher levels of MHC II and CD40 in agonistic 
anti-TIGIT-treated mice. Since TIGIT normally binds to PVR expressed on DCs to 
induce a tolerogenic phenotype, and agonistic anti-TIGIT blocks TIGIT-PVR signaling, 
this may explain a more pro-inflammatory phenotype of DCs in agonistic anti-TIGIT-
treated mice. Despite agonistic anti-TIGIT treatment did not affect atherosclerosis, the 
TIGIT-PVR pathway could still be of interest to modulate pro-inflammatory immune 
responses in atherosclerosis and other autoimmune diseases.
Cellular targets of immune regulation to treat atherosclerosis
Another approach to regulate pathogenic immune responses in atherosclerosis is to 
promote suppressor cells, such as Tregs and myeloid-derived suppressor cells (MDSCs). 
Tregs play an important role in the regulation of T cell-mediated immune responses 
through suppression of T cell proliferation and cytokine production. Impaired Treg 
function has been associated with the pathogenesis of numerous diseases and in 
atherosclerosis, an imbalance between pro-inflammatory/pro-atherogenic cells (Th1/
Th2) and Tregs exists.28, 29 Therefore, increased Treg numbers may be beneficial for 
patients suffering from atherosclerosis. The role and therapeutic potential of Tregs 
in atherosclerosis has been the subject of intense investigation. Adoptive transfer of 
CD4+CD25+ T cells causes a reduction in atherosclerotic lesion development30 while 
a depletion of CD4+CD25+ T cells aggravates lesion development.30 Furthermore, van 
Puijvelde et al. showed that induction of antigen-specific Tregs via oral tolerance 
induction against oxLDL and HSP60 inhibits the initiation and progression of 
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atherosclerosis.31, 32
Tregs originate from the thymus and are characterized by the expression of the 
surface molecules CD4 and CD25, and expression of the transcription factor Forkhead 
box protein 3 (Foxp3).33 Tregs may also acquire Foxp3 after oral tolerance induction. 
To study the effect of the elimination of Foxp3+ Tregs in atherosclerosis, we used 
a novel vaccination strategy directed against Foxp3 expressing cells. The effect of 
Foxp3 specific elimination on initial and advanced atherosclerosis is described in 
Chapter 7. A dendritic cell based vaccine was used to provoke a cytotoxic T cell 
response against Foxp3 expressing cells. During the time course of the experiment 
we observed significant less Foxp3+ Tregs in the circulation and lymphoid tissues 
of Foxp3 vaccinated mice. Furthermore, vaccination against Foxp3 aggravated 
atherosclerotic plaque formation in both initial and advanced atherosclerosis. This 
increase in lesion size was associated with increased cellularity, which may result from 
impaired inhibition of pathogenic T cells within the plaque upon depletion of Treg cells. 
Additionally, splenocytes from Foxp3 vaccinated mice proliferated more vigorously 
than splenocytes from control mice, which is indicative for a reduced number of 
Tregs since these cells suppress effector T cells. The results from this study further 
established the role of Foxp3+ Tregs in atherosclerosis and are in line with the results 
of Ait-Oufella et al.30 
Tregs have been shown to depend on IL-2 for optimal growth and survival.34-37 Recently, 
it is shown that repeated injections of an IL-2 complex consisting of recombinant IL-2 
and a specific anti-IL-2 monoclonal antibody expands Tregs38, which very potently 
induces resistance to EAE and suppressed graft rejections39, type I diabetes40, murine-
asthma41 and myasthenia gravis.42 The protective role of Tregs in atherosclerosis has 
been extensively investigated, however, only a modest increase in Treg numbers was 
achieved in the order of 1.5- to 2-fold, mostly for 2-3 weeks. In Chapter 8 we 
therefore determined the effect of a vast IL-2 complex-mediated expansion of Tregs 
on the initiation and regression of well-established lesions. Administration of the IL-2 
complex resulted in a 10-fold increase in Tregs in blood of LDLr-/- mice, which potently 
suppressed effector T cells and reduced initial atherosclerosis with 39%. Furthermore, 
we observed an increase in gene expression of IL-10 in the spleen and increased IL-
10 secretion by Tregs, which suggests that IL-2 complex expanded Tregs exert their 
suppressive capacity via IL-10. These data are in line with previous reports in which 
IL-2 complex expanded Tregs suppressed airway inflammation41 and EAE in an IL-10 
dependent manner.39 The increase in IL-10 in splenocytes of IL-2 complex treated 
mice may at least partially be responsible for the decrease in lesion size since IL-10 is 
protective in atherosclerosis.43-45
We also determined the role of IL-2 complex expanded Tregs in a more clinically 
relevant regression model of atherosclerosis, as most of the cardiovascular patients 
already have well-established lesions. Despite high Treg levels, no lesion regression 
was found in the IL-2 complex-treated group. However, we observed that Treg induction 
increased lesion stability as indicated by increased collagen content in the lesions. 
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Additionally, a 60% increase of adventitial CD3+ T cells within lesions of IL-2 complex 
treated mice was observed, which most likely are the IL-2 complex-expanded Tregs. 
These data suggest a differential role for Tregs in different stages of atherosclerosis. 
Where Tregs inhibit lesion development during initial stages of atherosclerosis, they 
are important in the stabilization of well-established lesions during regression. 
Besides Tregs, MDSCs also strongly suppress T cell responses. MDSCs are a population 
of early myeloid progenitor cells and immature myeloid cells that expand in the bone 
marrow under various pathological conditions and accumulate in lymphoid and non-
lymphoid tissues where they serve a negative feedback function.46 In contrast to cancer 
where expanded MDSCs aggravate the disease by the suppression of cytotoxic T cells, 
MDSC activity is highly appreciated in autoimmune diseases where the unwanted 
activation of the immune system needs to be suppressed. Although accumulating 
evidence implicates MDSCs as potent suppressors of several autoimmune diseases47-51, 
the role of MDSCs in atherosclerosis is unknown.    
In Chapter 9 we isolated bone marrow-derived CD11b+Gr-1+ cells (MDSCs) from 
LDLr-/- mice in which the immune system was boosted by feeding a high-fat diet for 
2 weeks.28 These high-fat diet-associated MDSCs potently suppressed in vitro T cell 
proliferation in an IFN-γ/iNOS-dependent manner without inducing T cell apoptosis. 
Adoptive transfer of MDSCs into LDLr-/- mice fed a high-fat diet for 6 weeks ameliorated 
atherosclerosis with 35%. No differences were observed in collagen and macrophage 
content of the lesions. This reduction in atherosclerosis formation was associated with 
increased percentages of naive T cells and decreased percentages of effector T cells 
in the spleens of mice that received MDSCs. More specifically, MDSC-treated mice 
showed a 50% reduction in splenic Th1 and Th17 cells, subsets that are generally 
considered pro-inflammatory in atherosclerosis.52-54 Additionally, adoptive transfer of 
MDSCs reduced B cell percentages, in particular pro-atherogenic B2 cells, possibly as 
a consequence of impaired proliferative capacity. 
In conclusion, our study describes a novel cellular therapy using MDSCs to inhibit 
atherosclerosis. However, MDSCs can be subdivided in monocytic-MDSCs, induced 
by Th1 signals and expressing iNOS, or granulocytic-MDSCs, induced by Th2 signals 
and expressing arg-1, and whereas we adoptively transferred both monocytic 
and granulocytic MDSC subsets, it seems that monocytic-MDSCs are most likely 
responsible for the observed inhibition of atherosclerosis. In the Perspectives section, 
future approaches are described to investigate the relative potency of monocytic and 
granulocytic MDSCs to provoke immune suppression in atherosclerosis.
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Perspectives
In this thesis, several mechanisms to regulate pathogenic immune responses in 
atherosclerosis have been studied. T cells play a major role in the pathogenesis of 
atherosclerosis by promoting inflammation and destabilizing advanced lesions. T cells 
are regulated by a network of costimulatory and coinhibitory molecules and by several 
suppressor cells such as Tregs and MDSCs. These pathways of immune regulation 
form potent candidates for an immunotherapy of atherosclerosis. Novel therapeutic 
strategies to treat atherosclerosis are needed since death from cardiovascular diseases 
continues to increase worldwide, despite the use of statins, anti-thrombotic drugs, 
and anti-hypertensive treatment.55
Modulation of costimulatory and coinhibitory pathways
In cardiovascular disease, modulation of costimulatory and coinhibitory molecules 
can be a powerful tool to target specific stages of atherosclerosis or specific cell 
types involved in the pathogenesis of atherosclerosis. A highly relevant feature of 
costimulatory and coinhibitory pathways is that they individually have a unique effect 
on the behaviour of specific immune cells and thus on the outcome of disease. As 
shown in Chapter 3 and 4, interference of OX40-OX40L and CD30-CD30L signaling 
both reduce atherosclerosis via different pathways; anti-OX40L specifically targets Th2 
responses and mast cell activity, whereas anti-CD30L limits all CD4+ T cell responses 
without affecting a specific T cell subset or other immune cells. In addition, several 
costimulatory and coinhibitory molecules are involved in the induction and function of 
Tregs. This enables the development of a treatment that particularly targets different 
subsets of T cells. Ultimately, it would be ideal to modulate antigen-specific pro-
atherogenic T cells with blocking costimulatory antibodies and agonistic coinhibitory 
antibodies without affecting all T cells and other immune cells to limit any adverse 
effects on the immune system. Although several candidates of atherosclerosis specific 
antigens have been investigated, such as oxLDL, HSP60 and ApoB100, to date the 
exclusively atherosclerosis-associated antigen is not identified yet, which makes it 
difficult to specifically target the pro-atherogenic T cells. However, some costimulatory 
molecules, such as OX40, are virtually absent on naive T cells but are upregulated 
on activated T cells. Targeting these costimulatory molecules with blocking antibodies 
could specifically eliminate the pathogenic T cells without causing any side effects. 
Furthermore, the ligand of OX40, OX40L, is expressed on endothelial cells, which upon 
blockade can also reduce the attraction of OX40+ T cells to the site of inflammation. 
Blocking and agonistic antibodies for costimulatory and coinhibitory molecules 
have already been extensively explored in cancer and allograft rejections. Blocking 
antibodies for CTLA-4 and PD-1 to boost T cell responses are approved for treatment 
of patients with several types of cancer.56 In contrast to cancer where T cell activity 
is highly appreciated, the unwanted activation of the immune system needs to be 
suppressed in atherosclerosis. Therefore, whereas in cancer for example a blocking 
Chapter 10182
PD-1 antibody to promote T cell activity is beneficial, in atherosclerosis an agonistic 
PD-1 antibody is needed to suppress T cells. CTLA-4-Ig has already been established 
as an effective treatment for human autoimmune diseases including rheumatoid 
arthritis57 and psoriasis.58 At present, one clinical trial has been completed using anti-
OX40L in the prevention of allergen-induced airway obstruction in adults with mild 
asthma.59 However, no study results are reported yet. 
Although many antibodies against costimulatory and coinhibitory molecules have been 
approved and are used in clinical settings, caution is needed when translating animal 
experiments to the clinic, as a Phase I clinical trial with an agonistic monoclonal anti-
CD28 antibody induced a strong cytokine storm (IFN-γ, TNFα, IL-2) several hours 
after drug infusion, which caused multiorgan failure in six human volunteers who 
ended up on the intensive care unit.60 Moreover, blocking costimulatory pathways 
and stimulating coinhibitory pathways may enable opportunistic infections to emerge. 
However, treatment can be adjusted in a way that patients will only receive blocking 
antibodies for costimulatory molecules or agonistic antibodies for coinhibitory 
molecules temporarily until the lesion is stabilized.  
No clinical trials investigating antibodies for costimulatory and coinhibitory molecules 
in cardiovascular disease have been started yet. In fact, only recently the first clinical 
trial involving interference of inflammatory pathways to reduce major cardiovascular 
events in persons with pre-existing coronary artery disease was launched.61, 62 This 
CANTOS trial is a large-scaled study in which over 17.000 subjects will be included 
to test three different doses of Canakinumab, a humanized monoclonal antibody 
specific for IL-1β, compared with placebo. Canakinumab is already approved in other 
autoimmune diseases where IL-1β plays a major role, such as Muckle-Wells syndrome 
and familial cold autoinflammatory syndrome.63 This study will provide the first 
evidence whether interference in specific inflammatory pathways can reduce clinical 
events in cardiovascular patients and will possibly initiate numerous clinical trials 
focused on modulating immune responses in atherosclerosis. 
Interestingly, some anti-tumor therapy studies have indicated that treatment with 
only a single costimulatory agonist, in addition to existing cytostatic therapy or 
cancer-antigen vaccination, is not effective or induces adverse immunological events. 
The co-administration of a second agonist or another factor that stimulates T cell 
function is necessary to achieve a greater anti-tumor reactivity. For example, a clinical 
trial with an anti-CTLA-4 antibody (MDX-010) in conjunction with anti-cancer antigen 
vaccination resulted in regression of cancer but unfortunately also induced severe 
autoimmune diseases in melanoma patients.64 Kocak et al. showed that a combination 
therapy in mice with pre-existing tumors with anti-CTLA-4 and anti-4-1BB enhances 
anti-tumor immunity without any adverse effects on the immune system.65 The 
mechanism through which the combination of anti-CTLA-4 and anti-41BB reduce each 
other’s side effects is not fully explained but it is shown that they synergistically 
enhance the suppressive capacity of regulatory T cells. Currently, a phase I clinical 
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trial is carried out in which anti-CTLA-4 (Ipilimumab) is combined with anti-PD-1 
(BMS-936558) to treat melanoma patients.66
It may be very likely that a combinatorial therapy may also be very effective in 
atherosclerosis. For example, previous studies reported a synergistic effect of OX40L 
and CD30L on T cell responses. Blocking CD30 together with OX40 signaling prevented 
lethal X-linked CD4 T cell-dependent Th1- and Th2-driven autoimmune disease in 
mice lacking regulatory T cells67 and affected effector and memory T cell formation 
and function.68 Moreover, a combined blockade of costimulatory signals, e.g. anti-
OX40L or anti-CD30L, with activation of coinhibitory signals, e.g. PD-1 or Tim-3 
agonists, could be explored to suppress for example pro-atherogenic T cells while 
stimulating athero-protective Tregs. More research should be performed to identify 
the most relevant combinations of blocking and agonistic antibodies for costimulatory 
and coinhibitory molecules respectively, which could be used as an immunotherapy to 
inhibit atherosclerosis.  
Costimulatory and coinhibitory molecules are also essential for the establishment 
and maintenance of immunological tolerance via the induction of tolerogenic DCs 
and Tregs. A frequently used method to induce tolerance is by oral immunization. In 
atherosclerosis, oral tolerance induction to oxLDL31, HSP6032, β2-glycoprotein I69 and 
ApoB100 peptide70 has been shown to suppress atherosclerosis. Van Puijvelde et al. 
showed that oral tolerance induction against oxLDL and HSP60 increased Tregs and 
their CTLA-4 expression.31, 32 Possibly, oral tolerance induction against auto-antigens, 
such as oxLDL, can be combined with blocking antibodies against costimulatory 
molecules or agonists for coinhibitory molecules to achieve T cell non-responsiveness 
against these auto-antigens and to promote the induction of antigen-specific Tregs. 
Treg-based cell therapy 
As  shown in Chapter 7 and 8, Tregs are also efficient regulators of pathogenic 
immune responses and the usage of Tregs as a therapeutic agent shows great potential 
in the treatment of atherosclerosis. In several diseases the number or function of 
Tregs is decreased and restoring the balance between Tregs and pro-inflammatory 
cells may be beneficial. Therefore, a lot of research is nowadays focussed on the 
development of Foxp3+ regulatory T cells (Figure 3). One possible treatment strategy 
is an adoptive transfer of Tregs. This procedure will require an enormous quantity of 
Tregs and can be achieved by isolation of Foxp3+ T cells from the blood of a patient 
and subsequent ex vivo expansion to obtain large numbers for therapy.71, 72 Two Phase 
I clinical trials have tested the ability of ex vivo expanded Tregs to prevent GVHD after 
allogeneic bone marrow transplantation.73, 74 This Treg cell-based therapy proved to be 
safe and reduced GVHD. Moreover, new clinical trials are starting in which the safety 
and effectiveness of Treg cell-based therapy is tested in individuals with autoimmune 
diseases such as type 1 diabetes75 and in organ transplantation patients.76 
Alternatively, Tregs can be expanded in vivo. This can be achieved by targeting some 
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costimulatory and coinhibitory molecules as described previously but also with an IL-2 
complex consisting of recombinant IL-2 and anti-IL-2. Besides effectively reducing 
atherosclerosis (Chapter 8), this IL-2 complex very potently induced resistance to EAE 
and suppressed graft rejections39, type I diabetes40, murine-asthma41 and myasthenia 
gravis42 in mouse studies. Future research should reveal whether administration of 
this IL-2 complex would also be beneficial in patients with cardiovascular disease. 
Although current experimental treatments and clinical trials are based on the 
expansion of aspecific Tregs, it may be of great interest to induce antigen-specific 
Tregs. Previously, oral tolerance induction against oxLDL and HSP60 inhibited 
atherosclerosis development via the induction of antigen-specific Tregs31, 32 Possibly, 
oral tolerance induction can be combined with an IL-2 complex treatment to first 
induce antigen-specific Tregs and thereafter expand these Tregs. 
MDSC-based cell therapy
In atherosclerosis, elevated numbers of CD11b+Ly6G-Ly6Chi cells (inflammatory 
monocytes) and CD11b+Ly6G+Ly6Clow cells (neutrophils) are considered pro-
inflammatory and correlate to lesion size.36, 37 However, in the cancer field cells with the 
exact same phenotype exert an anti-inflammatory function and are called monocytic-
MDSCs and granulocytic-MDSCs, respectively. MDSCs are known to expand in the 
bone marrow of diseased individuals and migrate into several lymphoid and non-
lymphoid tissues. Elevated levels of circulating MDSCs are found in patients with 
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Figure 3. Schematic overview of different approaches to target Tregs for immunotherapy.
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investigate whether MDSCs also accumulate in the blood of patients suffering from 
cardiovascular disease and to what extent these cells overlap with the inflammatory 
monocytes and neutrophils. 
In Chapter 9 we show that adoptive transfer of MDSCs (mo-MDSCs and gr-MDSCs) 
regulated T and B cell responses in an experimental model of atherosclerosis and 
inhibited lesion development. This shows the therapeutic potential of MDSCs as a 
novel immune-therapy to treat cardiovascular disease and opens an exciting new 
area of investigation. To fully characterize and comprehend the role of MDSCs in 
atherosclerosis multiple experiments should be performed. To determine the underlying 
mechanism of MDSC-mediated suppression, MDSCs can be isolated from Arg-1-/- and 
iNOS-/- mice, which lack functional gr-MDSCs and mo-MDSCs, respectively. To further 
determine the relative potency of mo-MDSCs and gr-MDSCs to inhibit atherosclerosis, 
each subset can be sorted with FACS or with magnetic bead labeling and subsequently 
adoptively transferred into Western-type diet fed LDLr-/- mice. Furthermore, since 
MDSCs respond to their microenvironment it is possible that they exhibit distinct 
biological activities depending on the microenvironment in the different pathological 
stages of atherosclerosis. It has also been shown that MDSC subpopulations from 
blood and tumors can differ in their capacity to mediate T cell suppression.80 This 
raises the question whether MDSCs are present in lesions and whether MDSCs in 
lesions will have a different phenotype and suppression capacity in comparison with 
MDSCs present in the bone marrow and possibly in other sites. 
Collectively, before MDSCs are considered as an innovative immunotherapeutic 
strategy to prevent atherosclerosis in cardiovascular patients, more research is 
required.
In conclusion, the research described in this thesis provided novel approaches to 
dampen the immune response in atherosclerosis. However, further characterization of 
these potential new drug targets and cellular therapies are necessary before they can 
be applied in clinical research.
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Hart- en vaatziekten 
Hart- en vaatziekten zijn doodsoorzaak nummer 1 in de westerse wereld. In 2008 waren 
hart- en vaatziekten verantwoordelijk voor 30% van alle sterfgevallen, wat neerkomt 
op ongeveer 17.3 miljoen sterfgevallen wereldwijd. In Nederland overleden in 2010 
meer vrouwen (30%) dan mannen (28%) aan de gevolgen van hart- en vaatziekten. 
Hart- en vaatziekten manifesteren zich vaak als een hartinfarct of beroerte en worden 
voornamelijk veroorzaakt door slagaderverkalking, ook wel atherosclerose genoemd. 
Atherosclerose ontwikkelt zich al tijdens de adolescentie en uit zich als een verdikking 
van de vaatwand. Deze verdikking is het gevolg van een chronische ontsteking in 
het bloedvat die samengaat met een plaatselijke ophoping van vetten. Het eerste 
stadium van atherosclerose, de ‘fatty streak’ is asymptomatisch. Pas als de verdikking 
uitgroeit tot een bloedvatvernauwende atherosclerotische plaque leidt dit tot klinische 
symptomen. De groei van een ‘fatty streak’ tot een onstabiele atherosclerotische 
plaque wordt beïnvloed door zowel erfelijke factoren, zoals dyslipidemie, een hoge 
bloeddruk, hoge cholesterol waardes en type 1 diabetes, als risicofactoren, zoals een 
vetrijk dieet, overgewicht, roken en te weinig lichaamsbeweging. 
Behandeling van hart- en vaatziekten
Patiënten met acute klinische symptomen ondergaan vaak chirurgische ingrepen, 
zoals ballondilatatie (dotteren), soms in combinatie met plaatsing van een metalen 
buisje in het verkalkte bloedvat (stent) of een open hartoperatie waarbij een omleiding 
(bypass) langs vernauwde of afgesloten bloedvaten van de kransslagader wordt 
aangelegd om de bloeddoorstroming weer te herstellen. Verdere behandeling van 
hart- en vaatziekten berust op het verlagen van de risicofactoren met behulp van 
medicatie en aanpassingen in de levensstijl van de patiënten. Veel voorgeschreven 
medicatie bestaat uit bloeddrukverlagende medicijnen en statines. Statines remmen 
de productie van cholesterol in de lever, waardoor het cholesterolgehalte in het bloed 
verlaagd wordt. Daarnaast kunnen statines ook een ontstekingsremmende werking 
hebben. Alhoewel statines het risico op hart- en vaatziekten met 30% verminderen, 
hebben ze weinig effect op al bestaande atherosclerotische plaques. Dit is juist zo 
belangrijk aangezien patiënten met hart- en vaatklachten al een vergevorderde 
vorm van atherosclerose hebben. Het ontwikkelen van nieuwe behandelmethoden 
is noodzakelijk om de verdere progressie van atherosclerose te remmen en 
cardiovasculaire complicaties te voorkomen. 
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Atherosclerose; een chronische auto-immuunziekte
Het ontstaan van atherosclerose begint met een beschadiging van endotheelcellen die 
een laagje vormen aan de binnenkant van de vaatwanden. Deze beschadiging wordt 
meestal veroorzaakt door een turbulente bloedstroom, een verhoogde bloeddruk, 
verhoogd cholesterol, roken en andere risicofactoren zoals hierboven beschreven. 
De beschadigde endotheellaag is nu doorlaatbaar geworden voor vetten en 
ontstekingscellen die zich kunnen ophopen in de vaatwand. Cholesterol is een van de 
belangrijkste vetten in het menselijk lichaam. Het bevindt zich in alle celmembranen, 
zorgt voor de elasticiteit van de huid en is een essentiële bouwsteen voor hormonen 
en galzuren. Cholesterol kan onderscheiden worden in ‘goed’ en ‘slecht’ cholesterol. 
Het ‘slechte’ cholesterol, ofwel lage dichtheids lipoproteinen (LDL), hoopt zich 
op in de vaatwand en ondergaat daar verschillende modificaties, zoals oxidatie of 
aggregatie. Deze modificaties zorgen ervoor dat LDL niet meer herkend wordt als 
‘lichaamseigen’ en het immuunsysteem komt in actie om dit vreemde molecuul op 
te ruimen. Verschillende soorten ontstekingscellen van het immuunsysteem worden 
vervolgens aangetrokken naar de vaatwand. Allereerst hechten monocyten zich aan 
de beschadigde endotheellaag en migreren de vaatwand in. Eenmaal in de vaatwand 
veranderen deze monocyten in macrofagen die het daar opgehoopte gemodificeerde 
LDL kunnen opnemen. Overmatige opname van het cholesterol leidt tot de vorming 
van zogenaamde ‘foamcellen’. Deze foamcellen vormen een verdikking aan de 
binnenkant van de vaatwand, ook wel een ‘fatty streak’ genoemd: het beginstadium 
van de atherosclerotische plaque. Na opname van gemodificeerd LDL, produceren 
macrofagen allerlei ontstekingsmediatoren, zoals cytokines en chemokines, die andere 
ontstekingscellen zoals monocyten en T cellen aantrekken naar de plaque. Daarnaast 
behoren macrofagen ook tot ‘antigen presenterende cellen’ (APCs) wat inhoudt dat 
ze ook stukjes (antigenen) van het gemodificeerde LDL aan andere ontstekingscellen 
zoals T cellen kunnen presenteren. De T cellen die dit antigen herkennen worden 
geactiveerd en beginnen ook allerlei cytokines te produceren die vervolgens nog 
meer ontstekingscellen richting de plaque sturen. Dit leidt tot een chronische auto-
immuun reactie waarbij er dus een immunologische reactie is ontstaan tegen een 
lichaamseigen antigen (gemodificeerd LDL). Naast gemodificeerd LDL zijn er nog 
meer antigenen die atherosclerose kunnen veroorzaken, zoals heat shock eiwitten 
die grote structurele overeenkomsten hebben met bacteriële moleculen en dus als 
lichaamsvreemd herkend worden. Naast een toename in het aantal ontstekingscellen 
in de plaque, migreren gladde spiercellen vanuit de wand naar de endotheellaag 
om daar samen met bindweefsel en collageen een beschermende ‘cap’ te vormen. 
Deze cap houdt de ontstekingscellen en vetdeposities op hun plaats en verhindert 
dat deze weer loskomen in de circulatie. Echter, gedurende de verdere ontwikkeling 
van atherosclerose kan er een scheur ontstaan in de cap waardoor de inhoud van de 
plaque in zijn geheel aan het bloed wordt blootgesteld. Dit leidt tot bloedstolling en 
de vorming van een bloedprop die het bloedvat of bij loslaten van de bloedprop een 
bloedvat elders compleet blokkeert zodat achterliggend orgaan onthouden wordt van 
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alle voedingsstoffen en zuurstofrijk bloed met bijvoorbeeld een hart- of herseninfarct 
als gevolg. 
Regulatie van het immuunsysteem als behandeling van atherosclerose
Aangezien het immuunsysteem een grote rol speelt in de pathogenese van 
atherosclerose, kan regulatie van het immuunsysteem een veelbelovende therapie 
vormen om hart- en vaatziekten te voorkomen. Zoals hierboven beschreven zijn T 
cellen nauw betrokken bij het ontstaan van een chronische ontstekingsreactie. Er 
zijn echter verschillende soorten T cellen die ieder hun eigen functie hebben en na 
activatie hun eigen set ontstekingseiwitten (cytokines) produceren. In atherosclerose 
worden vooral T helper 1 (Th1) cellen geactiveerd die grote hoeveelheden van het 
cytokine IFN-γ uitscheiden, dat atherosclerose verergert. Deze pro-inflammatoire Th1 
cellen kunnen geremd worden door een anti-inflammatoire T cel: de regulatoire T 
cel (Treg). Deze Tregs produceren de atherosclerose-remmende cytokines IL-10 en 
TGF-β en kunnen direct Th1 cellen remmen via cel-cel contact. In atherosclerose is 
er echter een verstoorde balans tussen de pro-inflammatoire, ‘slechte’, T cellen en 
de anti-inflammatoire, ‘goede’ T cellen, waarbij de balans verschoven is naar de pro-
inflammatoire T cellen. Recent onderzoek richt zich daarom op het herstellen van 
deze balans door (1) pro-inflammatoire responsen te remmen of (2) het aantal anti-
inflammatoire cellen te laten toenemen. Beide methoden van immuunregulatie maken 
deel uit van het in dit proefschrift beschreven onderzoek.
Modulatie van costimulatoire en coinhibitoire moleculen op ontstekingscellen
Voor de optimale activatie van T cellen zijn 3 signalen nodig: (1) de presentatie 
van een antigen op MHC moleculen van een antigen presenterende cel aan de T cel 
receptor aanwezig op het oppervlak van een T cel, (2) interactie tussen costimulatoire 
of coinhibitoire moleculen op antigen presenterende cellen en T cellen en (3) cytokines 
in de omgeving die onder andere kunnen beïnvloeden wat voor type, pro- of anti-
inflammatoire, T cel er ontstaat. Signaal 1 kan zonder signaal 2 geen T cel activeren, 
wat signaal 2 erg belangrijk maakt. Costimulatoire en coinhibitoire moleculen komen 
voor in paren: een ligand (L), en een receptor waaraan het ligand kan binden. Bij 
sommige paren bevindt het ligand zich op de antigen presenterende cel en de receptor 
zich op de T cel, terwijl bij andere paren de receptor op de antigen presenterende cel 
zit en het desbetreffende ligand op de T cel. Wanneer een costimulatoir ligand bindt 
aan de bijbehorende receptor worden ontstekingscellen (in combinatie met signaal 
1) geactiveerd, maar wanneer een coinhibitoir ligand aan zijn receptor bindt worden 
ontstekingscellen juist geremd. Er zijn veel verschillende costimulatoire en coinhibitoire 
paren met elk hun eigen unieke effect op verscheidene ontstekingscellen. Zo kunnen 
bijvoorbeeld OX40-OX40L en CD40-CD40L beiden atherosclerose verergeren, maar 
werken allebei via andere routes: binding van OX40 met OX40L zorgt ervoor dat T 
cellen veranderen in Th2 cellen, terwijl binding van CD40 met CD40L T cellen richting 
een Th1 fenotype stuurt. In Hoofdstuk 2 wordt een overzicht gegeven van alle 
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costimulatoire en coinhibitoire moleculen en hun rol in atherosclerose. 
Aangezien het remmen van pro-inflammatoire ontstekingscellen een veelbelovende 
therapie is om hart- en vaatziekten te behandelen, kan modulatie van signaal 2 door 
(1) het blokkeren van costimulatoire paren of (2) het stimuleren van coinhibitoire 
paren, een nieuwe basis voor immunotherapie vormen. In Hoofdstuk 3-6 zijn met 
behulp van blokkerende en stimulerende antilichamen verschillende costimulatoire en 
coinhibitoire signaleringsroutes bestudeerd in muizen met atherosclerose. Normaliter 
zijn muizen ongevoelig voor de ontwikkeling van hart- en vaatziekten, maar muizen 
die deficiënt zijn in de LDL receptor (LDLr-/- muizen) hebben verhoogde gehaltes van 
LDL cholesterol in het bloed. Wanneer deze LDLr-/- muizen een vetrijk dieet ontvangen 
ontwikkelen ze “spontaan” atherosclerose.
In Hoofdstuk 3 is de rol van de costimulatoire OX40-OX40L route in combinatie met 
een verlaging van lipiden in het dieet bestudeerd op het verminderen (regressie) 
van al bestaande atherosclerotische plaques. OX40 en OX40L hebben invloed op de 
activatie en functie van verschillende ontstekingscellen die nauw betrokken zijn bij 
de ontwikkeling van atherosclerose, zoals T en B cellen en mestcellen. Om de rol 
van OX40-OX40L in de regressie van atherosclerose te bestuderen, hebben LDLr-/- 
muizen eerst 10 weken een vetrijk dieet gekregen om atherosclerose te ontwikkelen. 
Vervolgens zijn ze op een vetarm dieet geplaatst om het cholesterol verlagende effect 
van statines na te bootsen en zijn ze behandeld met een blokkerend OX40L antilichaam 
om het immuunsysteem te reguleren. Na 10 weken vetarm dieet en de anti-OX40L 
behandeling is de atherosclerose ontwikkeling geanalyseerd in het drie-kleppen gebied 
van de aorta en in de aortaboog. Alleen het veranderen van een vetrijk dieet naar 
een vetarm dieet heeft geen invloed op de hoeveelheid atherosclerose: hoewel de 
plaques stabieler zijn, groeien de plaques zelfs nog in geringe mate door. Behandeling 
met anti-OX40L in combinatie met het vetarme dieet induceert echter wel regressie 
van atherosclerose. Dit komt enerzijds door een vermindering in het pro-atherogene 
IL-4, verlaging van IgE serum niveaus en mestcel activatie, en anderzijds door een 
toename in de productie van het beschermende IL-5 en IgM antilichaam productie 
door B cellen. Deze beschermende IgM antilichamen zijn gericht tegen geoxideerd 
LDL wat resulteert in verminderde atherosclerose.
In Hoofdstuk 4 wordt de rol van een andere costimulatoire signaleringsroute 
gevormd door CD30 en CD30L in atherosclerose beschreven. Net zoals OX40 en 
OX40L zijn CD30 en CD30L betrokken bij de activatie en proliferatie van T en B cellen. 
Een eerdere studie heeft aangetoond dat CD30 positieve macrofagen aanwezig zijn 
in gescheurde atherosclerotische plaques van patiënten met hart- en vaatziekten, 
maar de exacte rol van CD30-CD30L aan atherosclerose ontwikkeling was onbekend. 
Daarom hebben we LDLr-/- muizen 8 weken een vetrijk dieet gegeven en zijn ze twee 
keer per week behandeld met een antilichaam tegen CD30L. Anti-CD30L behandelde 
muizen ontwikkelen 35% minder atherosclerose, onafhankelijk van cholesterol niveaus 
in het bloed en de samenstelling van de plaque. Deze afname in atherosclerose gaat 
gepaard met een verminderde hoeveelheid, activatie en proliferatie van CD4+ T cellen 
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in de milt en daarnaast is er een 31% afname in CD3+ T cellen in de adventitia 
van anti-CD30L behandelde muizen. Anti-CD30L behandeling heeft geen effect op de 
functie van andere ontstekingscellen zoals B cellen en mestcellen in LDLr-/- muizen 
op een vetrijk dieet. Samenvattend hebben we vastgesteld dat blokkade van de 
costimulatoire signaleringsroute CD30-CD30L specifiek via de remming van CD4+ T 
cellen atherosclerose remt. 
In Hoofdstuk 5 bestuderen we de rol van Tim-3 in atherosclerose. Tim-3 behoort 
tot de familie van T cel immunoglobuline en mucine domein (Tim) eiwitten en is 
coinhibitoir. Tim-3 komt tot expressie op verschillende onstekingscellen zoals 
NK cellen, monocyten, macrofagen en T cellen en kan na binding van zijn ligand, 
galectin-9, celdood induceren. Daarnaast hebben eerdere studies beschreven dat 
signaaltransductie via Tim-3 regulatoire T cellen kan induceren. Allereerst hebben 
we vastgesteld dat Tim-3 tot expressie komt in de plaque en toeneemt naarmate 
muizen langer een vetrijk dieet gegeten hebben. Het percentage Tim-3+ natural killer 
cellen, monocyten en dendritische cellen (DCs) is ook verhoogd in LDLr-/- muizen op 
een vetrijk dieet in vergelijking met muizen op een vetarm dieet. Vervolgens hebben 
we LDLr-/- muizen op een vetrijk dieet behandeld met een selectief antilichaam 
tegen Tim-3 gedurende 8 weken. Anti-Tim-3 behandeling leidt tot een toename in 
atherosclerose van 35% in het drie-kleppen gebied van de aorta en van 50% in de 
aortaboog. Deze verergering van atherosclerose wordt veroorzaakt door een toename 
in circulerende monocyten en in de plaque zijn 20% meer macrofagen aanwezig. Anti-
Tim-3 behandeling leidt ook tot een toename in CD4+ T cellen en een vermindering 
van regulatoire cellen zoals Tregs en regulatoire B cellen (Bregs). Hieruit kunnen we 
concluderen dat Tim-3 als een negatieve regulator van atherosclerose werkt. 
In Hoofdstuk 6 is de bijdrage van een ander recent ontdekt coinhibitoir paar gevormd 
door TIGIT en PVR, aan de ontwikkeling van atherosclerose bepaald. Signalering 
via TIGIT, een T cel immunoreceptor met immunoglobuline, en PVR, de poliovirus 
receptor, remt T cellen zowel direct door het down-reguleren van de T cel receptor, als 
indirect via de inductie van beschermende IL-10 producerende DCs. Het stimuleren 
van TIGIT met behulp van een agonist in vitro zorgt voor een sterke remming van 
de activatie en proliferatie van T cellen. Vervolgens hebben we LDLr-/- muizen op een 
vetrijk dieet behandeld met deze TIGIT agonist gedurende 4 en 8 weken. De muizen 
behandeld met de TIGIT agonist hebben minder T cellen en deze T cellen tonen een 
verminderde proliferatie. Ondanks dit sterke effect op T cellen heeft een behandeling 
van LDLr-/- muizen met deze TIGIT agonist nauwelijks effect op atherosclerose. Dit 
komt mogelijk door een verhoogde activiteit van DCs in TIGIT agonist behandelde 
muizen. 
Immuunregulatie door suppressor cellen 
Een andere manier om de balans tussen goede en slechte ontstekingscellen te 
herstellen is door het aantal goede ontstekingscellen te laten toenemen. Deze 
goede ontstekingscellen kunnen de slechte ontstekingscellen onderdrukken en zo 
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atherosclerose remmen. In Hoofdstuk 7-9 hebben we gekeken naar de rol van twee 
soorten goede ontstekingscellen: regulatoire T cellen en ‘myeloid-derived suppressor 
cellen’. 
Zoals eerder beschreven verminderen Tregs ontsteking en kunnen daardoor 
beschermend zijn in auto-immuunziekten, zoals atherosclerose. Allereerst is in 
Hoofdstuk 7 het effect van de blokkering van Tregs bestudeerd om de rol van Tregs 
in atherosclerose verder te bevestigen. In dit hoofdstuk wordt een vaccinatiemethode 
beschreven waarbij dendritische cellen gebruikt zijn om een immuunrespons op 
te wekken tegen cellen die Foxp3 tot expressie brengen. Foxp3 is een eiwit dat 
voornamelijk gemaakt wordt door Tregs. Door cellen die Foxp3 tot expressie brengen 
te vernietigen kan de bijdrage van Tregs in atherosclerose bestudeerd worden. We 
zien in deze studie dat de vaccinatie leidt tot minder Tregs in de muis. Dit heeft 
tot gevolg dat de atherosclerotische plaque toeneemt in grootte. Hetzelfde is ook 
waargenomen in muizen met een vergevorderde atherosclerotische plaque. Dit geeft 
aan dat Tregs zowel bij beginnende als gevorderde atherosclerose betrokken zijn. 
Vervolgens zijn in Hoofdstuk 8 Tregs gestimuleerd met behulp van een IL-2-anti-
IL-2 complex en hebben we gekeken naar de rol van Tregs in de ontwikkeling en 
regressie van atherosclerose. Tregs worden gekenmerkt door de hoge expressie van 
CD25 op hun celoppervlak. Een complex van IL-2 en anti-IL-2 kan binden aan CD25 
en zorgt ervoor dat er wel 10 keer zoveel Tregs aanwezig zijn in het bloed en in 
verschillende organen. Dit resulteert in een 39% reductie van de atherosclerotische 
plaque tijdens een vroeg stadium van atherosclerose, terwijl in een regressie model 
van atherosclerose de enorme expansie van Tregs geen invloed heeft op plaque 
grootte, maar wel de stabiliteit van de plaque sterk doet toenemen. 
Naast Tregs zijn myeloid-derived suppressor cellen (MDSCs) ook goede kandidaten 
om heel gericht ontsteking te remmen. MDSCs vormen een populatie ‘onrijpe’ 
macrofagen, dendritische cellen en granulocyten die verhindert zijn om van beenmerg 
precursoren te veranderen tot rijpe ontstekingscellen. MDSCs kunnen geïdentificeerd 
worden door de expressie van CD11b en Gr-1 en zijn vooral beschreven in kanker, 
waar de aanwezigheid van MDSCs zorgt voor de verhindering van T cel reacties 
wat resulteert in progressie van de ziekte. In atherosclerose is een remming van T 
cellen juist gewenst, maar de rol van MDSCs in atherosclerose is tot op heden niet 
onderzocht.
In Hoofdstuk 9 hebben wij daarom allereerst met behulp van magnetische opzuivering 
CD11b+Gr-1+ cellen geïsoleerd uit het beenmerg van LDLr-/- muizen die 2 weken op 
een vetrijk dieet hebben gestaan. We hebben aangetoond dat de geïsoleerde cellen 
daadwerkelijk MDSCs zijn en ze heel sterk T cellen kunnen remmen. Deze remming 
van T cellen door de MDSCs is afhankelijk van IFN-γ en iNOS, twee factoren die ervoor 
zorgen dat de voedingsstoffen voor T cellen weggenomen worden. Om te kijken of 
MDSCs beschermend zijn in atherosclerose, hebben we elke 10 dagen intraveneus 
MDSCs toegediend aan LDLr-/- muizen, terwijl zij gedurende 6 weken een vetrijk dieet 
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ontvingen. Muizen die MDSCs toegediend hebben gekregen ontwikkelen 35% minder 
atherosclerose in vergelijking met controle muizen. Deze muizen hadden aanzienlijk 
meer naïve T cellen en veel minder pro-atherogene Th1 en Th17 cellen. Daarnaast 
zijn er ook minder circulerende B cellen, met name pro-atherogene B2 cellen, in 
MDSC-behandelde muizen. 
Toekomstige studies zijn nodig om de exacte rol van MDSCs in atherosclerose te 
beschrijven. Er zijn namelijk verschillende subtypes van MDSCs, en ieder subtype kan 
weer een uniek effect hebben op atherosclerose. Daarnaast zou het erg interessant 
zijn om de aanwezigheid en expansie van MDSCs in muismodellen van atherosclerose 
en patiënten met hart- en vaatziekten in kaart te brengen.
Samenvattend zijn in dit proefschrift een aantal studies beschreven die gericht zijn 
op het vinden van nieuwe targets om de balans tussen pro- en anti-inflammatoire 
ontstekingscellen in atherosclerose te herstellen. Aan de ene kant heeft het remmen 
van ontstekingscellen door costimulatoire en coinhibitoire eiwitten te beïnvloeden 
geleid tot een sterke afname in de grootte van atherosclerotische plaques. Aangezien 
er ontzettend veel verschillende costimulatoire en coinhibitoire eiwitten zijn en ze 
allemaal hun eigen functie hebben, kan modulatie van deze eiwitten een veelbelovende 
therapie zijn om hart- en vaatziekten te behandelen. Op dit moment zijn er al een 
aantal antilichamen voor costimulatoire en coinhibitoire moleculen goedgekeurd voor 
de behandeling van verschillende soorten kanker en zijn er klinische trials gaande 
met betrekking tot de rol van deze antilichamen in ziekten zoals astma. Deze kunnen 
waarschijnlijk op korte termijn ook toegepast worden op het gebied van hart- en 
vaatziekten.
Aan de andere kant is gebleken dat het gebruik van regulatoire T cellen en myeloid- 
derived suppressor cellen ook veelbelovende immunotherapiën kunnen vormen 
om atherosclerose te remmen. Vermeerdering of toediening van deze cellen in 
muismodellen voor atherosclerose leidt tot een sterke afname in plaque formatie. 
Vooral in het geval van myeloid-derived suppressor cellen, maar ook voor regulatoire 
T cellen dient er in de toekomst nog veel onderzoek verricht te worden naar de 
bruikbaarheid, veiligheid en effectiviteit van een cellulaire therapie voor patiënten met 
hart- en vaatziekten. 
Al met al hebben de in dit proefschrift beschreven studies geleid tot meer en nieuwe 
inzichten in de immunologische processen van atherosclerose en deze kunnen mogelijk 
leiden tot nieuwe klinische toepassingen zodat hart- en vaatziekten patiënten in de 
toekomst beter en eerder behandeld kunnen worden. 
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